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ABSTRACT 
Microfluidic devices play an important role in improving global health because they reduce 
the study of biological phenomena into physiological scales and lay the foundation for point-
of-care (POC) diagnostics. Health is improved and lives are saved because POC diagnostics 
can enable earlier diagnosis of diseases and therefore more effective treatment. Accurate and 
available diagnostics also prevent accelerated drug resistance that stems from overtreatment 
or mistreatment with antibiotics, which is projected to cause up to $100 trillion in lost 
economic output and 10 million deaths by 2050. This work details new diagnostic assays and 
theoretical analysis of microfluidic devices that can be implemented at the point-of-care to 
improve global health. 
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C h a p t e r  I  
Introduction 
The main objective of the research in this thesis is to improve global health, with an 
emphasis on making these innovations applicable limited-resource settings. Microfluidic 
devices play an important role in improving global health because they can reduce the study 
of biological phenomena into physiological scales and lay the foundation for point-of-care 
(POC) diagnostics. 
The improvement of global health centers around two interdependent factors: 
treatment and diagnosis. Treatment receives a majority of the attention paid to healthcare, 
but if there is no accurate or reliable diagnosis of the infirmity, then treatment can become 
ineffective and expensive [1]. For example, a new POC malaria test with 90% sensitivity and 
specificity would prevent 447 million unnecessary treatments per year, in addition to saving 
2.2 million adjusted lives [2]. A POC diagnostic test for Chlamydia and Gonorrhoea in sub-
Saharan Africa, China, and southeast Asia would save ~4 million disability-adjusted life 
years, avert >16.5 million incident gonorrheoa and chlaymadia infections and prevent 
>212,000 HIV infections [2]. These lives are improved and saved because POC diagnostics 
enable earlier diagnosis of diseases, which increases life expectancy and treatment success 
[1]-[4]. Accurate and available diagnostics also prevent accelerated drug resistance that 
stems from overtreatment, which is projected to cause up to $100 trillion in lost economic 
output and 10 million deaths by 2050 [5]. 
Chapters II and III of this thesis address the challenge of drug resistance by 
demonstrating how microfluidics can be used to rapidly test bacteria for their susceptibility 
or resistance to antibiotics. Gold-standard antibiotic susceptibility testing (AST) methods 
currently used in clinical laboratories take several days to obtain a result [6]. Because 
knowing the phenotypic AST result of an organism in less than 30 min is crucial for 
appropriate treatment and antibiotic stewardship [7]-[8], the goal for our AST method was 
to provide susceptibility information with comparable accuracy to gold-standard methods, 
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but in much shorter times (30 min or less). In Chapter II, previously published work on 
which I am a contributing author is presented which develops an AST method to determine 
the phenotypic susceptibility of E. coli to several classes of antibiotics commonly prescribed 
for urinary tract infections (UTI). Schoepp and Khorosheva show that this digital antibiotic 
susceptibility testing (dAST) method correctly determines antibiotic susceptibility or 
resistance for UTI E. coli isolates after only 15 min of antibiotic exposure, which is a 
dramatic reduction in time from the traditionally required overnight or 24-hour cultures. 
Chapter III of this thesis details unpublished work on which I am a co-first author 
where we build upon the work from Chapter II and make several important advances to 
achieve our goal of a phenotypic AST in less than 30 min. First, we further developed the 
dAST method to test antibiotic susceptibility from clinical UTI urine samples instead of 
isolates grown in media. Second, we used microfluidic devices (SlipChips [9]) and 
isothermal nucleic acid amplification (LAMP, ref) to precisely measure the nucleic acid 
concentrations and decrease the measurement time from 2 hours (necessary for digital PCR 
in the method of Chapter II) to less than 10 min. Third, we optimized the workflow to enable 
an antibiotic susceptibility call to be determined directly from a clinical UTI sample in less 
than 30 min, with all sample handling and image analysis steps included. This achievement—
obtaining an AST call in less than 30 min—is a world-record for phenotypic AST and 
introduces a new dAST method that can potentially be used to address many of the drug-
resistance diagnostic challenges the world is encountering today. 
In Chapter IV of this thesis, previously published work on which I am a co-first 
author demonstrates the use of a porous matrix to rapidly (< 10 min) capture zeptomolar 
amounts of nucleic acids (~1 copy/mL) from large volumes (> 1 mL). Low concentration 
detection of nucleic acids is important in many fields: for infectious diseases, latent infections 
and drug effectiveness studies can only be done with a high sensitivity diagnostic device; in 
environmental monitoring, low pathogen concentrations are present in water and diagnostics 
are necessary to ensure safe drinking water [10]-[11]. Microfluidic point-of-care (POC) 
devices have been designed to address these needs, but they are not able to detect NAs present 
in zeptomolar concentrations in short time frames because they require slow flow rates and/or 
they are unable to handle milliliter-scale volumes. This paper evaluates the reaction and 
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transport tradeoffs theoretically and demonstrates a new method using microfluidic 
principles in a porous nylon matrix that can successfully detect zeptomolar concentrations. 
In Chapter V of this thesis, previously published work on which I am a contributing 
author expands the dynamic range of a quantitative protein assay by incorporating Brownian 
trapping with drift into a digital protein assay. Typically, digital protein measurements are 
very precise, but with a limited dynamic range. This work contributes an understanding of 
the transport and capture processes in a digital protein assay with flow and uses this 
understanding to dictate the optimal parameters that result in an exponential decay of positive 
signal over the length of the microfluidic channel. Achieving this exponential decay was 
essential to improving the dynamic range, which is desired in assays testing for a traumatic 
brain injury biomarker, glial fibrillary acidic protein (GFAP). 
In Chapter VI of this thesis, previously published work on which I am a contributing 
author studies the effect that various forms of polyphosphate (polyP) have on blood clotting. 
The principal hypothesis tested was whether localizing polyP onto a surface would trigger 
blood clotting in the presence of various shear rates. This question was analyzed with 
microfluidics mimicking a capillary both theoretically and experimentally. Although the 
physiological mechanisms for polyP localization onto platelet or vascular surfaces remain 
unknown, this study gives insight into the clotting mechanisms, their dependence on various 
forms of polyP, and potential therapeutic applications. 
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Chapter II 
 
Digital Quantification of DNA Replication and Chromosome Segregation 
Enables Determination of Antimicrobial Susceptibility After Only 15 Minutes 
of Antibiotic Exposure1 
 
Abstract 
 
Rapid antimicrobial susceptibility testing (AST) would decrease misuse and overuse of 
antibiotics. To achieve the “holy grail” of AST, a phenotype-based test that can be performed 
within a doctor visit, requires determining a pathogen’s susceptibility after a short antibiotic 
exposure. We used digital PCR (dPCR) to test whether assessing DNA replication of the 
target pathogen via digital single-molecule counting would shorten the required antibiotic 
exposure. Partitioning bacterial chromosomal DNA into many small volumes during dPCR 
enabled AST via (i) precise quantification and (ii) a measure of how antibiotics affect the 
states of macromolecular assembly of bacterial chromosomes. This digital AST (dAST) 
determined susceptibility of clinical isolates from urinary tract infections (UTI) after 15 min 
of exposure for all four antibiotic classes relevant to UTI. This work lays the foundation to 
develop a rapid, point-of-care AST and strengthen global antibiotic stewardship. 
 
Introduction 
 
The increasingly liberal use and misuse of antibiotics (ABX) has led to widespread 
development of antibiotic resistance.[1] To address this crisis, we need rapid and reliable 
tests of a pathogen’s susceptibility to the drugs available (antimicrobial susceptibility test, 
AST) to provide correct, life-saving treatment, facilitate antibiotic stewardship[2] and 
drastically decrease hospital costs.[1a,3] Having a rapid AST that provides results within the 
                                                 
1This chapter was first published in Angewandte Chemie with authorship belonging to Nathan G. Schoepp, 
Eugenia M. Khorosheva, Travis S. Schlappi, Matthew S. Curtis, Romney M. Humphries, Janet A. Hindler and 
Rustem F. Ismagilov. The original manuscript can be found at: http://dx.doi.org/10.1002/anie.201602763. 
Specific contributions from each author are listed at the end of the chapter. 
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period of a doctor visit would lead to improved patient outcomes and reduced spread of 
antibiotic resistance.[4] Development of a rapid AST is currently the focus of significant 
research efforts[5] that aim to supplant traditional clinical methods. To reduce the spread of 
resistance, one urgently needed AST is for urinary tract infections (UTIs), which are among 
the most common bacterial infections, yet can progress to pyelonephritis or sepsis.[6]  
 
Two types of ASTs are currently used in clinical settings: traditional culture-based methods 
and genotypic methods. Culture-based tests remain the gold standard for determining 
antibiotic susceptibility because they detect phenotypic susceptibility to a drug, however 
these tests require a long period of antibiotic exposure (typically 16–24 h).[7] We[8] and 
others[5a,5b,5k,9] have proposed using confinement of single, or a small number of, 
bacterial cells in small volumes to reduce the duration of antibiotic exposure required to read 
out the phenotype of the target pathogen. However, these methods typically do not 
differentiate between the pathogen and the potential contamination of the sample with 
commensal bacteria. Alternative genotypic methods (detecting genes responsible for known 
mechanisms of resistance) are more rapid than culture-based approaches.[10] However, 
these resistance genes constitute only a fraction of all possible mechanisms of resistance,[11] 
and new forms of resistance evolve quickly.[12] Therefore, predicting resistance by 
analyzing a few known resistance genes is not a general solution.[13] 
 
To develop more rapid and specific phenotypic tests, hybrid approaches have been proposed 
that use quantification of nucleic acids to determine the susceptibility or resistance phenotype 
after a short antibiotic exposure. These tests do not rely on detecting specific resistance 
genes.[5g,5i] For example, quantification of RNA has allowed determination of 
susceptibility to ciprofloxacin (cip) and rifampin,[5i] which impair transcription, after 
exposures as short as 15 min. However, these methods require longer incubation times when 
using antibiotics with different mechanisms of action. Using quantitative PCR (qPCR), 
quantification of DNA after 2–9 h of antibiotic exposure was used to detect bacterial growth 
and determine susceptibility,[5d,5e] however an ideal exposure time would be shorter than 
one cell division. 
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Here we tested the hypothesis that digital methods of nucleic acid quantification,[14] such as 
digital PCR (dPCR), would enable use of DNA markers to perform a phenotypic AST after 
short antibiotic exposure. Digital methods partition bacterial chromosomal DNA into 
thousands of compartments and then use targeted amplification to determine the number of 
“positive” compartments containing DNA carrying one or more copies of the target gene. 
This partitioning should enable more precise and robust measurements of concentrations of 
bacterial DNA, achieving higher statistical power with fewer replicates relative to 
qPCR.[14c,15] Further, we hypothesized that this partitioning would provide unique 
capabilities for AST when analyzing target genes present in a macromolecular assembly, 
such as a bacterial chromosome during replication. In contrast to qPCR, dPCR results should 
reflect the state of the macromolecular assembly, providing a different count for a pair of 
segregated chromosomes (two positives) vs the chromosomal assembly just prior to 
segregation (one positive). We test our hypotheses in the context of four of the main 
antibiotics used in UTI treatment: ciprofloxacin (cip), nitrofurantoin (nit), 
sulfamethoxazole/trimethoprim (sxt), and amoxicillin/clavulanic acid (amc).[6a,7b,16] 
 
Results and Discussion 
 
We first determined the minimum antibiotic exposure time necessary to differentiate 
susceptible and resistant clinical UTI isolates using qPCR analysis of DNA after incubation 
in the presence (“treated”) or absence (“control”) of antibiotics (see SI). Cycle thresholds 
were used to calculate relative fold change
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compared to t = 0 min (Fig. 2-1). When treated with cip, DNA replication in susceptible 
isolates was significantly inhibited, resulting in an increasing difference in fold change 
between target concentration in treated and control samples. If the isolate was resistant, DNA 
replication continued regardless of exposure.  To align with FDA requirements for very 
major errors[17] we used a conservative alpha, 0.02 (see SI). Susceptibility to cip could be 
determined after 15 min of exposure. We obtained similar results using isolates pre-cultured 
in media and in urine (SI Fig. 2-S1), and chose to conduct all subsequent experiments in 
media in order to reduce the work with human samples and to ensure reproducibility. The 
focus of this work is to evaluate the differences in minimum antibiotic exposure time 
necessary to determine susceptibility when quantification of changes in DNA is performed 
with qPCR vs dPCR. 
 
 
Figure 2-1. Quantitative PCR (qPCR) time course for exposure of (A) susceptible and (B) 
resistant UTI E. coli isolates to ciprofloxacin. For cycle thresholds (Ct) error bars are 2.8 
S.D. (see SI), N=3. Fold change values represent change from t = 0 min; error bars represent 
the upper and lower bounds of the 98% C.I. (see SI), N=2. Significant differences (p-value 
≤ 0.02) are marked with a green check. 
  
These results are the first evidence of detection of phenotypic susceptibility based on DNA 
quantification after only 15 min of antibiotic exposure. The rapid effect of cip on DNA 
replication is logical because the drug’s mechanism of action is to inhibit DNA-gyrase and 
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topoisomerase IV, producing double stranded breaks in DNA and directly inhibiting DNA 
replication.[18] To test generality, we evaluated AST with three other antibiotics: nit,[19] sxt,[20] 
and amc (which is not known to specifically affect DNA replication) (see SI). Using qPCR, 
15 min of exposure to these three antibiotics was not sufficient to detect a significant 
difference in DNA replication in susceptible isolates (Fig. 2-2 B–D), while statistically 
significant differences were detectable with cip treatment (Fig. 2-2 A).  
 
Figure 2-2. Comparison of susceptible and resistant isolates from UTI samples after a 15 
min exposure with each of four antibiotics, analyzed by quantitative PCR. Fold change 
values represent change from t = 0 min; error bars are 98% C.I. (see SI), N=3. Significant (p-
value ≤ 0.02) and nonsignificant differences detected using the susceptible isolate are marked 
with a green check and red x respectively. 
 
We then tested AST with digital quantification by quantifying the same DNA samples using 
digital PCR (Fig. 2-3). For cip, we observed a more statistically significant difference 
(smaller p value) between target concentrations in treated and control susceptible isolates 
(Figure 2-3A), while target concentrations did not differ between treated and control resistant 
isolates (Figure 2-3B). A significant difference was also detected after 15 min exposures to 
nit (Figure 2-3C) or sxt (Fig. 2-3C). 
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Interestingly, neither qPCR or dPCR detected susceptibility after exposure to amc when 
samples were denatured and treated with protease during extraction (SI Figure 2-S2). This 
confirmed that genome replication proceeded (resulting in an increase in the total number of 
amplifiable targets) during incubation with amc regardless of phenotype. We therefore tested 
the hypothesis that dPCR would be sensitive not only to the total gene copy number, but also 
to the state of macromolecular assembly of chromosomal DNA. If exposure to amc causes 
changes in chromosome segregation, even without affecting replication, dPCR should still 
be able to differentiate susceptible and resistant phenotypes. To preserve chromosome 
structure and macromolecular complexes, we performed DNA extraction in non-denaturing 
conditions without protease treatment. Under these conditions, dPCR provided susceptibility 
phenotype after 15 min of exposure to amc (Figure 2-3D).
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Figure 2-3. AST results using dPCR. (A,B) Time course results for exposure of susceptible 
(A) and resistant (B) UTI E. coli isolates to ciprofloxacin. (C,D) Fold changes after treatment 
with all four antibiotics tested. Significant (p-value ≤ 0.02) and nonsignificant p-values for 
susceptible isolates are denoted with a green check and red x respectively. Samples treated 
with amoxicillin/clavulanic acid (D) were extracted using a non-denaturing protocol. 
Concentrations are calculated using Poisson statistics. Fold change values represent change 
from t = 0 min; all error bars are 98% C.I. (see SI), N=3 for qPCR, N=2 for dPCR. 
 
To test whether dPCR differentiated susceptible and resistant isolates via quantifying 
macromolecular assemblies, we designed control experiments in which all assemblies were 
sheared into ~1000 bp DNA fragments, much smaller than the average distance between 23S 
genes within the genome (see SI). As expected, shearing caused an increase in measured 
target concentration when quantified using dPCR, but not using qPCR (Fig. 2-4 A–B). In 
samples that were not sheared, dPCR detected the susceptible phenotype after 15 min of amc 
exposure (Fig. 4C). Shearing these samples to disrupt macromolecular assemblies eliminated 
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the ability to detect susceptibility (Fig. 4D); qPCR measurements confirmed this was not due 
to loss of DNA. This suggests that in amc-susceptible isolates short exposure to amc does 
not result in a change of the total number of target gene copies, but does change the 
macromolecular assembly of these copies.
 
Figure 2-4. A mechanistic investigation of AST by digital PCR (dPCR) after beta lactam 
exposure and non-denaturing DNA extraction using shearing to disrupt macromolecular 
assemblies; error bars for qPCR are 2.8 S.D. (see SI), N=3; error bars are 98%C.I. for dPCR 
(see SI), N=2. Significant (p-value ≤ 0.02) and nonsignificant p-values for susceptible 
isolates quantified using dPCR are denoted with a green check and red x respectively (see 
SI).
 
Our results suggest a previously unknown effect of brief beta-lactam antibiotic exposure: 
 a delay in chromosome segregation. Using dPCR (but not qPCR) this effect can be 
quantified by counting the number of macromolecular DNA assemblies containing 23S 
target genes, and used for AST. The high resolution of digital quantification enables 
measuring small (less than two-fold) changes in chromosome replication and segregation 
after antibiotic exposure shorter than the average time of cell division. The dAST approach 
developed here adds chromosome segregation to the list of the phenotypic markers suitable 
for rapid antibiotic susceptibility detection. The ability to partition macromolecular 
assemblies allows dAST to be used even when genome replication proceeds on the timescale 
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of antibiotic exposure, while the high precision of digital quantification allows accurate 
determination of susceptibility after shorter exposure times than would be required using 
less-precise methods such as qPCR. 
 
Conclusion 
 
These dAST results warrant a follow-up study with a wide range of Gram-positive and Gram-
negative bacterial isolates from urine, blood, and other sample types, and then a clinical study 
comparing dAST directly from patient samples to the gold standard culture-based methods. 
Elucidating the effects of using variable clinical samples with a range of background matrices 
is a critical next step in the development of a rapid, sample-to-answer AST. Ultimately, a 
sample-to-answer AST at the point of care must be robust, rapid, and require minimal sample 
handling and instrumentation. Ideally, such a workflow will integrate sample handling, 
antibiotic exposure, and quantification into a single device. We anticipate that digital 
isothermal amplification chemistries will replace dPCR in dAST.[15a,21] When integrated with 
sample preparation[22] and combined with simple readouts,[23] we envision that digital 
quantification will establish a new paradigm in rapid point of care AST. 
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Materials and reagents 
All reagents purchased from commercial sources were used as received unless otherwise 
stated. BBL Trypticase Soy Agar plates with 5% Sheep Blood and Bacto Brain Heart 
Infusion (BHI) media were purchased from BD (Franklin Lakes, NJ, USA). BHI was 
dissolved in deionized water at the manufacturers recommended concentration and 
autoclaved prior to use. All antibiotic stock solutions and PCR reactions were prepared using 
sterile, nuclease-free water (NF-H2O) purchased from Thermo Fisher (Waltham, MA, USA).  
 
All antibiotics and clavulanic acid were purchased from Sigma-Aldrich (St. Louis, MO, 
USA), with the exception of amoxicillin, which was purchased from Alfa-Aesar (Ward Hill, 
MA, USA). Ciprofloxacin and clavulanic acid were prepared as a 1 mg/mL stock solutions 
in NF-H2O. Nitrofurantoin was prepared as a 10 mg/mL stock solution in 
dimethylformamide (DMF). Sulfamethoxazole was prepared as a 10 mg/mL stock solution 
in dimethyl sulfoxide (DMSO). Trimethoprim was prepared as a 1 mg/mL stock solution in 
DMSO. All antibiotic stock solutions were stored at -20 °C. Amoxicillin was prepared fresh 
as a 1 mg/mL stock solution in NF-H2O before each experiment. 
 
QuickExtract DNA Extraction Solution and QuickExtract RNA Extraction Kit were 
purchased from Epicentre (Madison, WI, USA). SsoFast EvaGreen Supermix (2X) and 
QX200 ddPCR EvaGreen Supermix was purchased from Bio-Rad Laboratories (Hercules, 
CA, USA) and used for all qPCR and dPCR experiments respectively. 
 
Pooled human urine (catalog no. 991-03-P) was obtained from Lee Biosolutions (Maryland 
Heights, MO, USA). 
 
Isolate maintenance 
Ten E. coli isolated from the urine of 10 unique patients were obtained from the University 
of California Los Angeles (UCLA) Clinical Microbiology Laboratory with approval from 
the UCLA and Veterans Affairs Institutional Review Boards and appropriate Health 
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Insurance Portability and Accountability Act exemptions. All isolates were identified as 
E. coli using the Vitek2 GNID panel (bioMerieux, Durham, NC, USA), and chosen for use 
based on their determined MICs. Urine cultures were performed by routine semi-quantitative 
methods, by inoculating 1 µL of urine to a BBL Trypticase Soy Agar plate with 5% Sheep 
Blood (BAP, BD, Sparks MD) and a MacConkey plate followed by overnight incubation at 
35 +/-2 °C in ambient air. In all cases, the E. coli grew in pure culture at  >100,000 colony 
forming units. Minimum inhibitory concentrations (MIC) for each isolate was determined by 
UCLA for ciprofloxacin (cip), nitrofurantoin (nit), sulfamethoxazole/trimethoprim (sxt), and 
amoxicillin/clavulanic acid (amc) using the Clinical and Laboratory Standards Institute 
(CLSI) reference broth microdilution method,[1] in panels prepared by UCLA with cation-
adjusted Mueller-Hinton broth (MHB). BMD tests were incubated at 35 +/- 2 oC in ambient 
air conditions for 16-20 h. MICs were interpreted using CLSI M100S 26th edition 
breakpoints.[1]  E. coli isolates were stored at -80 °C in Brucella broth with 20% glycerol 
(Becton, Dickinson, Sparks, MD, USA). Isolates were subcultured twice on BAP and well-
isolated colonies were used for antibiotic exposure time course experiments. 
 
Antibiotic exposure time course experiments 
In order to generate liquid culture for use in experiments, E. coli isolates were cultured 
overnight (10-12 hours) after scraping a small portion of the plate and inoculating in 4 mL 
BHI. Overnight cultures were re-inoculated into 4 mL of fresh BHI and grown for an 
additional 4–6 h until early logarithmic phase. Cultures were then diluted 10 fold into pre-
warmed BHI, and optical density (600 nm) was measured using a portable spectrophotometer 
(GE Healthcare Ultrospec 10). OD was converted to approximate cell count using the 
correlation factor OD600 1.0 = 8.0*10^8 cells/mL). The dilutions prepared for OD 
measurements were then immediately diluted a second time into 2 mL polypropylene tubes 
to a final volume of 500 µL (dilution factor dependent on desired final cell concentration). 
These tubes were incubated for 5 min at 37 °C with shaking at 500 rpm in a heating/shaking 
block (Thermo Fisher Digital Heating Shaking Drybath) to ensure thorough mixing. During 
this time, separate 2 mL polypropylene tubes containing 450 µL of BHI with and without 
antibiotics were prepared. All exposure time courses were conducted with antibiotic 
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concentrations above the minimum inhibitory concentration (MIC) of the susceptible 
isolate and below the MIC of the resistant isolate being tested. Ciprofloxacin exposure in 
media and urine was conducted at a final antibiotic concentration of 2.00 and 0.75 µg/mL 
respectively. Nitrofurantoin experiments were performed at 64.00 µg/mL. 
Sulfamethoxazole/trimethoprim experiments were performed at 76.00/4.00 µg/mL. For 
amoxicillin experiments, susceptible isolates were exposed to a final concentration of 12.00 
µg/mL, and resistant isolates were exposed to a final concentration of 14.00 µg/mL. Cultures 
were then diluted a final 10 fold (50 µL culture into 450 µL) into single tubes containing 
media with or without antibiotics, and time was started. 10 µL aliquots were removed at 0, 
15, and 30 min., and immediately mixed with 90 μL of a one-step extraction buffer suitable 
for direct use in PCR. Denaturing extraction conditions used Epicentre QuickExtract DNA 
Extraction Solution. Cells were mixed with Epicentre QuickExtract DNA Extraction 
Solution, pipette mixed, incubated at 65 °C for 6 min., 98 °C for 4 min., then chilled on ice. 
Non-denaturing extraction conditions used Epicentre Quick Extract RNA Extraction 
solution. Aliquots were mixed with RNA extraction immediately via pipette, gently vortexed 
to ensure thorough mixing, and chilled on ice. All samples were stored at -20 °C for several 
days during use before being moved to -80 °C for long-term storage. 
 
DNA fragmentation 
DNA was fragmented to a predicted 1000 bp fragment size using a Covaris 220M 
ultrasonicator. Samples were diluted 10 fold into a 130 µL microTUBE AFA Fiber Snap-
Cap, and sheered for 90 seconds at 20 °C with a Peak Incident Power of 50 W, duty factor 
of 2%, and 200 cycles per burst. This size was chosen to ensure that all copies of the 23S 
gene will be separated from each other. Based on an analysis of 11 E.coli strains isolated 
from UTIs, the average distance between 23S genes is 1,169 kb with the closest genes being 
38 kb apart. These genomes may be accessed with the following accession numbers: 
CP011018.1; HG941718.1; CP007265.1; CP007391.1; CP002797.2; CP002212.1; 
CP001671.1; CU928163.2; CP000247.1; CP000243.1; CP011134.1. 
 
DNA quantification 
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All qPCR reactions were performed using a Roche LightCycler 96. All reactions contained 
only SsoFast EvaGreen Supermix at a final concentration of 1X, forward and reverse primers 
(forward primer TGCCGTAACTTCGGGAGAAGGC, reverse primer 
TCAAGGCTCAATGTTCAGTGTC) specific for Enterobacteriaceae[2] at a final 
concentration of 500 nM, template DNA at variable concentrations, and NF-H2O. A single 
master mix containing supermix, primers, and NF-H2O was prepared and aliquoted into PCR 
tubes. Template was then added, bringing the final volume to 30 µL. Each tube was then 
mixed thoroughly via pipette and technical triplicates (9 µL each) were aliquoted into the 96 
well plate. Cycling conditions consisted of an initial denaturation step at 95 °C for 3 min. 
followed by 30 cycles of 95 °C for 20 s, 62 °C for 20 s, and 72 °C for 20 s. Following 
amplification a continuous melt curve was obtained between 55 and 95 °C. Total cycling 
time (including melt analysis) was 60 min. 
 
Digital PCR reactions were carried out in a BioRad QX200 Droplet Digital PCR system 
according to the manufacturer's instructions. Samples were prepared in identical fashion as 
those prepared for qPCR. For each sample, two wells of the droplet generation chip and well 
plate were used to generate and thermocycle droplets, respectively. This resulted in 
approximately 40,000 droplets being analyzed for each sample. Cycling conditions consisted 
of an initial denaturation step at 95 °C for 5 min followed by 40 cycles of 95 °C for 30 s, 60 
°C for 30 s, and 72 °C for 30 s. Following initial thermocycling, the sample was cooled to 4 
°C for 5 min followed by a final heating step at 95 °C for 5 min. All thermocycling steps 
were performed with a 2 °C/s ramp rate. Total cycling time was 115 min. 
 
Statistical analyses 
Raw Ct values are not normally distributed; therefore, a typical plot showing the mean Ct +/- 
2·SD does not mean that the true mean will lie in the confidence interval 95% of the time.  
Understanding this fact, we would still like to represent the variability in qPCR 
measurements for the raw Ct plot.  We did this with a standard confidence interval 
calculation: 
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 𝐶𝐶𝑡𝑡𝑈𝑈/𝐿𝐿 = 𝐶𝐶𝑡𝑡𝑎𝑎𝑎𝑎𝑎𝑎  ± 𝑡𝑡𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 ∙ 𝑠𝑠𝐶𝐶𝐶𝐶
√𝑛𝑛
 (1) 
 
The critical 𝑡𝑡 value (𝑡𝑡𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐) for a 98% confidence interval with 2 degrees of freedom is 4.85; 
with 𝑛𝑛 = 3 replicates, this results in the SD being multiplied by 2.80 for the confidence 
intervals.  This does not mean that the true Ct is within this interval 98% of the time, but it 
does give a representation of the variability in Ct measurements. 
 
In order to calculate the p-value for comparing treated and untreated samples, the raw Ct 
values (which are exponential) were linearized into a relative quantity (𝐹𝐹𝐶𝐶) with t = 0 min as 
the reference point using 𝐹𝐹𝐶𝐶 = 2𝐶𝐶𝑐𝑐(𝑐𝑐)−𝐶𝐶𝑐𝑐(0).  The log ratio of these linearized quantities was 
compared to ln(1.1) using a one-tailed 𝑡𝑡 test.  A one-tailed test was chosen because the 
untreated sample should have a higher concentration than the treated sample; if by some 
random event the treated sample has a statistically significant higher concentration than 
untreated, we don’t want to draw the false conclusion that the isolate is susceptible.  To 
account for pipetting variation (the treated sample could have randomly had 10% more 
bacteria pipetted into its media at time = 0 than the untreated sample), the null hypothesis is ln �𝐹𝐹𝐶𝐶𝑢𝑢𝑢𝑢
𝐹𝐹𝐶𝐶𝑢𝑢
� − ln(1.1) = 0 instead of ln �𝐹𝐹𝐶𝐶𝑢𝑢𝑢𝑢
𝐹𝐹𝐶𝐶𝑢𝑢
� = 0.  This makes the AST more conservative 
(reducing very major errors) by requiring that the untreated sample have at least 1.1 fold 
more copies than the treated sample. P-values for digital PCR were calculated with a one-
tailed 𝑍𝑍 test comparing ln �𝐹𝐹𝐶𝐶𝑢𝑢𝑢𝑢
𝐹𝐹𝐶𝐶𝑢𝑢
� to ln (1.1), with 𝐹𝐹𝐶𝐶𝑢𝑢𝑐𝑐 representing the fold change in 
concentration of the untreated sample with respect to time = 0 and 𝐹𝐹𝐶𝐶𝑐𝑐 representing the same 
quantity, but for the treated sample. 
 
Discussion of mechanism of action of antibiotics tested 
In addition to ciprofloxacin, we evaluated three other antibiotics used in the treatment of 
UTIs: (i) nitrofurantoin, which is reduced to a reactive radical inside the cell, reacting with 
multiple cellular targets including enzyme involved in DNA synthesis[3], which would 
directly affect replication; (ii) the combination of sulfamethoxazole and trimethoprim, which 
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synergistically inhibit folic acid biosynthesis, subsequently impairing multiple metabolic 
reactions including thymidine synthesis[4]; and (iii) amoxicillin, which disrupts the synthesis 
of the peptidoglycan layer of bacterial cell walls leading to lysis[5], but is not known to 
specifically affect DNA replication. 
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Figures and Tables 
 
 
Table 2-S1. Minimum inhibitory concentrations for all isolates tested, as determined by 
broth dilution. AMC = amoxicillin/clavulanic acid, CIP = ciprofloxacin, NIT = 
nitrofurantoin, SXT = sulfamethoxazole/trimethoprim. ND = not determined. 
 
 
Table 2-S2. Raw data and additional experiments performed with multiple isolates. “S or R” 
refers to susceptible or resistant as determined by MIC. ABX = antibiotic. * indicates samples 
were sheared prior to quantification (see methods section of SI). Experiment exposing isolate 
1 to ciprofloxacin was performed in 1:1 media:urine, all other experiments were performed 
in media. 
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Figure 2-S1. qPCR time course for exposure of (A) susceptible and (B) resistant UTI E. coli 
isolates to ciprofloxacin pre-cultured in urine and exposed to antibiotics in 1:1 urine:BHI. 
Raw cycle thresholds represent the average of technical triplicates; error bars represent 2.8 
standard deviations (see SI). Fold change values represent change from t = 0 min; error bars 
represent the upper and lower bounds of the 98% confidence interval. Significance was 
defined as a p-value <= 0.02 when comparing the fold change in 23S concentration of 
samples incubated without antibiotics (blue) to 1.1 times the fold change in 23S 
concentration of samples with antibiotics (brown) at a specific time point. Significant 
differences detected using the susceptible isolate are marked with a green check.  
 
 
Figure 2-S2. Comparison of susceptible isolate analyzed by qPCR and digital PCR after a 
15 min exposure to amoxicillin/clavulanic acid and extracted using a denaturing buffer with 
protease treatment (A) and a non-denaturing buffer without protease treatment (B). Fold 
change values represent change from t = 0 min; error bars are 98% confidence intervals. 
Significance was defined as a p-value <= 0.02 when comparing the fold change in 23S 
concentration of samples incubated without antibiotics (blue) to 1.1 times the fold change in 
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23S concentration of samples with antibiotics (brown) at a specific time point. Significant 
and non-significant differences are marked with a green check and red x respectively. 
 
 
Figure 2-S3. Fold change plots from Figures 1 and 3 with corresponding Ct and 
concentration plots to demonstrate conversion from either Ct or concentration to fold change. 
(A, B) AST results using qPCR. Time course for exposure of (A) susceptible and (B) resistant 
UTI E. coli isolates to ciprofloxacin. For cycle thresholds (Ct) error bars are 2.8 S.D. Fold 
change values represent change from t = 0 min; error bars represent the upper and lower 
bounds of the 98% C.I. Significant differences (p-value ≤ 0.02) are marked with a green 
check. (C, D) AST results using dPCR. Time course for exposure of susceptible (C) and 
resistant (D) UTI E. coli isolates to ciprofloxacin. Concentrations are calculated using 
Poisson statistics; error bars represent the upper and lower bounds of the 98% C.I. Fold 
change values represent change from t = 0 min; error bars represent the upper and lower 
bounds of the 98% C.I. Significant (≤ 0.02) p-values for susceptible isolates are denoted with 
a green check.  
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Chapter III 
 
Digital Pathogen-specific Phenotypic Antibiotic Susceptibility Test Directly 
from Clinical Samples in as Fast as 30 Minutes Using Digital LAMP 
Quantification2 
 
Abstract 
 
Rapid antimicrobial susceptibility testing (AST) is desperately needed for informing 
treatment decisions and preventing the spread of antimicrobial resistance resulting from the 
misuse and overuse of antibiotics. To date, no phenotypic AST exists that can be performed 
within a single patient visit (30 min) directly from clinical samples. Here we show that AST 
results can be obtained by exposing clinical urine samples to an antibiotic for 15 min and 
using digital nucleic acid quantification to measure precisely the phenotypic response of the 
infecting E. coli. We perform this AST method using for analysis both a commercial ~2 h 
digital PCR assay (AUC=0.98), and an ultrafast ~7 min digital real-time loop-mediated 
isothermal amplification (LAMP) assay (AUC=0.96) that we developed. We also 
demonstrate that the rapid digital LAMP assay can be used with SlipChips to determine the 
phenotypic antibiotic susceptibility of E. coli directly from clinical urine samples in less than 
30 min sample-to-answer, including all sample processing and data analysis steps. Such a 
rapid digital AST (dAST), once fully developed and FDA approved for additional pathogens, 
antibiotics, and sample types, would enable rapid clinical decision-making, improve 
management of infectious diseases, and increase antimicrobial stewardship. 
 
Introduction 
                                                 
2 This chapter was submitted for publication with authorship belonging to Nathan G. SchoeppϮ, Travis S. 
SchlappiϮ, Matthew S. Curtis, Slava S. Butkovich, Shelley Miller, Romney H. Humpries, and Rustem 
Ismagilov. “Rapid pathogen-specific phenotypic antibiotic susceptibility testing using digital LAMP 
quantification in clinical samples”, doi: 10.1126/scitranslmed.aal3693. Specific contributions from each 
author are listed at the end of the chapter. 
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Emergence of antibiotic resistance is an impending threat to global health. It is projected to 
cause 10 million deaths and more than $1 trillion (USD) in total economic impact by 2050 if 
left unchecked (1, 2). In order to combat antimicrobial resistance, increase stewardship, and 
improve patient outcomes, healthcare providers need to be able to determine antibiotic 
susceptibility rapidly, and ideally directly at the point of care (POC) (3-6). The need for a 
rapid antimicrobial susceptibility test (AST) to guide antibiotic treatment is recognized by 
all major health organizations, including the Centers for Disease Control and Prevention and 
the World Health Organization (7-11). Urinary tract infections (UTIs) are among the most 
common bacterial infections, accounting for ~8 million primary care visits annually, and are 
almost always treated with antibiotics (12, 13). In the absence of a rapid AST, UTIs are 
among many infections that are treated with second-line antibiotics (e.g. the fluoroquinolone 
ciprofloxacin, cip) instead of first-line antibiotics (e.g. nitrofurantoin, nit) (14). This 
increased use of fluoroquinolones is accompanied by emergence of fluoroquinolone 
resistance, limiting treatment options, which is especially critical in life-threatening cases, 
such as when UTIs progress to sepsis. Thus, UTIs are a specific clinical scenario where an 
inexpensive and rapid (within the ~30 min duration of a patient visit) AST would 
significantly impact patient outcomes and antimicrobial stewardship. No such diagnostic 
currently exists. 
 
Phenotypic AST methods based on culture of the target pathogen are the current gold 
standard, but are too slow (days) to support immediate treatment decisions or to be 
implemented at the POC (15). Genotypic methods, which detect known resistance genes, are 
faster because they do not require a culturing step (16-18). Genotypic methods have shown 
promise in select clinical settings where the presence of a single gene yields high predictive 
value, such as testing for mecA to detect methicillin-resistant Staphylococcus aureus 
(MRSA) (19-21). However, genotypic tests have not been implemented more broadly 
because they are not generalizable to different pathogens or mechanisms of resistance, 
especially in the case of Gram-negative bacteria for which more than 800 resistance genes 
are known for beta-lactam class antibiotics alone (22). 
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An ideal AST would test the phenotypic response of a pathogen to antibiotics (ABX) in a 
pathogen-specific manner and provide an AST answer in under 30 min (23, 24). This is a 
critical bar to meet because if the AST result can be obtained within the timespan of a patient 
visit, then the information can be used to inform treatment and increase antimicrobial 
stewardship at the POC. Additionally, in some infections such as sepsis, accelerated time-to-
treatment is directly correlated with improved patient outcome (25). To achieve this speed, 
the AST method needs to work directly from a clinical sample. Several methods, including 
our previous work (26), have improved the speed of individual steps of the phenotypic AST 
workflow (such as pathogen isolation and identification, antibiotic exposure time, sample 
preparation, readout, etc.), but few of these papers report performing the entire workflow 
from start to finish using a clinical sample. 
 
To date, no phenotypic AST has achieved a sample-to-answer result in less than 30 min 
directly from a clinical sample. The majority of methods under development were validated 
with isolates of pathogens, not with clinical samples (see Supplementary Materials Table 3-
S2 for a quantitative summary of the published state of the art). Among the rapid phenotypic 
AST methods used with clinical samples, one microscopy-based method could detect 
differences in bacterial growth during antibiotic treatment after as few as 6 min of antibiotic 
exposure using isolates, but the total assay time for a clinical sample was 155 min (27). As 
discussed by the authors (27), clinical sample matrices, such as urine, present a challenge for 
rapid microscopy-based ASTs, affecting the speed and sensitivities (required cell 
concentrations) of these assays. Furthermore, identification and differentiation of target 
pathogens from commensal organisms can be challenging if these steps only rely on imaging, 
without the molecular specificity offered by other methods. A microfluidic-based 
microscopy method using isolates (imprecisely referred to in the abstract and the body of the 
paper as clinical samples) reported AST in ~3–4 hours without an identification step and this 
paper estimated that the total assay time from a clinical sample would be 52 hours (28). 
Another microscopy-based method in clinical testing performs identification and AST from 
a positive culture in 5–6 hours, with additional overnight or longer time required to first grow 
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the culture from a clinical sample (29, 30). An electrochemical method was used to 
determine susceptibility in as few as 25 min using non-specific redox markers for reference 
strains (31), but the workflow lacked a pathogen-identification step and the AST was not 
pathogen-specific. Other electrochemical methods are pathogen-specific, but required at 
least 45 min of assay time when using isolates (32). Pathogen-specific electrochemical 
methods have been also used to determine susceptibility from clinical samples, but assay 
times were on the order of hours (33). Methods that perform phenotypic AST by quantifying 
nucleic acids (NA) are promising because they provide molecular specificity, but so far most 
have required long antibiotic exposures (~2 h or more) in addition to the time required for 
measurement, which was as fast as 1.5 h using isothermal amplification (34-36). This 
promise of an NA-based AST was highlighted in a study that used RNA gene expression 
markers and demonstrated antibiotic exposure times as short as 10 min for isolates and as 
short as 30 min for clinical samples, although in that landmark study the total assay time was 
over 23 hours as a result of using slow quantification technology (37). 
 
We have shown previously that the antibiotic exposure time in a phenotypic AST can be 
shortened to 15 min by measuring DNA levels in a digital format (26). That work was 
performed with bacterial UTI isolates, and required a 2 h measurement step using 
commercial droplet digital PCR (dPCR). As explained above, the transition from clinical 
isolates to clinical samples is invariably challenging for phenotypic AST methods, and 
previous work has highlighted these challenges (27, 37, 38). Therefore, in this paper, we 
asked and answered two salient questions: (i) For clinical samples, can digital single-
molecule counting of pathogen DNA still enable phenotypic AST after a short (15 min) 
antibiotic exposure? and (ii) Is there a quantification strategy faster than PCR that can be 
used in a digital format to achieve a pathogen-specific, sample-to-answer phenotypic AST 
within 30 min directly from a clinical sample? 
 
To answer these questions, we developed an ultrafast digital isothermal amplification assay 
to shorten the readout step, a critical requirement of rapid assays. We then demonstrated that 
the entire contiguous sample-to-answer workflow could enable an AST result in less than 30 
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min from a clinical UTI urine sample. Finally, we tested this digital antibiotic susceptibility 
testing (dAST) method with 51 clinical UTI urine samples using both commercial digital 
PCR (dPCR) and the rapid digital LAMP (dLAMP) assay we developed as a measurement 
method. 
 
Results 
 
Key processes and operational space of digital AST (dAST) 
 
A phenotypic AST consists of two key processes: antibiotic (ABX) exposure and 
measurement of the AST marker (in dAST, we measure the concentration of a target NA 
sequence). To meet the demands of a rapid AST, these two processes, plus sample handling, 
must take less than 30 min. The workflow of the dAST method we used in this paper is as 
follows: we aliquoted and diluted a clinical urine sample into two equal volumes of media—
one with an antibiotic and a control without antibiotic—then incubated at 37 °C for 15 min. 
After antibiotic exposure, a target NA sequence (AST marker) was quantified in each sample. 
Then, the ratio of the marker concentrations in the control and antibiotic-treated samples is 
calculated (Fig. 3-1A), defined as the control–treated (CT) ratio. 
 
Antibiotic susceptibility was determined by comparing a CT ratio to a previously determined 
threshold value (susceptibility threshold). Sample pairs that yield a CT ratio that falls above 
this threshold are called susceptible and samples with a ratio below this threshold are called 
resistant. A CT ratio that is higher than the susceptibility threshold indicates that DNA 
replication continued in the control (-ABX) sample, but was slowed or halted in the 
antibiotic-treated (+ABX) sample, indicating that the sample is susceptible to the chosen 
antibiotic. A CT ratio that is lower than the susceptibility threshold indicates that DNA 
replication continued in both the control (-ABX) and antibiotic-treated (+ABX) samples at 
the same rate, indicating that the sample is resistant to the chosen antibiotic (Fig. 3-1A (step 
4)). 
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The time period of the antibiotic exposure step affects the resolution requirements for the 
quantification step: a shorter antibiotic exposure results in a smaller difference in the 
concentration of the target AST marker between antibiotic-treated and control samples. Thus, 
at shorter exposure periods, quantification with higher resolution is required to reliably 
quantify an AST marker. To illustrate the interplay of antibiotic exposure time and required 
measurement resolution, we explored computationally the tradeoff of these three parameters 
(exposure time, required resolution, and DNA replication rate) and made predictions about 
the resolution needed to detect susceptibility. We define this combination of parameters as 
the operational space (Fig. 3-1B). For simplicity, we assumed that for an antibiotic-
susceptible pathogen, DNA replication halts upon exposure to the antibiotic. Under this 
assumption, the DNA replication rate (which differs for different pathogens) directly 
determines the CT ratio at a given ABX exposure time. We also assumed that there was no 
lag phase upon transitioning from urine to liquid media; if there is a lag phase, then the 
requirements for resolution become even more stringent, further emphasizing the need for 
high-precision digital measurements. For example, if the measurement method is limited to 
2-fold resolution (such as in quantitative PCR, qPCR) and the pathogen’s DNA doubles 
every 30 min, then the minimum exposure time necessary to achieve a CT ratio of 2 is 30 
min. If the measurement method can instead resolve a 1.2-fold difference in concentrations, 
then the minimum exposure time decreases to 8 min. Measuring changes in DNA 
concentration with high resolution therefore allows detection of a pathogen’s response to 
antibiotics even faster than cell division time (26). 
 
 
Fig. 3-1. Experimental workflow of the digital AST (dAST) method and computationally 
estimated operational space. (A) The workflow for detecting antibiotic susceptibility by 
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measuring the replication of a specific nucleic acid sequence (AST marker). Samples are 
incubated without and with antibiotics (ABX): control (-ABX) and treated (+ABX) and 
control–treated (CT) ratios are analyzed. (B) Theoretical model that predicts a CT ratio as a 
function of pathogen DNA doubling time and ABX exposure time. Digital counting is 
predicted to enable shorter ABX exposure times than qPCR because it can resolve smaller 
differences in AST marker concentrations. The operational space gained by using digital 
counting compared with quantitative PCR (qPCR) is outlined in red. 
 
Compared with bulk methods (e.g. qPCR), digital quantification can resolve the difference 
between two concentrations with greater precision (26, 39, 40), which in turn has enabled 
shorter antibiotic exposure times (26). Digital quantification achieves higher resolution by 
partitioning target molecules into thousands of compartments such that each compartment 
contains a single molecule. Amplifying each partitioned molecule to a detectable level and 
counting the number of positive compartments at the endpoint yields precise quantification. 
Resolution can be increased (and antibiotic exposure time reduced) by increasing the number 
of digital compartments. However, the benefit of adding more digital compartments 
decreases beyond ~1,000 compartments and additional compartments are better utilized for 
multiplexing of multiple markers or antibiotics. For example, at UTI-relevant concentrations 
of DNA (e.g. 106 copies/mL), 1,000 digital compartments with 1 nL volume each provides 
1.23-fold resolution. Increasing the number of these compartments to 10,000 or 100,000 
(while correspondingly reducing their volumes to 0.1 nL and 0.01 nL each to keep the same 
total number of target molecules) provides 1.18-fold and 1.17-fold resolution, respectively 
(Fig. S2A). In another example, while 10,000 of 1 nL compartments provide 1.08 resolution, 
2,000 of 1 nL compartments provide 1.16 resolution each, enabling a 4-plex dAST (1 control 
and 4 ABX treated samples) to be performed with the same number of wells (Fig. S2C). 
 
We have previously demonstrated that a 15 min exposure step is sufficient to generate 
detectable differences in DNA concentrations between the control and antibiotic-treated 
samples using UTI isolates and four antibiotics commonly prescribed for UTIs (26). For a 
15 min exposure period (which is shorter than even the fastest reported uropathogenic E. coli 
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doubling time (16 min, (41)), we would expect the DNA concentration in the control 
sample to increase 1.4–1.6X (Fig. 1B, green star). Other uropathogenic organisms have 
doubling times of 13 min (K. pneumoniae) 25 min (P. mirabilis) and 29 min (S. 
saprophyticus) (42, 43). Therefore, a 15 min exposure should provide a 1.4–2.2-fold change 
and should also work with this method, though these theoretical estimates would need to be 
confirmed experimentally. These fold changes range are within the resolution of digital 
measurements, but such measurements in the past have taken 90 min or more (44, 45). If the 
total assay time is to remain under 30 min, digital NA quantification must be performed in 
less than 10 min. This assumes sample handling (including NA extraction) of at least 5 min, 
and antibiotic exposure of 15 min. This analysis compelled us to develop a method of digital 
NA quantification that can be performed in less than 10 min, which has never been 
accomplished before. 
 
Digital AST (dAST) in the presence of commensal organisms 
Next we evaluated a factor that may challenge phenotypic ASTs that are run directly on 
clinical samples: the presence of commensal or contaminating organisms that may respond 
differently to the antibiotic compared with the target pathogen. If the measurement method 
cannot differentiate between the response of the target pathogen and commensals, 
susceptibility cannot be determined accurately. NA amplification can be designed to target a 
sequence specific to a potential species of interest. Therefore, we hypothesized that when 
using a pathogen-specific NA target, the CT ratio (and AST call) would not be affected by 
varying levels of commensal bacteria. To test this hypothesis, dAST was performed in the 
presence of Lactobacillus jensenii (Lj), a common commensal bacterium found in urine. An 
E. coli culture (~106 CFU/mL) was mixed with each of three concentrations of Lj (0.1X, 1X, 
and 10X the optical density of the target pathogen) and exposed to the antibiotic 
ciprofloxacin (cip) for 15 min. The response was measured using droplet digital PCR (dPCR) 
and susceptibility of E. coli was determined correctly at all concentrations of the commensal 
organism (Fig. 3-2). 
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Fig. 3-2. Digital antimicrobial susceptibility test (dAST) using droplet digital PCR is robust 
to the presence of high levels of commensal bacteria due to the specificity of nucleic acid 
amplification. (A) A ciprofloxacin-susceptible E. coli isolate and (B) a ciprofloxacin-
resistant E. coli isolate from the urine of patients diagnosed with urinary tract infections 
(UTIs) was exposed to 1.0 μg/mL ciprofloxacin in the presence of varying levels of 
Lactobacillus jensenii (Lj), a common urine commensal. Fold changes relative to time 0 were 
compared and used to determine susceptibility. The susceptibility calls remained unchanged 
at all three concentrations of commensal bacteria. (C) The calls were consistent when 
susceptibility was determined using control–treated (CT) ratios. N = 2 technical replicates 
for each single resistant and susceptible biological sample. Error bars are 98% confidence 
intervals. 
 
Optimization of isothermal amplification (LAMP) 
 
Having confirmed that the dAST method is capable of determining pathogen susceptibility 
in the presence of commensal organisms (Fig. 3-2), we next focused on shortening the 
measurement time from 2 h (using dPCR) to <10 min, to make the total dAST time <30 min. 
Digital LAMP (dLAMP) was investigated first, because it has been demonstrated previously 
by us and others (39, 46-49). However, these dLAMP assays took >45 min and were not 
shown to resolve small differences (~1.5X) in NA concentrations. Fast LAMP reactions 
often show significant background amplification in negative control treatments so we aimed 
to solve this problem as well. 
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We first designed primers and optimized real-time LAMP in bulk solutions to maximize 
amplification speed and specificity (initially, this was taken to mean the absence of 
background amplification with further testing of specificity later in the process). At very high 
NA concentrations, real-time bulk LAMP assays have been reported to be as fast as 5 min 
(18, 50), but at the lower concentrations of a single target molecule present in a single digital 
partition (~1 copy/ nL = 106 copies/mL), amplification takes 10 min or more (51-54). To 
mimic the concentration of template in a single digital partition, we performed our bulk 
optimization experiments at ~106 copies/mL. The pathogen-specific NA sequence we chose 
as the dAST marker was the E. coli 23S rDNA gene because we showed previously that it 
was a reliable marker for DNA replication in the context of AST (26). We did not 
purposefully design these primers to exclude other Enterobacteriaceae pathogens and we 
expected cross-reactivity, which was observed in pilot experiments but remains to be further 
validated. Pan-Enterobacteriaceae primers would be useful for targeting other UTI 
pathogens. BLAST was used to evaluate primer specificity relative to the major families of 
bacteria found in UTIs. 
 
The LAMP optimization process (Fig. 3-3A) consisted of four steps: 1) screening multiple 
LAMP primer sets for speed and specificity 2) screening multiple loop primer pairs with the 
selected primer set from step one for speed and specificity, 3) testing the selected LAMP + 
loop primers with a range of magnesium ion (Mg) concentrations, and 4) selecting the 
optimal amplification temperature from the data obtained in step three. Each parameter was 
tested using a temperature gradient, which proved to be critical to minimizing the time to 
positive (TTP). Of the four tested LAMP primer sets, we selected set B because it showed 
the fastest amplification and no background amplification (Fig. 3-3A (1)). No loop primer 
pair showed significantly earlier TTPs than any other pair, and no pair showed theoretical or 
experimental evidence of primer-dimers, so we arbitrarily chose loop A set (Fig. 3-3A (2)). 
Four concentrations of Mg were tested using the DNA polymerase Bst 3.0. The resulting 
TTPs varied by as much as 11 min depending on the amplification temperature. This 
optimization process resulted in TTPs as fast as ~4–5 min for ~700 target copies in a 6 μL 
amplification volume, with the fastest TTP (4.4 min) obtained using 6 mM Mg at 71 °C. 
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Once LAMP primers and protocols had been optimized, we further tested their specificity 
for the dAST marker. No positive signals were obtained when we ran real-time LAMP using 
L. jensenii (Lj) gDNA, human gDNA, or urine from healthy donors with no symptoms of 
UTI (Fig. 3-3B). When testing clinical UTI samples, a positive signal was only obtained 
when E. coli DNA was present. TTPs ranged from 4–5 min (Fig. 3-3C) for clinical UTI 
samples. We note that using this method (LAMP in a standard well-plate format) to resolve 
a 1.5X difference in concentration would require detecting a difference in TTP of ~8 s, which 
is difficult in practice to perform robustly (39). 
 
 
Fig. 3-3. Real-time LAMP optimization and compatibility with clinical samples. (A) Assay 
optimization protocol used to reduce the time-to-positive (TTP) from 15 min to < 5 min. 
Optimization was performed at a template concentration of ~700 copies/reaction or 0 
copies/reaction (no template control, NTC). A value of 0.5 means no amplification was 
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observed. (B) Real-time fluorescence readout of amplified DNA for UTI samples 
containing E. coli (blue lines), healthy urine samples, samples containing gDNA of 
Lactobacillus jensenii (Lj), and samples containing human (Hs) gDNA (dashed brown lines). 
(C) TTP values for clinical UTI samples containing a range of pathogen concentrations. Error 
bars represent a single standard deviation from the average of technical triplicates. 
 
Digital AST (dAST) using ultrafast single-molecule counting (digital LAMP) 
 
Our next goal was to test whether using this optimized LAMP chemistry in a digital format 
would yield correct antibiotic susceptibility calls, while preserving the speed observed in 
bulk solutions. To accomplish this, the digital LAMP (dLAMP) assay must be able to resolve 
the small changes in NA concentrations that occur after a 15 min exposure to antibiotics, 
despite any heterogeneity in TTPs (the difference in amplification kinetics of individual 
molecules), which has been observed previously (49, 55). We chose to test dLAMP using 
clinical samples because sample matrices might increase the heterogeneity in TTPs and thus 
decrease resolution. Clinical urine samples can contain urea, proteins, blood (containing 
heme as a potent PCR inhibitor), or other cellular components that could interfere with the 
assay. Furthermore, we were concerned that extracellular DNA present in clinical urine may 
affect CT ratios. To eliminate this potential source of error, the dAST procedure that we 
previously developed for isolates (26) was modified to include DNase during the exposure 
step to digest any extracellular DNA (Supplementary Materials). We used the optimized 
LAMP assay (Fig. 3) with SlipChip microfluidic devices in a digital format (56). This 
SlipChip partitioned samples into 1,280 digital compartments. In each compartment, single 
molecules were amplified and counted in real time (55). In a clinical setting, decisions are 
typically made from single assay runs and thus we specifically wished to test whether 
differences in NA concentrations between the control and antibiotic-treated samples could 
be resolved reliably using a single 1,280-well SlipChip for each measurement. 
 
Using dLAMP, most (>80%) single molecules amplified between 4–10 min, as shown by 
the fluorescence curves plotted in Fig. 3-4A,F. As expected, heterogeneity in TTP was 
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observed, likely as a result of the stochasticity of single-molecule amplification (49, 57). 
Despite heterogeneity and matrix effects of clinical urine, we detected a significant difference 
in NA concentration (P = 0.001) after only 5 min of amplification time for the cip-susceptible 
clinical urine sample (Fig. 3-4C). For the cip-resistant sample, no significant difference in 
concentration was detected during the dLAMP assay (P > 0.05) (Fig. 3-4H). In both samples, 
the CT ratios were stable after 6 min and 40 seconds (6.7 min) of amplification (Fig. 3-4D,I), 
were consistent with the ratios obtained by dPCR (Fig. 3-4E,J), and yielded the correct AST 
call. We then repeated this dLAMP assay for one nit-susceptible and one nit-resistant clinical 
urine sample. After 6.7 min of dLAMP amplification time, the CT ratios for both samples 
were stable, and the correct antibiotic susceptibility call was determined (Figure 3-S3). This 
demonstrates that the optimized dLAMP assay yields correct AST calls in only 6.7 min, well 
below the 10 min limit necessary to achieve a 30 min dAST. Further, this result demonstrates 
that because digital counting is ultrasensitive, individual DNA target molecules were 
detected and the DNA concentration could be accurately quantified even after the dilution 
that took place during antibiotic exposure and sample preparation (see Table 3-S3 for full 
range of urine DNA concentrations). 
 
Fig. 3-4. High-resolution single-molecule nucleic acid amplification using ultrafast digital 
LAMP (dLAMP) for digital antimicrobial susceptibility test (dAST) of clinical urinary tract 
infection (UTI) urine samples with antibiotic-susceptible (A–E) and antibiotic-resistant (F–
J) E. coli. (A,F) Real-time fluorescence amplification traces (only 200 of 1,280 traces shown 
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for clarity). NFU = normalized fluorescence units; dotted line = positive threshold; when 
the normalized fluorescence intensity of a compartment crosses the threshold, that 
compartment is counted as positive. (B,G) Time Time-to-positive (TTP) distribution was 
determined by counting the number of compartments that crossed the positive threshold at 
each time point. (C,H) Detected concentrations of the target dAST marker in control and 
antibiotic-treated samples for successive image cycles. Note these curves are distinct from 
amplification curves shown in panels A and F. Grey lines represent 95% confidence 
intervals. (D,I) Detected control–treated (CT) ratios over time. Dashed line indicates 
susceptibility threshold. (E,J) Comparison of CT ratios for droplet digital PCR (dPCR) after 
2 h and dLAMP (after 6.7 min of amplification). 
 
30 min sample-to-answer digital AST (dAST) directly from clinical urine samples 
 
Next, we tested whether the entire dAST workflow (antibiotic exposure, sample preparation, 
measurement, and data analysis) could give the correct AST call in less than 30 min. To 
accomplish this goal, three modifications were made to the dAST method used for Figure 3-
4 (see Materials and Methods). First, the sample-preparation time was shortened from 10 
min to 2 min while maintaining compatibility with dLAMP. Second, in parallel with 
antibiotic exposure of a clinical sample, rapid real-time LAMP was used to confirm the 
presence of E. coli and measure the approximate NA concentration of the dAST marker in 
the sample (Fig. 3-5B). This step provided identification of the pathogen (and could be used 
to select the amount of NAs loaded on the chip to maximize the performance of the digital 
assay), without adding time to the workflow. It also allows one to avoid the AST 
quantification step for samples that do not contain the pathogen, or contain it at levels too 
low to be of clinical significance. Third, the real-time image-analysis software we developed 
previously (55) was modified to calculate the concentrations of the dAST marker in real-time 
from each image, instead of after completion of amplification. After these modifications, the 
sum of all steps, 15 min (exposure) + 2 min (sample preparation) + 6.7 min (readout) was 
equal to a total of ~24 min. However, we also tested that these steps could be combined to 
provide a full sample-to-answer workflow (including all fluid transfer steps and data 
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analysis) in 30 min. We started a timer when an infected clinical urine sample was added 
to media with and without the antibiotic cip. After 29.8 min of total elapsed time (including 
6.7 min of dLAMP amplification time), the software reported the control and treated 
concentrations for the cip-susceptible sample to be significantly different (P = 1.5·10-9), with 
a CT ratio of 1.59. For the cip-resistant sample, no significant difference in concentration 
was reported through the entirety of the dLAMP assay (P > 0.05). At 29.2 min (6.7 min of 
dLAMP amplification time) the CT ratio for the cip-resistant sample was 0.98 (Fig. 3-5D). 
Thus, this result shows how a combination of rapid partitioning, fast isothermal 
amplification, and high-resolution digital measurements enabled antibiotic susceptibility to 
be determined in less than 30 min. 
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Fig. 3-5. Demonstration of a sample-to-answer antibiotic susceptibility test in less than 30 
min using one resistant and one susceptible clinical UTI sample. (A) A clinical UTI sample 
was added to media with and without the antibiotic ciprofloxacin and incubated for 15 min. 
(B) During the antibiotic exposure step, the optimized bulk LAMP assay was performed on 
nucleic acids prepared from an aliquot of the urine sample. Amplification indicated the 
presence of E. coli at clinically-relevant levels. (C) Aliquots of the control and antibiotic-
treated samples were added to extraction buffer; nucleic acids were prepared for 
quantification using digital LAMP; and samples were rapidly partitioned using SlipChips. 
(D) Digital LAMP was monitored in real time and a susceptibility call determined after 6.7 
min of amplification; data for one resistant and one susceptible sample are shown. NFU = 
normalized fluorescence units. Grey lines represent 95% confidence intervals. 
 
Digital AST (dAST) using clinical samples 
 
Having established that the dAST method could be performed sample-to-answer in less than 
30 min, we next tested this method with 51 clinical samples to evaluate its performance. A 
15 min antibiotic exposure and NA extraction were performed on a total of 51 clinical UTI 
samples containing ≥ 5·104 CFU/mL E. coli: 17 cip-susceptible, 14 cip-resistant, 18 nit-
susceptible, and 5 nit-resistant. Three clinical samples were tested separately with both cip 
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and nit, for a total of 54 tests. In this manuscript, we focus on categorical agreement of our 
binary susceptibility determination (susceptible or resistant) and did not test intermediate 
samples due to the variability in minimum inhibitory concentration (MIC) determination of 
gold-standard AST methods (58, 59). It is common to only challenge new AST methods 
against susceptible and resistant samples (33, 34, 60) and this excludes a small fraction of 
samples for cip (61). To ensure that there were no special issues with bacteria with 
intermediate MICs, we used the dAST method on a small set of cip-intermediate isolates to 
better understand its performance (see Supplementary Materials, Figure 3-S4). 
 
We quantified the DNA AST marker of the control and treated extractions on all 54 samples 
with both dPCR and dLAMP. For each sample, the CT ratio was calculated and compared 
to a susceptibility threshold (1.10, determined in (26)) to classify samples as resistant or 
susceptible (Fig. 3-6A). Discordant CT ratios were observed for five samples when 
compared with the gold-standard broth microdilution method. As is commonly done, we re-
ran discordant samples to resolve the discrepancy; however, our protocols and the potential 
for clinical samples to age disallowed many re-runs. Three of these five discordant samples 
were re-run and the second run CT ratio was averaged with the CT ratio from the first run to 
obtain a consensus value of the CT ratio (Samples #28, #29, #36 in Table 3-S1). We were 
unable to perform a second dAST assay on the other two discordant samples on the same 
day; rather than risk confounding effects due to aging of clinical samples on a different day, 
we did not rerun these samples and left them as errors that our method incurred relative to 
the gold-standard (Samples #22 and #30 in Table 3-S1). As a sanity check, we also reran one 
sample that was not discordant (Sample #122 in Table 3-S1). 
 
With 1.10 as the susceptibility threshold for dPCR measurements, the dAST method returned 
51 correct calls (94.4% categorical agreement), 2 very major errors for 19 resistant samples 
(10.5%), and 1 major error for 35 susceptible samples (2.9%). As 1.10 was a threshold based 
on experiments with isolates (26), we then generated a receiver operating characteristic 
(ROC) curve to inform the optimal threshold for clinical UTI samples (Fig. 3-6B). ROC 
curves show the ability of a diagnostic test to discriminate positives and negatives based on 
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a threshold: values below the threshold are called negative (e.g. a resistant AST call) and 
values above the threshold are called positive (e.g. a susceptible AST call). The area under 
the curve (AUC) for the generated ROC was 0.98. Using the optimal threshold given by the 
ROC curve (1.14), 53 of 54 dAST calls matched the gold-standard AST call (98.1% 
categorical agreement) with 1 very major error (5.3%) and 0 major errors (0%). 
 
We also used digital LAMP to quantify the same samples. The CT ratios at 6.7 min were 
calculated and plotted in Fig. 3-6C, along with the ROC curve for digital LAMP (Fig. 3-6D). 
With 1.10 as the susceptibility threshold for dLAMP measurements at 6.7 min, the dAST 
method returned 51 correct calls (94.4% categorical agreement), 2 very major errors for 19 
resistant samples (10.5%), and 1 major error for 35 susceptible samples (2.6%). The AUC 
for the generated ROC curve was 0.96. Using the optimal threshold given by the ROC curve 
(1.11), 52 of 54 dAST calls matched the gold-standard AST call (96.3% categorical 
agreement) with 1 very major error (5.3%) and 1 major error (2.9%). 
 
These data show that although the optimal thresholds derived from ROC curves (1.14 for 
dPCR and 1.11 for dLAMP) slightly improve the categorical agreement, they are consistent 
with the threshold established for isolates (1.10, (26)) and are consistent with each other. It 
is also evident that quantifying DNA with digital LAMP at 6.7 min produces similar CT 
ratios and antibiotic susceptibility calls as dPCR. 
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Fig. 3-6. Digital antimicrobial susceptibility test (dAST) directly from clinical samples using 
droplet digital PCR (dPCR) and digital LAMP (dLAMP) for quantification. (A/C) Antibiotic 
susceptibility of 51 clinical E. coli UTI samples was determined using the control–treated 
(CT) ratio after 15 min of exposure to two antibiotics, nitrofurantoin and ciprofloxacin (35 
susceptible, 19 resistant, and three samples tested for both antibiotics). Nucleic acid 
concentrations were quantified with dPCR (A) and dLAMP (C). (B/D) Receiver operating 
characteristic (ROC) curves for the dAST method as measured by dPCR (B) and dLAMP 
(D). 
 
Discussion 
 
Here, we solved three problems that previously prevented the determination of phenotypic 
antibiotic susceptibility in less than 30 min from a clinical sample. First, we used digital 
quantification of a DNA marker to shorten the antibiotic exposure time to 15 min for clinical 
samples. Second, we showed that dAST is robust to the presence of commensal bacteria and 
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clinical urine matrices. Third, we developed and optimized a rapid, high-resolution 
measurement method for quantifying NA targets that shortens the measurement step to less 
than 10 min. 
 
As discussed above, the introduction of commensal or contaminating organisms and clinical 
sample matrices to diagnostic workflows can cause major challenges in the development and 
translation of laboratory methods. It is therefore critical to prove that AST methods are 
compatible with clinical samples as soon as feasible. Here we have shown the dAST method 
is compatible with a wide range of urine matrices. Urine color of samples included colorless, 
yellow, dark yellow, and brown. pH ranged from <5.0–8.0. Protein concentrations ranged 
from 0.0~1.0 mg/mL (62). Additionally, red and white blood cell counts were as high as >106 
cells/mL each in separate samples, and several samples had elevated levels of glucose. One 
sample contained 3·104 CFU/mL of a lactose-positive Gram-negative rod bacterium in 
addition to the infecting E. coli. While this study warrants more extensive follow-up 
investigation into more detailed correlations between urine composition and dAST speed, 
and does not establish whether or not this method would work in a more complex matrix like 
whole blood, this study indicates that dAST is compatible with a wide range of urine matrices 
and contaminants in clinical samples. 
 
The digital LAMP assay developed here was capable of amplifying single target DNA 
molecules in less than 5 min. Despite the heterogeneity of single-molecule amplification 
times, high-resolution measurements were obtained even before all partitions with a target 
DNA molecule had amplified (~6.7 min). This makes dLAMP a strong tool for real-time, 
high-resolution, rapid measurements of NA, which increases the information gained in 
shorter times. Rapid, high-resolution measurements will also be invaluable for many other 
important assays, such as viral load measurements and genotyping (49, 63, 64). LAMP was 
chosen for translation to a digital format because it is a well-established amplification 
chemistry (50, 65, 66) with several readout methods (67-70). If necessary, other 
amplification chemistries—including NASBA, RPA, NEAR, HDA—could be tested and 
optimized for a digital format and used to measure a marker of interest. Additionally, we 
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show the LAMP assay is compatible with a rapid, one-step extraction method, which 
dramatically reduces sample preparation time. Due to the speed of extraction and 
amplification, the same LAMP assay can be used in a real-time bulk format for rapid 
pathogen identification in parallel with the 15 min antibiotic exposure step. This step, 
completed in <10 min (including sample preparation), did not extend the total assay time but 
provided two critical pieces of information prior to digital quantification: (i) whether a 
sample is infected with the pathogen of interest and (ii) whether a sample contains 
concentrations of the pathogen commensurate with levels found in UTI infections. UTI-
positive samples gave TTP values of 4–5 min (corresponding to ~105–106 DNA copies/mL, 
N = 7, Fig. 3-3C), whereas clean healthy urine samples remained negative for at least 20 min 
(N = 5, Fig. 3-3B). This specificity is critical in working with clinical samples, because it 
enables the dAST to provide information specific to the pathogens of interest rather than 
commensals, contaminating organisms, or mixtures of pathogens (although such mixtures 
have not been tested here). In addition, the digital LAMP used to calculate CT ratios and 
determine susceptibility was informative for estimating pathogen concentration in the urine 
sample (see Table 3-S3). 
 
The dAST method described herein was demonstrated with a specific scenario and thus there 
are inherent limitations to the extrapolations we can make to other pathogens and antibiotics. 
These limitations will guide future work in this area. We demonstrated dAST using a single 
clinical sample set of UTI urine samples infected with E. coli (E. coli causes 80% of UTIs). 
This is similar to other studies at this stage of technology development (71-73); multiple 
clinical sets will be run in the future. Ciprofloxacin was chosen because it has become one 
of the most commonly prescribed antibiotics for UTIs, despite being a second-line therapy 
that should be preserved for more severe cases (12, 13, 74). Nitrofurantoin was chosen 
because it is the recommended treatment for acute uncomplicated cystitis (6). Nit is a highly 
effective first-line therapy (antibiotic) that is often overlooked due to a lack of susceptibility 
data. The lack of AST data becomes especially important because nit is sometimes used a 
prophylactic treatment for recurrent UTIs and, despite its effectiveness, is not used to treat 
acute cases due to susceptibility concerns (12). Multiplexing with more pathogens and 
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antibiotics in a blinded study is an important next step and, if successful, would further 
validate and prove the clinical utility of this rapid dAST assay. Other UTI pathogens may 
have slower growth rates and smaller differences in control and treated concentrations (Fig. 
3-1B); however, these differences are theoretically resolvable with digital NA quantification. 
Furthermore, alternative dAST markers might yield larger control–treated ratios after shorter 
antibiotic exposure times. In particular, changes in RNA in response to antibiotic exposure 
have been shown to be both large and fast (37) and should be rapidly discernable with digital 
methods such as the ones described here. For example, we have demonstrated quantification 
of viral RNA on digital SlipChips (64, 75), including on a 5-plex chip for multiplexed 
measurements. Such multiplexed measurements (with designs properly adjusted for the 
desired level of multiplexing and resolution, Fig. 3-S2) could be useful for analyzing 
combinations of RNA markers (37). Additionally, RNA markers (37) and alternative DNA 
markers (26) may be required for antibiotics with different mechanisms of action (e.g. beta 
lactams not tested here but described previously (26) to achieve a 30 min sample-to-answer 
dAST. Pathogen concentration is also a consideration when working with clinical samples. 
Quantifying NAs with high resolution is challenging if the NA concentration drops below 
the optimal dynamic range of the system. For example, in sepsis, the concentration of 
pathogens in blood can be as low as ~1–10 CFU/mL (76). While blood cultures (overnight 
or longer) are currently used to increase the concentration of pathogens, they are too slow to 
inform the initial treatment as each additional hour of delayed treatment in sepsis results in a 
7.6% increase in mortality (25), emphasizing the need for rapid AST. Performing dAST in 
cases of sepsis therefore requires overcoming the major challenge of low concentrations of 
pathogens and will require alterations to the methodology, such as addition of a pathogen-
concentrating step prior to antibiotic exposure, not tested here. Lastly, we have not tested 
dAST against heteroresistant microbial populations. While these have been documented in 
Gram-positive organisms (77), they are not common in Gram-negative organisms. 
 
We have streamlined many aspects of the workflow for the dAST demonstration described 
in this paper, and believe this workflow can be performed by trained personnel in diagnostic 
laboratories. However, because this process requires several pipetting and handling steps, 
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operator error is possible. We anticipate that dAST, once developed and validated for 
multiple pathogens and antibiotics and cleared by regulatory agencies, would have the 
greatest impact on antibiotic stewardship if it can be performed by minimally trained 
personnel at the POC (in a CLIA-waived format in the U.S.). Therefore, the dAST workflow 
needs to be integrated into an inexpensive, simple-to-use device operated with inexpensive 
equipment. Additionally, such an integrated dAST device would increase throughput and 
reduce the potential biohazard risks from several open pipetting steps, which are a limitation 
of our current protocol. This integrated device has not been demonstrated here, but should 
be feasible because all steps of the dAST workflow (basic heating and mixing steps, digital 
quantification) are straightforward. Isothermal digital quantification can be performed using 
a range of technologies and amplification chemistries (39, 46, 48, 63, 78), including 
SlipChips, which are compatible with untrained users (79) and can be read out with optics as 
inexpensive as a cell phone camera (39, 70). Whereas reusable glass SlipChips, used by us 
in the past, required cleaning (75) disposable injection-molded SlipChips further simplify the 
workflow. Furthermore, the SlipChip platform supports multiplexed digital measurements 
(44), which is desired to perform AST on multiple antibiotics and/or pathogens 
simultaneously. Finally, the robustness of isothermal digital amplification to temperature, 
imaging conditions, reaction time (39), sample preparation methods (80, 81), and inhibitors 
(82-84) could further simplify the instrument requirements. This rapid digital AST (dAST), 
if fully developed and validated for additional microorganisms, antibiotics, and sample types, 
and transitioned to a CLIA-waivable POC device and FDA approved, would enable rapid 
clinical decision-making, improve management of infectious diseases, and increase 
antimicrobial stewardship. 
 
Materials and Methods 
 
Experimental design 
 
The objective of this study was to develop a rapid phenotypic antibiotic susceptibility test 
(AST) using digital NA quantification. The two key hypotheses of this work were: i) 15 min 
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of antibiotic exposure can cause sufficient differences in pathogen-specific DNA 
concentrations between control and antibiotic-treated samples such that a high-resolution 
digital quantification measurement method (e.g. dPCR) can reliably detect a difference in 
NA concentrations for a susceptible sample and ii) a rapid digital LAMP assay can resolve 
these small differences in NA concentration in less than 10 min. To test the first hypothesis, 
51 clinical samples were tested with the dAST method (three samples run with both 
antibiotics for a total of 54 antibiotic-susceptibility calls) and the results were compared to 
gold-standard broth microdilution. Clinical UTI samples with E. coli as the pathogen of 
interest were chosen as a test case for the dAST method using one first-line antibiotic 
(nitrofurantoin, nit) and one second-line antibiotic (ciprofloxacin, cip). To test the second 
hypothesis, the rapid digital LAMP assay we developed was compared with a commercial 
dPCR system for calculating CT ratios and determining antibiotic susceptibility from clinical 
UTI samples. 
 
Theoretical analysis 
 
To explore the tradeoffs among antibiotic exposure time, the growth rate of the bacteria in 
question, and the required resolution of the measurement method, we developed a simple 
model to inform optimal AST methods when DNA replication is used as the differentiating 
marker between susceptible and resistant bacteria. We assumed that i) a sample containing 
bacteria with an initial concentration of a specific NA sequence, C0 [mol/L], has a DNA 
doubling time of tdouble [min] when incubated in media for tinc [min], ii) an antibiotic-
susceptible bacteria sample incubated in media with antibiotics does not grow at all, and iii) 
antibiotic-resistant bacteria grow at the same rate with and without antibiotics. 
 
Under these assumptions, the ratio of the NA concentrations of a control sample (Ccontrol) 
compared to an antibiotic-treated sample (CABX)—the control–treated ratio (CT ratio)—after 
a certain time of antibiotic exposure (tinc) would be: 
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𝐶𝐶𝐶𝐶 𝑟𝑟𝑟𝑟𝑡𝑡𝑟𝑟𝑟𝑟 = 𝐶𝐶𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐(𝑡𝑡𝑐𝑐𝑐𝑐𝑐𝑐)
𝐶𝐶𝐴𝐴𝐴𝐴𝐴𝐴(𝑡𝑡𝑐𝑐𝑐𝑐𝑐𝑐) = 𝐶𝐶0 ∙ 2𝑐𝑐𝑖𝑖𝑛𝑛𝑛𝑛/𝑐𝑐𝑑𝑑𝑑𝑑𝑢𝑢𝑑𝑑𝑑𝑑𝑑𝑑𝐶𝐶0 = 2𝑐𝑐𝑖𝑖𝑛𝑛𝑛𝑛/𝑐𝑐𝑑𝑑𝑑𝑑𝑢𝑢𝑑𝑑𝑑𝑑𝑑𝑑  
 
Plotting CT ratio as a function of tinc and tdouble yields Fig. 3-1B. Typically, qPCR is capable 
of resolving 2-fold differences in concentration, whereas digital PCR (dPCR) can resolve as 
low as 1.2-fold differences in concentration (40). Due to the higher resolving power of dPCR, 
phenotypic AST can be performed with shorter antibiotic exposure times than if qPCR was 
used as the measurement method. 
 
Digital AST (dAST) in the presence of commensal bacteria 
 
Antibiotic-susceptible and antibiotic-resistant isolates of E. coli (Ec) from patients diagnosed 
with urinary tract infections (UTIs) were treated separately with (+ABX) and without (-
ABX) antibiotics in the presence of varying concentrations of Lactobacillus jensenii (Lj), 
also isolated from a clinical UTI urine sample. Three concentrations of Lj were spiked into 
clinical urine samples: 0.1X, 1X, and 10X relative to the concentration of E. coli. 
Concentrations of Ec and Lj were determined by measuring optical density at 600 nm. 
Samples were exposed to 1 µg/mL cip for a total of 30 min under the same conditions as 
described previously (26). After 0, 15, and 30 min of exposure, a 10 µL aliquot of the sample 
was removed and added to 90 µL of QuickExtract DNA extraction solution (Epicentre, 
Madison, WI, USA). Target DNA from each extraction was quantified using droplet digital 
PCR (dPCR) as described previously (26). The fold change in the concentration of target 
DNA relative to time 0 in the control and antibiotic-treated samples after 15 min of antibiotic 
exposure was compared (Fig. 3-2A,B). The significance of this difference is measured by 
the p-value as described previously (26). The CT ratios at 15 min (Fig. 3-2C) were calculated 
as described in Results (“Key processes and operational space of digital AST (dAST)”). 
 
The primers used for all dPCR amplification experiments target the 23S gene of the 
Enterobacteriacea family (26). The concentrations of components in the dPCR mix used for 
these experiments and all subsequent dPCR experiments for this manuscript are as follows: 
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1X QX200 ddPCR EvaGreen Supermix (Bio-Rad, Hercules, CA, USA), 500 nM forward 
primer, and 500 nM reverse primer. The NA extraction composed 10% of the final volume 
in the dPCR mix. The remaining volume was nuclease-free water (NF-H2O). 
 
Rapid loop-mediated isothermal amplification (LAMP) 
 
LAMP primer optimization experiments (Fig. 3-3A, steps 1–2) were performed on a Roche 
LightCyler 96 using the SYBR Green I channel for readout, 6 µL reaction volumes, and the 
following concentrations of reagents: 20 mM Tris-HCl pH 8.8, 50 mM KCl, 10 mM 
(NH4)2SO4, 0.1% Tween-20, 1.4 mM dNTPs, 2 µM Syto-9, 400 U/mL Bst 2.0, ~700 
copies/µL E. coli gDNA, and 8 mM MgSO4. All samples were run across a temperature 
gradient spanning 60 – 72 ˚C. 
 
The experiments optimizing magnesium concentration (Fig. 3-4A, step 3) were performed 
using the same protocol as above with the following concentrations of reagents: 20 mM Tris-
HCl pH 8.8, 150 mM KCl, 10 mM (NH4)2SO4, 0.1% Tween-20, 1.4 mM dNTPs, 2 µM Syto-
9, 360 U/mL Bst 3.0, ~700 copies/µL E. coli gDNA, and variable concentrations of MgSO4 
(Fig. 4A). All samples were run across a temperature gradient spanning 60–74 ˚C. 
 
Primer concentrations were kept constant in all experiments: 1.6 µM FIP/BIP, 0.2 µM 
FOP/BOP, and 0.4 µM loopF/loopB (when included). The final selected primer set was as 
follows: GGCGTTAAGTTGCAGGGTAT (FOP), TCACGAGGCGCTACCTAA (BOP), 
CGGTTCGGTCCTCCAGTTAGTGTTTTCCCGAAACCCGGTGATCT (FIP), 
TAGCGGATGACTTGTGGCTGGTTTTTCGGGGAGAACCAGCTATC (BIP), 
ACCTTCAACCTGCCCATG (LoopF), GTGAAAGGCCAATCAAACC (LoopB). 
 
Identification and specificity experiments were performed using the same concentration of 
reagents as the experiments to optimize MgSO4 concentration, but were run with 5 mM 
MgSO4. Although 6 mM MgSO4 yielded the fastest TTP, 5 mM MgSO4 was used in 
subsequent experiments in order to minimize the risk of background amplification. We have 
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not observed background amplification with the primers described here, but other primer 
sets are sensitive to MgSO4 concentration. The optimal TTP using 5 mM MgSO4 was only 
12 s slower than when using 6 mM MgSO4. 
 
BLAST was used to evaluate primer specificity against the families Enterobacteriaciae, 
Staphylococcaceae, and Enterococcaceae. The specificity of the LAMP primers targeting 
the E. coli 23S rDNA gene was tested against human genomic DNA (Hs gDNA), 
Lactobacillus jensenii genomic DNA (Lj gDNA), urine from healthy donors, and water (Fig. 
4A,B). Hs gDNA was tested at 0.002, 0.02, and 0.2 ng/µL final reaction concentration as 
measured using a NanoDrop 2000c (Thermo Fisher Scientific, Waltham, MA, USA). Lj 
gDNA was tested at final reaction concentrations of 0.16, 0.8, and 1.6 ng/µL, as measured 
using a NanoDrop 2000c. Urine from healthy donors was run at 10% final reaction volume. 
Real-time LAMP amplification was performed using a range of concentrations of E. coli 
gDNA (Ec gDNA) prepared from clinical UTI urine samples and quantified using droplet 
digital PCR (Fig. 3-3C). 
 
Digital AST (dAST) using clinical UTI samples 
 
We obtained clinical urine samples under approved IRB protocols in place at the University 
of California Los Angeles Clinical Microbiology Laboratory (UCLA CML). Samples were 
de-identified before being transported to Caltech. Samples were stored in Vacutainer Plus 
C&S Boric Acid Sodium Borate/Formate Tubes (BD, Franklin Lakes, NJ, USA), transported 
at ambient temperature, and stored at 4 °C once received at Caltech. Urine samples were 
from otherwise healthy patients suspected of having a UTI (based on urinalysis results). The 
presence of E. coli was confirmed by the UCLA CML, and MICs determined as described 
previously (26). Urine samples were selected for dAST analysis based on the determined 
MIC of the infecting E. coli. Samples were considered cip-susceptible if the determined MIC 
≤ 0.25 µg/mL and considered cip-resistant if the MIC ≥ 4 µg/mL. Samples were considered 
nit-susceptible if the MIC ≤ 16 µg/mL and nit-resistant if the MIC ≥ 128 µg/mL. Viable 
bacteria are a requirement of phenotypic ASTs. Non-viable samples were excluded if a 
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decrease in DNA concentration was observed (indicating digestion of DNA from non-
viable cells). If the change in DNA concentration was not easily discernible by dPCR, DNA 
concentration at 30 min. was measured to determine whether the sample was viable (DNA 
concentration increased at 30 min) or non-viable (DNA concentration decreased at 30 min). 
 
Before the start of each experiment, urine (as received, still containing boric acid) was 
warmed to 37 °C over 30 min to mimic the temperature of fresh urine samples. At the start 
of each dAST experiment (t=0), warmed urine was added to media with (+ABX) and without 
(-ABX) antibiotics to initiate DNA replication and begin exposure. This addition to media 
dilutes the boric acid present in the transport media, allowing bacterial replication to proceed. 
The final 500 μL sample mixture in the control and treated tubes contained 250 μL BHI 
(Becton Dickinson, Franklin Lakes, NJ, USA), 25 μL DNase I (New England Biolabs, 
Ipswich, MA, USA), 5 μL DNase buffer (100 mM Tris-HCl, 25 mM MgCl2, and 5 mM 
CaCl2), an aliquot of the urine, with the remaining volume NF-H2O. 1 µg/mL cip or 16 
µg/mL nit was added to the +ABX sample, with an equal volume of NF-H2O (in the case of 
cip) or dimethylformamide (in the case of nit) added to the control sample (-ABX). Antibiotic 
concentrations were chosen based on our previous work with isolates (26) and are near CLSI 
and EUCAST breakpoints. 10 μL aliquots of urine were added to the control and treated 
tubes in the case of cip treatment. 25 μL aliquots were used in the case of nit treatment. This 
was done following the observation that higher concentrations of urine matrix sometimes 
showed cip-neutralizing effects (data not shown). Samples were shaken at 750 rpm at 37 °C 
for 30 min. After 0, 15, and 30 min of exposure, 10 μL aliquots of the control and treated 
samples were removed and added to 90 μL of QuickExtract DNA Extraction Solution. The 
extracted samples were heated according to a modified version of the manufacturer's protocol 
(65 °C for 6 min, 95 °C for 4 min, chilled on ice), vortexed, and centrifuged. Next, 5 μL of 
each extraction was added to 45 μL ddPCR mix and quantified using dPCR. If the DNA 
concentration of the sample was too high, template was diluted in NF-H2O and dPCR was 
re-run. CT ratios were then calculated (see above). If the dAST call did not match the gold-
standard AST call, then the sample was re-run several hours later on the same day. For the 
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four samples that were re-run, only the second set of NA extractions were quantified by 
dLAMP. 
 
Rapid digital LAMP (dLAMP) 
 
Clinical urine samples were treated with and without 1 µg/mL cip or 16 µg/mL nit for 15 
min and nucleic acids extracted as described above. The dLAMP mix consisted of 20 mM 
Tris-HCl pH 8.8, 150 mM KCl, 10 mM (NH4)2SO4, 0.1% Tween-20, 1.4 mM dNTPs, 1X 
EvaGreen (Biotium, Fremont, CA, USA), 360 U/mL Bst 3.0, 1X RNase Cocktail 
(ThermoFisher, Waltham, MA, USA), 5 mM MgSO4, and 1 mg/mL BSA prepared in NF-
H2O. Aliquots of NA extractions composed 10% or 20% of the final volume in the dLAMP 
mix. Two aliquots of dLAMP mix containing equal volumes of NA extractions from the 
control and treated samples were simultaneously loaded into two separate SlipChip devices. 
The top piece of each SlipChip was slipped, which partitioned the solution into 1,280 3-nL 
compartments (lab made glass SlipChips) or 5,376 2.4-nL compartments (injection molded 
plastic SlipChips) (see Supplementary Materials). The SlipChips were then placed onto the 
thermal cycler of a digital real-time imaging instrument and incubated at 72 °C for 20 min 
(55). Amplification time was recorded starting from when the SlipChips reached 69 °C (as 
measured using a temperature probe). 
 
Images were taken either every 20 s or every 30 s and the fluorescent intensity was measured 
for each compartment (Fig. 3-4A). Wells that showed liquid movement or bubbles were 
excluded form analysis. The concentration of the target was calculated using Poisson 
statistics and was based on the number of “positive” compartments that exceeded the 
fluorescence intensity threshold (calculations were performed for time points where 13 or 
more compartments were positive). The concentration of the control and treated samples was 
calculated in real-time, along with a p-value representing the probability that the ratio of 
concentrations being greater than 1.10 was a result of random chance (Fig. 3-4D). If P < 
0.05, we can be reasonably certain that the bacteria are susceptible to the antibiotic. If the p-
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value remains > 0.05, we can be reasonably certain that the bacteria are resistant to the 
antibiotic. 
 
Sample-to-answer digital AST (dAST) in less than 30 min 
 
Clinical urine samples were treated with (“treated”) and without (“control”) 1 µg/mL cip for 
15 min as described above. After 0 and 15 min, a 20 μL aliquot of each sample was added to 
80 μL of QuickExtract DNA Extraction Solution (Epicentre). The two samples were then 
heated at 65 °C for 1 min followed by 98 °C for 1 min, after which they were chilled by 
incubation on an ice block for 30 s, vortexed, and centrifuged. 
 
In parallel with the 15 min antibiotic exposure step, we used the semi-quantitative ability of 
qLAMP to predict the appropriate dilution factor for our 1,280-well digital SlipChips. A 2 
μL aliquot from each of the control and treated DNA extractions from time 0 were added to 
8 μL LAMP mix. The samples, along with 2 standards with known DNA concentration 
(S1=128.5 copies/µL and S2=766.0 copies/µL), were then incubated at 72 °C for 5 min on a 
Roche LightCycler 96 and fluorescent traces were monitored in real-time. If the TTP of the 
average of the samples was earlier than the TTP of S1, then 3 μL of the NA aliquot extracted 
at 15 min were added to 24 μL of dLAMP mix, along with 3 μL of NF-H2O. If the TTP of 
the sample was between the TTPs of S1 and S2, then 6 μL of the 15-min NA extraction was 
added to 24 μL of dLAMP mix, with no additional NF-H2O added. This step was completed 
within the 15 min of antibiotic exposure. In the experiments with both antibiotic-resistant 
and -susceptible samples (Fig. 3-5), the TTP was earlier than the TTP of S1. 
 
After semi-quantification and mixture of the dLAMP mix with template, the dLAMP 
solutions were pipette-mixed, loaded into SlipChips, partitioned into 1,280 compartments, 
and placed on the thermal cycler of a digital real-time imaging instrument at 72 °C. 
 
Images were taken every 30 s and the fluorescence intensity was measured for each 
compartment (Fig. 3-5D). The concentration of the dAST marker was calculated using 
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Poisson statistics and was based on the number of compartments that had exceeded a 
fluorescence intensity threshold. The concentration of the control and treated samples was 
calculated in real-time by modifying the National Instruments LabView software previously 
developed (55). We calculated a p-value representing the probability that the control 
concentration was greater than 1.10X the treated concentration merely by random chance in 
real-time as each image was processed. 
 
Statistical analysis 
 
Poisson statistics were used to calculate the 95% or 98% confidence interval of the NA 
concentration for each digital measurement (44). To calculate the error in fold change we 
used standard error propagation methods (85). With 𝜆𝜆 as a concentration and 𝜎𝜎 the standard 
deviation, the equation is: 
𝜎𝜎𝑐𝑐𝑎𝑎𝑐𝑐𝑐𝑐𝑐𝑐 =  ��𝜎𝜎𝜆𝜆2𝜆𝜆1 �2 + �𝜆𝜆2 ∙ 𝜎𝜎𝜆𝜆1𝜆𝜆12 �2 
P-values to compare digital NA concentrations were calculated with a one-tailed Z test 
asking if the control NA concentration (𝜆𝜆𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐) was 1.10X higher than the treated NA 
concentration (𝜆𝜆𝐴𝐴𝐴𝐴𝐴𝐴) (26, 44): 
𝑍𝑍 = ln(𝜆𝜆𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐) − ln(1.10 ∙ 𝜆𝜆𝐴𝐴𝐴𝐴𝐴𝐴)
�𝜎𝜎ln(𝜆𝜆𝑛𝑛𝑑𝑑𝑛𝑛𝑢𝑢𝑐𝑐𝑑𝑑𝑑𝑑)2 + 𝜎𝜎ln(𝜆𝜆𝐴𝐴𝐴𝐴𝐴𝐴)2  
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Supplementary Materials 
 
Table 3-S1. Clinical samples used in this study. Clinical urinary tract infection (UTI) urine 
samples tested for ciprofloxacin (cip) or nitrofurantoin (nit) susceptibility testing by gold-
standard broth microdilution and by digital AST (dAST). Nucleic acids were quantified with 
both digital PCR (dPCR) and digital LAMP (dLAMP). Sample reruns (indicated by a “(2)”) 
were performed several hours later on the same day when the control-treated ratio was 
discordant with the gold-standard AST call (CT ratio > 1.10 for a resistant sample or < 1.10 
for a susceptible sample). S = antibiotic-susceptible; R = antibiotic-resistant; *major error; 
**very major error. 
Caltech 
Sample 
# 
UCLA ID # 
Description 
 (Color, Turbidity) 
ABX 
MIC 
(μg/mL) 
Gold-
standard 
AST call 
CT Ratio 
(dPCR) 
dAST 
call 
(dPCR) 
CT Ratio 
(dLAMP, 
6.7 min) 
dAST call 
(dLAMP) 
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1 15-31A-020 red, clear nit <16 S 1.48 S 1.64 S 
2 15-31A-022 light yellow, clear cip <=0.25 S 1.44 S 1.34 S 
3 15-31A-025 light yellow, clear nit <16 S 1.33 S 1.33 S 
4 15-31A-026 light yellow, clear nit <16 S 1.36 S 1.35 S 
5 15-31A-027 light yellow, clear nit <16 S 1.25 S 1.24 S 
6 15-31A-031 colorless, clear cip >=4 R 1.09 R 0.95 R 
6 15-31A-031 colorless, clear nit 256 R 0.95 R 0.77 R 
7 15-31A-039 light yellow, clear cip >=4 R 0.99 R 0.84 R 
8 15-31A-040 light yellow, clear nit 128 R 1.06 R 1.09 R 
9 15-31A-042 dark yellow, clear cip <=0.25 S 1.92 S 1.83 S 
10 15-31A-043 light yellow, clear cip <=0.25 S 1.66 S 1.85 S 
10 15-31A-043 light yellow, clear nit 128 R 0.91 R 0.92 R 
11 15-31A-049 light yellow, clear cip >=4 R 0.96 R 1.04 R 
12 15-31A-050 dark yellow, cloudy cip >=4 R 0.88 R 0.96 R 
13 15-31A-051 light yellow, cloudy cip >=4 R 0.98 R 0.97 R 
14 15-31A-054 light yellow, cloudy cip <=0.25 S 1.42 S 1.48 S 
15 15-31A-056 light yellow, cloudy nit 256 R 1.09 R 1.106 S** 
16 15-31A-060 light yellow, cloudy cip <=0.25 S 1.83 S 1.31 S 
17 15-31A-063 yellow, cloudy cip <=0.25 S 1.28 S 1.111 S 
18 15-31A-066 yellow, cloudy cip >=4 R 0.85 R 0.80 R 
19 15-31A-067 light yellow, cloudy cip >=4 R 0.82 R 0.59 R 
20 15-31A-068 light yellow, cloudy cip >=4 R 0.84 R 0.57 R 
21 15-31A-071 light yellow, cloudy cip >=4 R 1.04 R 0.92 R 
22 15-31A-079 light yellow, cloudy nit 128 R 1.25 S** 1.43 S** 
23 15-31A-084 yellow, clear cip >=4 R 1.01 R 0.96 R 
24 15-31A-086 yellow, cloudy cip <=0.25 S 2.01 S 2.21 S 
25 15-31A-088 yellow, cloudy cip <=0.25 S 1.25 S 1.22 S 
26 15-31A-089 light yellow, clear cip >=4 R 0.94 R 0.91 R 
27 15-31A-091 yellow, cloudy cip <=0.25 S 1.18 S 1.19 S 
28 15-31A-093 orange/red, clear cip <=0.25 S 1.08 R - - 
28(2)† 15-31A-093 orange/red, clear cip <=0.25 S 1.88 S 1.59 S 
28_avg 15-31A-093 orange/red, clear cip <=0.25 S 1.48 S - - 
29 15-31A-096 light yellow, cloudy cip >=4 R 1.20 S - - 
29(2)† 15-31A-096 light yellow, cloudy cip >=4 R 0.93 R 0.98 R 
29_avg 15-31A-096 light yellow, cloudy cip >=4 R 1.07 R - - 
30 15-31A-097 light yellow, cloudy cip >=4 R 1.13 S** 0.98 R 
31 15-31A-101 light yellow, clear nit <16 S 1.39 S 1.19 S 
32 15-31A-102 dark yellow, clear nit <16 S 1.63 S 1.68 S 
33 15-31A-103 light yellow, clear nit <16 S 1.38 S 1.28 S 
34 15-31A-105 light pink, cloudy nit <16 S 1.47 S 1.44 S 
35 15-31A-108 yellow,  cloudy nit <16 S 1.29 S 1.37 S 
36 15-31A-111 yellow, clear nit <16 S 1.02 R* - - 
36(2) 15-31A-111 yellow, clear nit <16 S 1.16 S 0.95 R* 
36_avg 15-31A-111 yellow, clear nit <16 S 1.09 R - - 
37 15-31A-112 yellow, clear nit <16 S 1.49 S 1.12 S 
38 15-31A-114 light yellow, clear nit <16 S 1.34 S 1.36 S 
39 15-31A-115 yellow, clear nit <16 S 1.44 S 1.48 S 
40 15-31A-116 dark yellow, cloudy cip >=4 R 1.05 R 0.75 R 
40 15-31A-116 dark yellow, cloudy nit <16 S 1.96 S 2.33 S 
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41 15-31A-118 yellow, clear nit <16 S 1.25 S 1.15 S 
42 15-31A-119 light yellow, clear cip <=0.25 S 2.21 S 1.95 S 
43 15-31A-122 light yellow, clear nit <16 S 1.17 S - - 
43(2) 15-31A-122 light yellow, clear nit <16 S 1.79 S 1.45 S 
43_avg 15-31A-122 light yellow, clear nit <16 S 1.48 S - - 
44 15-31A-123 yellow, cloudy nit <16 S 1.18 S 1.15 S 
45 15-31A-126 light yellow, clear nit <16 S 1.24 S 1.19 S 
46 15-31A-131 light yellow, clear cip <=0.25 S 1.61 S 1.28 S 
47 15-31A-132 dark yellow, clear cip <=0.25 S 1.27 S 1.14 S 
48 15-31A-133 dark yellow, cloudy cip <=0.25 S 1.30 S 1.29 S 
49 15-31A-134 dark yellow, clear cip <=0.25 S 2.36 S 1.85 S 
50 15-31A-136 light yellow, clear cip <=0.25 S 2.04 S 1.89 S 
51 15-31A-137 dark yellow, clear cip <=0.25 S 1.43 S 1.28 S 
 
Table 3-S2. Rapid phenotypic AST literature summary showing the state of the art. 
Phenotypic antibiotic susceptibility tests using clinical samples, blood culture, contrived 
samples, clinical isolates, or reference strains with reported total assay time less than 3.5 hrs 
(210 min). References are sorted by sample type then by combined time of all steps. NR = 
not reported. Literature from 1997–present. 
 
Sample Type Method 
Pre-assay 
Enrichment 
Time (min) 
Minimum ABX 
Exposure Time 
(min) 
Combined 
Time of All 
Steps (min) 
Fastest Reported 
Sample-to-
Answer Time 
(min) 
Reference 
Clinical Samples dAST (using dLAMP) 0 15 24 29 This work 
Clinical Samples ATP Bioluminescence 0 90 105 NR (1) 
Clinical Samples Microscopy 120 30 155 NR (2) 
Clinical Samples NA Quantification 0 120 204a NR (3) 
Clinical Samples Microscopy 0 206 206b NR (4) 
Clinical Samples Electrochemical 0 150 NR 210 (5) 
       
Contrived Samples Microfluidics 0 60 60 NR (6) 
Contrived Samples Electrochemical 0 60 100 NR (7) 
Contrived Samples Microfluidics 0 120 120 NR (8) 
       
Blood Culture Microscopy 0 40 45c NR (9) 
       
Clinical Isolates Microscopy 0 40 40 NR (9) 
Clinical Isolates Electrochemical 0 15 45 NR (10) 
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Clinical Isolates FACS 0 90 95 NR (11) 
Clinical Isolates Magnetic Bead 
Rotation 
90 15 120d NR (12) 
Clinical Isolates Microscopy 120 6 126 NR (2) 
Clinical Isolates Raman Spectroscopy 0 120 130e NR (13) 
Clinical Isolates Raman Spectroscopy 0 120 130e NR (14) 
Clinical Isolates dAST (using dPCR) 0 15 140 NR (15) 
Clinical Isolates FACS 0 120 150 NR (16) 
Clinical Isolates FACS 0 60 180 NR (17) 
Clinical Isolates Mass Spectrometry 0 60 180 NR (18) 
Clinical Isolates Microscopy 0 180 200f NR (19) 
Clinical Isolates Electrochemical 0 90 NR NR (5) 
       
Reference Strains Electrochemical 0 10 25 NR (20) 
Reference Strains Raman Spectroscopy 0 20 25e NR (14) 
Reference Strains Electrochemical 0 20 42 NR (21) 
Reference Strains Microfluidics 0 60 60 NR (22) 
Reference Strains FACS 0 120 120g NR (23) 
Reference Strains Raman Spectroscopy 0 120 130e NR (13) 
atime does not include washing and centrifugation steps 
bdetailed times of each step not reported, listed time is median time reported for all samples 
cdoes not include time of overnight blood culture growth 
dtime does not include washing steps 
ewashing, imaging, and agarose embedding time not included 
freported as “clinical samples” in the abstract, but methods clearly state that all work was performed with clinical 
isolates: “We tested 189 clinical isolates…Before testing, each isolate was subcultured on cation-adjusted MHA 
for 20-24 hours” 
gdoes not include time of FACS measurement 
 
Table 3-S3. Concentration of clinical urine samples. Pathogen-specific 23S DNA 
concentration as determined by digital LAMP after 6.7 min of amplification time (Fig. 3-
4C/H). Taking into account the number of rDNA copies per E. coli chromosome, and the 
efficiency of dLAMP in counting DNA in 6.7 min, the concentration of full genomes is ~6 
times lower than the number reported in this table. CFU/mL was determined by plate 
counting at the UCLA Clinical Microbiology Laboratory. 
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Caltech 
Sample # 
23S Conc. 
(cop/mL) 
CFU/mL 
 Caltech 
Sample # 
23S Conc. 
(cop/mL) 
CFU/mL 
1 1.59E+07 >100,000  27 4.63E+07 >100,000 
2 2.52E+07 >100,000  28 3.62E+07 >100,000 
3 3.94E+07 >100,000  29 6.21E+06 >100,000 
4 5.63E+07 >100,000  30 2.38E+07 >100,000 
5 3.14E+07 >100,000  31 2.98E+07 >100,000 
6 7.86E+06 >100,000  32 9.57E+07 >100,000 
7 7.07E+06 >100,000  33 1.08E+08 >100,000 
8 5.08E+07 >100,000  34 1.13E+08 >100,000 
9 1.72E+07 >100,000  35 4.84E+07 >100,000 
10 2.64E+07 >100,000  36 5.73E+07 >100,000 
11 7.44E+06 >100,000  37 1.59E+07 >100,000 
12 2.75E+07 >100,000  38 8.49E+07 >100,000 
13 2.07E+07 >100,000  39 3.18E+06 50,000 
14 1.55E+07 >100,000  40 2.45E+07 >100,000 
15 2.12E+08 >100,000  41 1.02E+08 >100,000 
16 1.59E+07 >100,000  42 1.26E+07 >100,000 
17 5.12E+07 >100,000  43 4.97E+06 >100,000 
18 1.44E+07 >100,000  44 1.69E+08 >100,000 
19 2.62E+07 >100,000  45 2.46E+08 >100,000 
20 4.52E+06 >100,000  46 8.78E+06 >100,000 
21 4.25E+07 >100,000  47 8.58E+06 >100,000 
22 1.30E+08 >100,000  48 1.21E+07 >100,000 
23 3.04E+07 >100,000  49 1.41E+07 >100,000 
24 2.38E+07 >100,000  50 3.06E+06 >100,000 
25 4.19E+07 >100,000  51 8.02E+06 >100,000 
26 1.92E+07 >100,000     
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Figure 3-S1. Reproducibility of dAST method with clinical urine samples. Three 
ciprofloxacin-susceptible samples (#37, #38, #45) were analyzed with the dAST method in 
triplicate and control–treated (CT) ratios were calculated from DNA concentration 
measurements using digital droplet PCR. 
 
 
 
Figure 3-S2. Resolution of digital devices. The resolution of digital quantification depends 
on the number and volume of compartments. Simulations were performed with the methods 
described in (24). A) For a fixed sample size, and fixed input concentration of 106 cop/mL 
relevant to UTIs, increasing the number of compartments (and reducing the volume of each 
compartment accordingly) beyond 1,000 does not improve resolution in a useful way. B) For 
fixed compartment volume, and fixed input concentration of 106 copy/mL relevant to UTIs, 
the resolution improves with increasing number of compartments, although this increase 
requires a larger input of sample and amplification reagents. C) Dependence of resolution on 
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the number of multiplexed measurements made for a constant number of total wells.  For 
example, while 10,000 of 1 nL compartments provide 1.08 resolution, 2,000 of 1 nL 
compartments provide 1.16 resolution each, enabling a 4-plex dAST (1 control and 4 ABX 
treated samples) to be performed. 
 
Figure 3-S3. Real-time digital LAMP DNA quantification of a UTI sample with 
nitrofurantoin treatment 
 
A clinical UTI sample treated with and without 16 μg/mL nitrofurantoin. After 15 min, DNA 
was extracted and quantified with digital LAMP on SlipChips. The protocols followed and 
materials used are described in “Materials and Methods, Digital AST (dAST) using clinical 
UTI samples” and “Materials and Methods, Rapid digital LAMP (dLAMP)”. 
 
 
Figure 3-S3. High-resolution single-molecule nucleic acid amplification using 
ultrafast digital LAMP (dLAMP) for digital antimicrobial susceptibility test (dAST) 
of clinical urinary tract infection (UTI) urine samples with antibiotic-susceptible (A–
E) and antibiotic-resistant (F–J) E. coli. (A,F) Real-time fluorescence amplification 
traces (only 200 of 1,280 traces shown for clarity). NFU = normalized fluorescence units; 
dotted line = positive threshold; when the normalized fluorescence intensity of a 
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compartment crosses the threshold, that compartment is counted as positive. (B,G) Time 
Time-to-positive (TTP) distribution was determined by counting the number of 
compartments that crossed the positive threshold at each time point. (C,H) Detected 
concentrations of the target dAST marker in control and antibiotic-treated samples for 
successive image cycles. Grey lines represent 95% confidence intervals. (D,I) Detected 
control–treated (CT) ratios over time. Dashed line indicates susceptibility threshold. (E,J) 
Comparison of CT ratios for droplet digital PCR (dPCR) after 2 h and dLAMP (after 6.7 
min of amplification). 
 
Section 1. Intermediate samples 
 
In this manuscript, we focus on categorical agreement of our binary susceptibility 
determination (susceptible or resistant). We chose to design our study this way and to exclude 
intermediate samples for the following reasons: 
 
The current gold-standard antibiotic susceptibility testing method is broth dilution. This 
method, used every day in central clinical laboratories, is only accurate to +/- one dilution 
step. For example, E. coli with an initially determined ciprofloxacin MIC of 2.0 μg/mL 
might have an MIC of 1, 2, or 4 μg/mL if tested again using the same gold-standard 
method. According to the CLSI standards used in the US, 1.0 μg/mL is considered 
“susceptible”, while 2 μg/mL is considered “intermediate” and 4.0 μg/mL is considered 
resistant. This is well-known in the clinical microbiology community.  In fact, the CLSI 
manual (25) states that one of the roles of the intermediate category is to include a buffer 
zone which should prevent small, uncontrollable, technical factors from causing major 
discrepancies in interpretation. Furthermore, when gold standard broth dilution vs gold 
standard inhibition zone diameter is compared, intermediate samples do not show 
consistent results (see FIG. 4 of (26); of the five samples tested with intermediate MICs 
(as determined by the gold-standard), the inhibition zone method called one of them 
resistant, two intermediate, and two susceptible (26)). 
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A further issue is the discrepancy of the meaning “resistant and susceptible” around 
these concentrations.  For example, using The European Committee on Antimicrobial 
Susceptibility Testing – (EUCAST) standards, susceptible isolates are those with 
ciprofloxacin MIC of 0.25 μg/mL and below, while intermediate isolates have MIC of 0.5 
μg/mL and resistant isolates are 1.0 μg/mL and above. 
 
We chose to exclude samples with MICs of 0.5, 1.0, and 2.0 μg/mL to ensure that the gold 
standard method would not frequently switch between a susceptible and resistant call if 
repeated. 
 
Importantly, this approach is still applicable to “real world” samples and does not correspond 
to only looking at extremes of MIC.  Excluding these samples only eliminates a small 
percentage of E. coli samples based on epidemiological data (see Figure below), with the 
caveat that these distributions may change at different times in different locations.   
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Ciprofloxacin MIC distribution for E. coli. Note that a broader range of antibiotic 
concentrations is tested when generating epidemiological data than is tested in 
clinical microbiology laboratories. Also note that the cut-off MIC for defining 
resistant and susceptible organisms is different between the epidemiological and 
clinical microbiological data.  Epidemiological cut off is defined relative to the wild-
type susceptibility while the clinical cut off is defined relative to clinically relevant 
susceptibility.  Finally, note that these data should not be used to infer the rates of 
resistance in a particular geographical location at a particular time (27). 
 
For nitrofurantoin (nit), MIC of >=128 is considered resistant and MIC of <= 32 is considered 
susceptible. Similarly, we chose to exclude the minimal possible number of samples with 
MICs that might switch between a susceptible or resistant call when repeated. For this reason, 
we excluded samples with MICs of 32 and 64 μg/mL. 
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Therefore, it should not be surprising that when validating a new AST method with clinical 
samples, it is common to challenge the method only against susceptible and resistant samples 
that are above or below the MIC breakpoints, while avoiding intermediate samples (1, 3, 5). 
 
To test whether intermediate or near-intermediate samples provide any unexpected results, 
we did run a small separate study of 8 clinical  isolates (2 operators with 4 isolates each) with 
intermediate and near-intermediate MICs using dPCR readout. We exposed these isolates 
with (1.0 μg/mL ciprofloxacin) and without antibiotics for 15 min and measured the nucleic 
acid concentrations with dPCR. Isolates with MIC of 1.0 μg/mL are clustering very close to 
the threshold and slightly below, while isolates with MIC of 0.5 μg/mL are comfortably 
above the threshold and would be read as susceptible (Figure 3-S4). 
 
 
Figure 3-S4. The digital AST (dAST) method with clinical isolates from urinary tract 
infections using a 15 min treatment of 1 μg/mL ciprofloxacin. Three isolates with 
different MICs were analyzed with the dAST method in triplicate or duplicate (two 
operators with four samples each). Control–treated (CT) ratios were calculated from 
dPCR DNA concentration measurements. 
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Section 2. Supplementary Materials and Methods 
 
Materials and reagents 
 
All reagents purchased from commercial sources were used as received unless otherwise 
stated. BBL trypticase soy agar (TSA) plates with 5% sheep blood and Bacto brain heart 
infusion (BHI) media were purchased from BD Biosciences (Franklin Lakes, NJ, USA). All 
antibiotic stock solutions and nucleic acid amplification reactions were prepared using 
sterile, nuclease-free water (NF-H2O) purchased from Thermo Fisher (Waltham, MA, USA). 
Ciprofloxacin was purchased from Sigma-Aldrich (St. Louis, MO, USA) and prepared as a 
1 mg/mL stock solution in NF-H2O. Nitrofurantoin was purchased from Sigma-Aldrich (St. 
Louis, MO, USA) and prepared as a 10 mg/mL stock solution in NF-H2O. QuickExtract 
DNA Extraction was purchased from Epicentre (Madison, WI, USA). QX200 ddPCR 
EvaGreen Supermix was purchased from Bio-Rad Laboratories (Hercules, CA, USA). Bst 
3.0 and 10 mM dNTPs were purchased from NEB (Ipswich, MA, USA). Pooled healthy 
human urine was obtained from Lee Biosolutions (Maryland Heights, MO, USA). Primer 
sequences were ordered as dried stocks from IDT (Coralville, IA, USA). 
 
Digital quantification with dPCR 
 
Droplet digital PCR reactions were carried out as described previously (15). 
 
Design, fabrication and preparation of SlipChips 
 
Details of the design, fabrication, preparation, and assembling of the single-volume 1,280-
well SlipChip glass devices are described in previous work (28). For this manuscript, the 
workflow in Figure 3-5 was performed with lab-made reusable glass microfluidic chips 
(Samples 28-29,48-51). To run the rest of the 54 samples with the rapid dLAMP assay, we 
obtained a set of disposable injection molded chips (5,376 2.4-nL compartments) from 
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SlipChip Corp, which enabled shorter turnaround times between experiments (Samples 1-
27,30-47). 
 
Clinical sample handling and gold-standard broth microdilution AST 
 
Urine from patients suspected of having urinary tract infections (UTIs) was collected and 
transported in a BD Vacutainer Urine Collection Tube containing formate and borate as 
preservatives. Next, pathogens from the urine samples were isolated and identified using 
mass spectrometry. Broth microdilution AST was performed on samples positive for E. coli. 
 
dAST with clinical samples 
 
One modification to our original dAST protocol (15) is the addition of DNase to digest 
extracellular DNA. We did this to eliminate the confounding effect that extracellular DNA 
could have on the CT ratio. Consider an antibiotic-susceptible sample with 500 cop/μL of 
cell-free DNA and 300 cop/μL DNA inside cells. If the genomes replicate 1.5X over a 15 
min exposure time, then the CT ratio in the case where cell-free DNA is also detected would 
be 950 cop/uL ÷ 800 cop/uL = 1.19; in the case where cell-free DNA is digested by DNase 
and not detected, the CT ratio would be 450 cop/uL ÷ 300 cop/uL = 1.50. 
 
If discordant AST calls (compared to the gold-standard) were noticed on the same day, we 
re-ran that sample to resolve the discordancy. Some reruns are accepted even in the FDA 
submissions of diagnostic AST devices, so rerunning samples in itself is not a problem.  It 
would have been better to rerun the samples twice, to get a third measurement as a tie-
breaker.  Unfortunately, we could not do so due to the limitations of our protocols and the 
concern for aging of clinical samples over time (and we were not able to rerun all of the 
samples).  
 
Because our data provide a quantitative measurement (CT ratio), we averaged the two runs 
to obtain a consensus value of the CT ratio. When we do this (using dPCR values as an 
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example), we find that three samples (#28, #29, #43) returned average CT ratios (1.48, 
1.07, 1.48) that were in agreement with the gold standard (S, R, S). For a fourth sample (#36), 
the average CT ratio (1.09) was also discordant with the gold standard (S) and we recorded 
it as an error in our analysis for both dPCR and dLAMP (see Table 3-S1). 
 
Isolate maintenance and exposure experiments. 
 
For all experiments involving isolates (Fig. 3-2), isolates were maintained and antibiotic 
exposure carried out as described in previous work (15). All E. coli isolates were maintained 
on solid or liquid BHI media (BD, Franklin Lakes, NJ, USA), all Lactobacillus jensenii 
isolates were maintained on solid or liquid MRS media (BD, Franklin Lakes, NJ, USA). 
 
Contributions of non-corresponding authors 
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Contributor to Figure 3C 
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Chapter IV 
 
Flow-through capture and in situ amplification can enable rapid  
detection of a few single molecules of nucleic acids from several milliliters of 
solution3 
 
Abstract 
 
Detecting nucleic acids (NAs) at zeptomolar concentrations (few molecules per milliliter) 
currently requires expensive equipment and lengthy processing times to isolate and 
concentrate the NAs into a volume that is amenable to amplification processes, such as PCR 
or LAMP. Shortening the time required to concentrate NAs and integrating this procedure 
with amplification on-device would be invaluable to a number of analytical fields, including 
environmental monitoring and clinical diagnostics. Microfluidic point-of-care (POC) devices 
have been designed to address these needs, but they are not able to detect NAs present in 
zeptomolar concentrations in short time frames because they require slow flow rates and/or 
they are unable to handle milliliter-scale volumes. In this paper, we theoretically and 
experimentally investigate a flow-through capture membrane that solves this problem by 
capturing NAs with high sensitivity in a short time period, followed by direct detection by 
amplification. Theoretical predictions guided the choice of physical parameters for a 
chitosan-coated nylon membrane; these predictions can also be applied generally to other 
capture situations with different requirements. The membrane is also compatible with in situ 
amplification, which, by eliminating an elution step enables high sensitivity and will 
facilitate integration of this method into sample-to-answer detection devices. We tested a 
wide range of combinations of sample volumes and concentrations of DNA molecules using 
                                                 
3This chapter was first published in Analytical Chemistry with authorship belonging to Travis S. Schlappi, 
Stephanie E. McCalla, Nathan G. Schoepp, and Rustem F. Ismagilov. The original manuscript can be found 
at: http://dx.doi.org/10.1021/acs.analchem.6b01485. Specific contributions from each author are listed at 
the end of the chapter. 
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a capture membrane with 2 mm radius. We show that for nucleic acid detection, this 
approach can concentrate and detect as few as ~10 molecules of DNA with flow rates as high 
as 1 mL/min, handling samples as large as 50 mL. In a specific example, this method reliably 
concentrated and detected ~25 molecules of DNA from 50 mL of sample. 
 
Introduction 
 
Detection of nucleic acids (NAs) at ultra-low concentrations (few molecules per milliliter of 
sample) in short time intervals is invaluable to a number of analytical fields, including 
environmental monitoring and clinical diagnostics1-6. Pathogens in aqueous environmental 
samples are frequently present at or below zeptomolar concentrations (~1000 
microorganisms per liter), requiring laborious filtration and concentration procedures before 
detection is possible.7,8 In many clinical applications, including minimal residual diseases9 
and latent Hepatitis C viral (HCV) or HIV infections, target NAs are also present at < 10 
molecules/mL.10,11 Blood bank donations are typically pooled before screening, so targets 
may be diluted by several orders of magnitude before being screened for pathogens, 
generating a sample where ultra-sensitive detection is critical.12,13 Each of these examples 
requires the processing of large volumes (mLs) of extremely dilute samples, and therefore 
the ability to concentrate NAs on the order of 1000X to reach PCR-suitable volumes (μLs). 
Additionally, the entire concentration process must be done within minutes and not rely on 
expensive equipment to be directly applicable to limited-resource settings (LRS) and at the 
point-of-care (POC).14,15 
 
Commercial systems for the purification and concentration of nucleic acids typically involve 
solid phase extraction (SPE), which uses chaotropic agents to control the absorption and 
release of NAs on silica.16,17 While this method is widely used, most available protocols 
require centralized laboratories for centrifuging samples or manipulating beads.18 NA 
precipitation19 methods are also commonly used to extract and concentrate NAs from clinical 
and environmental samples; however these methods are laborious and involve the use of 
hazardous reagents.20 These methods are challenging to deploy for LRS, where 
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instrumentation is limited, or for use at the POC, where diagnostics must be rapid and 
require minimal sample handling.18 To address these needs, several charge-based methods 
have been developed, which typically include a charged polymer matrix including chitosan, 
poly-L-lysine, and so on for NA capture (we are building on that work in this paper).21-25 To 
increase sensitivity, these and other systems concentrate NAs and then either elute before 
amplification21,22,24,25 or perform amplification in situ.23,26-29 Concentration factors up to 
15X21,30 and limits-of-detection as sensitive as 104 copies/mL23 or 500 cells/mL26 have been 
reported. While these methods have clear advantages over traditional solid-phase extraction 
methods, processing time and lowest detectable concentration are still limited by their 
inability to handle large sample volumes (>1 mL)26-28,31 and/or their slow processing rates, 
which range from μL/min to μL/hr.18,21,22,24,32,33 Thus, current methods—whether 
commercialized or from literature—lack the required combination of sensitivity, speed and 
ease of implementation, leaving a gap in the current NA detection workflow. 
 
We hypothesized that pressure-driven flow and capture in a porous matrix could facilitate 
the handling of large samples, while retaining many of the characteristics needed for both 
LRS and POC. Here, we analyze this approach theoretically and experimentally to determine 
a regime in which rapid, convection-driven capture is possible. Using a theoretical 
framework to predict capture efficiency as a function of flow-through conditions, we 
determined the parameters necessary for a detection matrix to capture a few nucleic acid 
molecules (<10) from several mLs of volume in short times (<10 minutes). We tested our 
predictions experimentally with respect to capture efficiency, lowest detectable 
concentration, processing time, and total sample volume. Furthermore, we demonstrated that 
the capture matrix is compatible with direct amplification, eliminating the need for an elution 
step. The ability to amplify in situ makes this approach amenable to integration into sample-
to-answer devices, and preserves the high concentration factors achieved during capture by 
preventing loss of target to the capture matrix during elution. 
 
Experimental Section 
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Capture Simulations. The fraction of nucleic acid molecules captured in a membrane 
pore compared to the amount flowed through (capture efficiency) was simulated at steady-
state using the Transport of Diluted Species module of Comsol Multiphysics (version 4.4). A 
complete description of the model geometry, transport parameters, kinetics, boundary 
conditions, mesh, and calculations performed is included in Supporting Information. 
 
Chitosan Membrane Fabrication. A nylon membrane (LoProdyne LPNNG810S, Pall 
Corp., New York City, NY) was used as a porous matrix support. Two methods were 
employed for chitosan functionalization of the membrane, summarized below as “Method 
A” and “Method B.” 
 
Method A: The LoProdyne membrane has hydroxyl surface chemistry and was 
functionalized with N,N carbonyldiimidazole (CDI) in methylene chloride according to the 
manufacturer’s protocol (http://www.pall.com; Supporting Information S-VII). 
 
Chitosan oligosaccharide lactate (No. 523682, Sigma-Aldrich, St. Louis, MO) was purified 
by dissolving 1.2 g chitosan in 40 mL nuclease-free (NF) water, then precipitated by adding 
3 mL 1M NaOH. This solution was mixed and filtered through Whatman paper #8 (12 cm). 
It was then rinsed with MilliQ water until the eluant was neutral. Washed chitosan was dried 
for 2 h under vacuum, then a rotary evaporator was used to remove residual moisture. 
 
The optimal pH at which to cross-link chitosan with CDI was determined to be pH 5.0. Based 
on the pKa of chitosan (pKa = 6.3), ~5% of the chitosan’s amines will be deprotonated and 
able to react. At pH > 5, a larger percentage of the chitosan amines will be deprotonated, 
resulting in a higher degree of crosslinking to the support surface, and fewer available amines 
to interact with nucleic acids. At a pH of 5.0, the chitosan polymer should crosslink to the 
support at either one or two positions, leaving the bulk of the polymer free in solution. 
 
To prepare chitosan-coated supports, a 6 mg/mL solution of purified chitosan was prepared 
in 34 mM HCl.  This solution was vortexed for 10 min until the chitosan was fully dissolved, 
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then sonicated to remove bubbles. The pH was then raised to 5.0 by addition of NaOH 
while vortexing. A CDI-functionalized LoProdyne membrane was then saturated with this 
chitosan solution. The membrane and chitosan solution were sandwiched between two glass 
slides, and pressed to remove excess chitosan solution. The wet membrane was blot-dried 
and placed in a desiccator to dry under vacuum for 20–30 min. After drying, the membrane 
was placed in a 50 mL Falcon tube and rinsed with NF water. The water was poured out, 0.1 
M HCl was added to quench any remaining CDI and remove non-crosslinked chitosan, and 
the membrane and HCl vortexed for 2 min. The HCl was poured out and the membrane was 
rinsed with NF water again. Next, the membrane was placed in a fresh Falcon tube, rinsed 
more with NF water, washed in NF water for 25 min while agitated, rinsed with NF water 
three more times, blot dried, then air dried in a desiccator. 
 
Method B: To prepare hydrogel coated membranes, a 0.5% (w/v) solution of chitosan (TCI 
OBR6I) was prepared in 150 mM HCl. A 25% (v/v) solution of glutaraldehyde was added 
to this solution to a final concentration of 4 mM. The solution was rapidly mixed, and added 
to the LoProdyne membrane in excess. The saturated membranes were then spun on a Laurel 
WS-400-6NNP/Lite spin coater at 500 rpm for 5 s with an acceleration setting of 410, 
followed by 15 s at 2000 rpm with an acceleration setting of 820. Membranes were allowed 
to crosslink for 2 h in air, washed 3 times with NF water, and dried under vacuum. 
 
Binding Capacity Measurements. 1000 ng of salmon sperm DNA (Invitrogen, Carlsbad 
CA) in 100 μL of 10 mM MES buffer (pH ~5) was sequentially flushed through a chitosan 
membrane (radius = 2 mm, fabricated with Method A) five times via a syringe/luer lock 
system (Figure 4-S4). The inlet and eluate DNA concentration of each flush was measured 
with PicoGreen dye (Invitrogen); subtracting the eluate from the inlet and converting to mass 
of DNA yielded the plot in Figure 4-3. 
 
Capture and In Situ Amplification. λ-phage DNA stocks were quantified via digital PCR.34 
This DNA was spiked into varying volumes of 10 mM MES buffer (pH ~5) to create 
concentrations ranging from 0.2 to 20 copies/mL (Table 4-S4). The solutions were flowed 
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through chitosan-coated nylon membranes (radius = 2 mm) using syringes and luer locks 
(Figure 4-S4), followed twice by 100 μL MES buffer.  The membranes were then removed 
from the syringe/luer lock system, placed in an Ilumina EcoTM well plate, and 5–10 μL of 
PCR mix was added to each membrane. The well plate was inserted into an Ilumina EcoTM 
real time PCR system (EC-101-1001, Ilumina, San Diego, CA) and thermal cycled; correct 
λ-phage product was verified with a gel and melt curve analysis (Figure 4-S5). 
 
The PCR mixture used for amplification of λ-phage DNA on the chitosan-coated nylon 
membranes contained the following: 5 μL 2X SsoFast Evagreen SuperMix (BioRad, 
Hercules, CA), 1 μL of BSA (20 mg/mL), 2 μL of 10 ng/uL salmon sperm DNA (Invitrogen), 
1 μL of 5 μM primers (SI-VI), and 1 μL of NF water. The PCR amplification was performed 
with an initial 95 °C step for 3 min and then followed by 40 cycles of: (i) 20 s at 95 °C, (ii) 
20 s at 62 °C, (iii) 15 s at 72 °C. 
 
Results and Discussion 
 
Theoretical Analysis. To predict a regime that would enable rapid flow-through capture of 
nucleic acids present at low concentrations, we developed a theoretical model that takes into 
account the convection, diffusion, and adsorption of nucleic acid molecules onto a capture 
agent layered within a porous matrix (Figure 4-1a and S-I). Although the structure of the 
nylon membrane is spongy and non-uniform, approximating the pores as cylinders is an 
appropriate simplification to estimate the transport processes and has been done 
previously.35,36 The parameters governing capture dynamics in a cylindrical pore are 
superficial velocity U [m/s], pore radius Rp [m], membrane radius Rm [m], membrane 
thickness (or, equivalently, pore length) δm [m], diffusivity of nucleic acid molecules37 D 
[m2/s], association rate constant38 kon [m3/(mol·s)], surface concentration of the capture agent 
γ [mol/m2], and mass transfer coefficient kc [m/s]. Instead of analyzing every relevant 
parameter individually, we condensed them into two dimensionless numbers:39,40 Damköhler 
(Da) and Péclet (Pe). Da characterizes the balance between adsorption rate and transport rate 
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(Eq. 1) while Pe characterizes the balance between convection rate and diffusion rate (Eq. 
2). 
 
𝐷𝐷𝑟𝑟 =  𝑎𝑎𝑎𝑎𝑎𝑎𝑐𝑐𝑐𝑐𝑎𝑎𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 𝑐𝑐𝑎𝑎𝑐𝑐𝑟𝑟
𝑐𝑐𝑐𝑐𝑎𝑎𝑐𝑐𝑎𝑎𝑎𝑎𝑐𝑐𝑐𝑐𝑐𝑐 𝑐𝑐𝑎𝑎𝑐𝑐𝑟𝑟 = 𝑘𝑘𝑑𝑑𝑛𝑛𝛾𝛾𝑘𝑘𝑛𝑛 ,𝑘𝑘𝑐𝑐 = 1.62 � 𝑈𝑈𝐷𝐷22𝛿𝛿𝑚𝑚𝑅𝑅𝑝𝑝�13   (2) 
 
𝑃𝑃𝑃𝑃 =  𝑐𝑐𝑐𝑐𝑐𝑐𝑎𝑎𝑟𝑟𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 𝑐𝑐𝑎𝑎𝑐𝑐𝑟𝑟
𝑎𝑎𝑐𝑐𝑑𝑑𝑑𝑑𝑢𝑢𝑎𝑎𝑐𝑐𝑐𝑐𝑐𝑐 𝑐𝑐𝑎𝑎𝑐𝑐𝑟𝑟 = 𝑈𝑈/𝛿𝛿𝑚𝑚𝐷𝐷/𝑅𝑅𝑝𝑝2                                        (2) 
 
Da > 1 indicates that the rate of DNA binding to the capture agent is faster than the rate of 
DNA transport to the pore wall; Pe < 1 means the rate at which molecules diffuse to the pore 
wall is faster than the rate at which they are convected through the pore. To capture dilute 
nucleic acids from large volumes in short times, two conditions must be met: i) efficient 
capture (Da >> 1), and ii) fast flow rates (Q ~ 1 mL/min) while maintaining Pe < 1. 
 
Figure 4-1. Theoretical model and numerical simulations for flow-through capture. a) 
A schematic drawing showing the process of capturing nucleic acids from a sample 
flowing through a porous membrane (which has been functionalized with a capture 
agent). b) Predictions for the percentage of molecules captured at the pore wall as a 
function of the Damköhler number (Da). c) Predictions for the percentage of molecules 
captured at the pore wall as a function of the Péclet number (Pe).  Pe is changed by 
  
93 
varying the velocity (U), pore length (δm), or pore diameter (Rp); all result in a similar 
dependence of capture percentage on Pe. 
 
Capture efficiency is a factor of binding kinetics (time for the nucleic acid molecule to bind 
to the capture agent) and transport (time for the nucleic acid molecule to travel from the bulk 
solution to the pore wall coated with capture agent).  High capture efficiency occurs when 
the transport rate is slower than the binding reaction rate (i.e., Da >>1), which can occur with 
fast reactions or slow transport. Many passive capture processes—such as wicking through 
a porous matrix or mixing with beads—rely on slow transport rates to achieve high Da.  
These processes capture efficiently at small length scales in microliter volumes;21-23,33 
however, for milliliter volumes and large length scales, passive capture processes would 
require impractical amounts of capture agent or time for Da to be greater than 1. A fast 
binding reaction with diffusion-limited kinetics would enable higher transport rates (and thus 
faster flow rates) without adversely affecting capture efficiency. Electrostatic binding and 
silica adsorption in the presence of Ca2+ are examples of diffusion-limited chemical 
reactions41,42 that would maintain high Da without relying on slow transport rates to ensure 
efficient capture. Our simulations show that when a capture agent coated on a pore wall has 
fast binding kinetics, Da > 10 ensures > 95% capture of nucleic acids flowing through the 
pore (Figure 4-1b and S-I). To scale up efficient capture processes to larger volumes, the 
mass transport rate can be increased. One way to increase mass transport rate is actively 
forcing fluid through a porous matrix,43 which has been used for protein capture44 and is well 
established in membrane chromatography35,36. However, flow-through capture has not been 
analyzed theoretically nor tested experimentally for rapid capture and detection of 
zeptomolar nucleic acids.  
In general, high flow rates increase the transport rate, decrease Da, and thus reduce capture 
efficiency. However, the transport rate can be maintained below the adsorption rate (keeping 
Da >> 1) by manipulating other transport parameters, thus counteracting the high flow rate. 
These transport parameters can be analyzed together by simulating the capture efficiency as 
a function of Pe (S-I): simulations show that keeping Pe < 1 ensures > 90% capture efficiency 
(Figure 4-1c). To achieve a high convection rate and maintain Pe < 1, a relatively high 
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diffusion rate is required, which ensures that the molecules don’t leave the pore before 
having a chance to diffuse to the wall and bind. To maintain this balance of a high convection 
rate with an even higher diffusion rate, the membrane radius, pore radius, and membrane 
thickness can be adjusted. Setting Pe < 1 in Eq. 2 provides the following constraint on flow 
rate through the membrane (Q) as a function of δm, Rm, and Rp, where ϕ represents the 
porosity of the membrane (see S-II for derivation). 
 
𝑄𝑄 < 𝜋𝜋𝜋𝜋𝐷𝐷𝛿𝛿𝑚𝑚𝑅𝑅𝑚𝑚2
𝑅𝑅𝑝𝑝
2    (3) 
  
Plotting Eq. 3 at different membrane thicknesses explores the relationship of these 
parameters (Figure 4-2a); trends favoring Pe < 1 and flow rates > 1 mL/min are decreasing 
pore radius, increasing membrane radius, and increasing membrane thickness. Decreasing 
the pore size enables faster diffusion rates and lower Pe, but it also increases the resistance 
to flow. Figure 4-2b considers this tradeoff, showing the pressure drop required for a sample 
to flow through the membrane at 1 mL/min at different membrane and pore radii.  The 
overlap of the green triangles (Pe < 1) with red color (ΔP < 1 atm) represents an ideal 
combination of parameters wherein Pe is low enough and a reasonable pressure drop is 
achieved to flow at 1 mL/min. 
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Figure 4-2. Predictions of membrane radius, pore radius, and membrane thickness 
tradeoffs for achieving high flow rates while also maintaining reasonable pressure drop 
(ΔP) and a low Péclet number (Pe). a) Combinations of membrane radius, pore radius, 
and flow rate that maintain Pe < 1 for different membrane thicknesses. Any point below 
the surface curvature has Pe < 1.  b) The influence of membrane and pore radius on 
pressure drop with the flow rate through the membrane held constant at 1 mL/min. 
The overlap of the green triangle (Pe < 1) and red colored area represents efficient and 
rapid capture with a reasonable pressure drop (ΔP < 1 atm). The white area signifies a 
combination of membrane and pore radius that results in prohibitively large pressure 
drops (ΔP > 1 atm) necessary to achieve 1 mL/min. 
 
Experimental Analysis. Based on these predictions, we chose an appropriate experimental 
system to evaluate the ability of a flow-through matrix to rapidly capture zeptomolar 
concentrations of nucleic acids. This matrix should be compatible with in situ amplification, 
so glass fiber, silica, and other common capture materials that inhibit amplification reactions 
were not considered.45,46 Nylon membranes do not prevent nucleic acid amplification and 
can be purchased in various pore sizes and thicknesses. The membrane thickness for a 
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LoProdyne nylon membrane from Pall Corporation ranges from 127.0-190.5 μm (see 
Experimental Section); at this thickness, a membrane radius of 2 mm is flexible and easily 
placed in a well plate for nucleic acid amplification. For a membrane thickness of 160 μm, 
flow rate of 1 mL/min, and membrane radius of 2 mm, Eq. 3 predicts that pore radii less than 
0.76 μm would maintain Pe < 1. Therefore, we chose LoProdyne membranes with a pore 
radius of 0.6 μm; coating the membrane pores with a capture agent makes the pore size even 
smaller, ensuring that we were well below the 0.76 μm requirement. As described, the 
capture agent must have diffusion-limited kinetics. Because electrostatic binding is very fast 
and can easily be used for nucleic acid capture utilizing a cationic polymer to attract the 
negatively charged phosphate backbone of DNA, we chose chitosan as the capture agent, 
which has previously been used for NA capture.21-25 Chitosan is an inexpensive 
biocompatible polymer with amine groups on its backbone that become positively-charged 
when the pH is below 6.3.22,47 We functionalized chitosan onto the nylon membrane as 
described in Experimental Section. To verify that functionalizing the membrane with 
chitosan does not reduce the pore size such that the pressure drop becomes untenable (Figure 
4-2b), we measured the capture efficiency at different flow rates. This experiment showed 
that the chitosan-functionalized nylon membrane captures > 90% of nucleic acids when 
solution is flowed through at 1 mL/min (see Figure 4-S2 of the Supporting Information). 
 
To test the predictions from our analysis, we  evaluated the capture efficiency as a function 
of Pe by flowing 500 ng/mL solutions of DNA through chitosan membranes at five different 
flow rates. Each flow rate was tested with three replicates and the capture efficiency along 
with one standard deviation is plotted in Figure 4-S2. These experiments confirmed that the 
chitosan membranes capture efficiently over a range of Pe, with > 90% capture of DNA 
when Pe < 1 (Figure 4-S2). We also measured the DNA binding capacity of chitosan-
functionalized nylon membranes and found that they have a capacity of 1000 ng or more 
(Figure 4-3). This capacity is much greater than needed for our target application of 
zeptomolar concentrations (10-21 M ~ 0.6 fg/mL for a bacterial genome). However, 
researchers in other fields may find this matrix useful in capturing large amounts of genetic 
material for other applications. 
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Figure 4-3. DNA binding capacity of chitosan-functionalized membranes fabricated 
with Method A. 
 
Next, we tested whether in situ amplification would be chemically compatible with the nylon 
membrane that had been functionalized with chitosan. We added serial dilutions of DNA to 
the membrane, then submerged in amplification mix and amplified DNA via PCR. The 
chitosan membrane was compatible with in situ PCR amplification down to ~2 copies per 
reaction (Figure 4-S3a). We also tested the chitosan membrane compatibility with in situ 
LAMP and showed successful amplification at 20 copies per reaction (Figure 4-S3b48). 
In this paper we did not study the location at which amplification occurs (i.e. whether 
amplification is initiated on the target molecules still attached to the surface of the membrane, 
or on the molecules released from the surface into the membrane pores, or on the molecules 
diffusing out of the pores). Further, we did not study the spatiotemporal mechanism of 
propagation of amplification once it is initiated. Such studies could provide interesting 
information in subsequent research.  
The final step was to use chitosan’s charge-switch capability to couple rapid capture with 
direct amplification without eluting the nucleic acids. A sample flows through the chitosan-
coated membrane at pH ~5 and the negatively-charged phosphate backbone of DNA will 
electrostatically bind to the positively-charged amine groups on the chitosan. Following 
capture of NAs, the addition of amplification mix at pH ~8 deprotonates the amine groups 
and releases the captured nucleic acids for amplification (Figure 4-4). 
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Figure 4-4. Schematic of capture and in situ amplification. a) Nucleic acids in a solution 
with pH < 6.3 will electrostatically bind to the protonated chitosan pore wall. b) 
Addition of amplification mix (pH ~8) deprotonates the chitosan and releases nucleic 
acids. Thermal cycling amplifies DNA. 
 
We then tested this idea (combining rapid capture and in situ amplification via charge-
switch) at ultra-low concentrations (~1 copy/mL) and fast flow rates. Various amounts of λ 
DNA were spiked into volumes ranging from 1 to 50 mL with 100 ng or less background 
DNA (Table 4-S4); the solution was then flowed through a 2 mm radius chitosan-
functionalized membrane at ~1 mL/min. After capture, the amplification was performed in 
situ with small volumes of PCR reagents (5–10 μL), as opposed to the traditional method of 
eluting from a capture matrix and using larger volumes of PCR reagents. DNA product was 
detected after thermal cycling using EvaGreen dye (see SI-V for details). This methodology 
detected a DNA target at concentrations as low as 0.5 copies/mL from as many as 50 mL 
(Figure 4-5b). Compiling data from replicate experiments run on different days, pre-
concentration using the chitosan-functionalized membrane allowed detection down to 1 
copy/mL over 85% of the time. Using any concentration above 10 copies/mL, detection 
results for the capture and amplification matrix were positive 100% of the time. No 
amplification was detected when flowing through buffer without DNA (see Figure 4-5a and 
Table 4-S4), ensuring that the λ DNA product detected is indeed from the sample flowed 
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through the membrane and not contamination of the membrane, lab materials, or PCR 
reagents with λ-phage DNA. 
 
 
Figure 4-5. Nucleic acid detection via flow-through capture and in situ amplification on 
chitosan membranes. a) Percent of membranes that were positive for λ DNA product 
over different experiments on different days for varying concentrations (0.2–20 
copies/mL). The volume flowed through ranged from 1 to 50 mL (Table 4-S4) and the 
flow rate was ~1 mL/min. Each bin of the histogram has 6–26 samples for a total of 82 
samples. b) Percent of membranes that were positive for λ DNA product over different 
experiments on different days. 50 mL solutions with 25 copies of target DNA and 10 or 
100 ng background DNA were flowed through membranes at ~0.3 mL/min. The 
number of replicates are N = 10 for 100 ng and N = 9 for 10 ng. All error bars are 1 
S.D. 
 
We observed that the chitosan membrane performance appeared to decrease slightly as larger 
volumes were flowed through (e.g., >10 mL volumes were 77% positive (23 out of 30 tests) 
and >20 mL volumes were 60% positive (9 out of 15 tests), see Table 4-S4). This decreased 
performance at higher volumes could be due to chitosan shedding off the membrane during 
flow or the fact that larger volumes have longer residence times and therefore more 
opportunity for the DNA molecule to release from its binding site and be flushed out of the 
membrane with the eluate. A thicker membrane with longer pores or a chitosan-
functionalization method that more strongly attaches chitosan to the nylon membrane could 
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potentially improve its performance at larger volumes; however, these parameters were 
not tested and are outside of the scope of this study. 
 
Our experiments have been using stringent conditions with high flow rate (~1 mL/min) and 
high level of added background DNA. For some applications, these conditions might be too 
stringent, and high sensitivity of detection may be more valuable. For example, drinking 
water samples do not always have the high level of background DNA we used. The presence 
of high levels of background DNA can affect capture efficiency of the target molecule during 
flow-through and can affect amplification efficiency during PCR. We therefore also tested 
detection of ultra-low concentrations of nucleic acids from large volumes with reduced 
background DNA at 10 ng and slower flow rates at 0.3 mL/min. We compared 50 mL 
solutions with 100 ng background DNA to 50 mL solutions with 10 ng background DNA. 
These experiments showed that 25 copies in 50 mL could be consistently detected under 
these conditions (Figure 4-5b). We have not yet further investigated how the performance of 
this method depends on the interplay of flow rate, pore geometry, level of DNA background, 
and the details of fabrication of the chitosan coating.To test whether salts in solution could 
interfere with electrostatic binding and decrease the ability of chitosan membranes to capture 
and detect nucleic acids, we performed six preliminary experiments. The experiments were 
identical to those performed for Figure 4-5, but instead of using 10 mM MES buffer as the 
medium comprising nucleic acids, various salt solutions were used (see S-VIII for details): 
i) Ringer’s solution (10 and 20 copies λ DNA in 1 mL), Ringer’s solution with 5 mM EDTA 
(10 and 20 copies λ DNA in 1 mL) and 5 mM EDTA alone (10 and 20 copies λ DNA in 1 
mL). All six experiments resulted in positive amplification, indicating that the presence of 
salts does not disrupt capture of nucleic acids on the chitosan membrane nor their subsequent 
amplification. 
 
Conclusion 
 
We evaluated an approach for ultrasensitive detection of nucleic acids using chitosan as a 
charge-switch matrix that enables concentration factors up to 5000X (defined as the ratio of 
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final detection volume to the starting sample volume, e.g., DNA from 50 mL of solution 
was detected in 10 μL of PCR mix) and subsequent in situ amplification. A theoretical model 
guided the parameters chosen for flow rate, membrane radius, and pore radius. Based on 
model predictions, membranes with specific pore and membrane radii were functionalized 
to capture low copy numbers of nucleic acids from large volumes in short times. Using this 
approach, we were able to capture zeptomolar concentrations of nucleic acids from up to 50 
mL of solution at a flow rate of 1 mL/min with ΔP < 1 atm.  In applications with different 
requirements for flow rate, pressure drop, or membrane size, this theory can be applied to 
guide choices of membrane parameters that meet those requirements. 
 
In addition, flowing through a matrix that is compatible with in situ amplification obviates 
the need for centrifugation or bead manipulation and simplifies the purification process by 
eliminating an elution step. Chitosan-functionalized nylon membranes are sturdy, flexible, 
and small enough to be incorporated into integrated devices for complete sample-to-answer 
diagnostics. In this study, we focused on the theory and the proof-of-principle experiments 
using solutions of purified nucleic acids in clean matrixes. However, more complex matrices 
are encountered in many applications. Ultrasensitive measurements of viral, bacterial, and 
cancer-associated nucleic acids provide important diagnostic information to clinicians, but 
require the extraction and detection of NAs from milliliters of plasma and in some cases cell 
lysis. Combining this approach with lysis buffers and/or sample pretreatment should be 
tested next to evaluate the efficacy of this methodology for detection from a variety of sample 
matrices, such as blood, plasma, urine, and water. Additional work on integration of this 
approach with isothermal amplification would enable rapid and ultra-sensitive nucleic acid 
measurements for point-of-care and limited-resource settings. 
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Supporting Information 
 
Flow-through capture simulations 
 
The fraction of nucleic acid molecules captured in a membrane pore compared to the amount 
flowed through (capture efficiency) is a function of pore geometry, flow parameters, and 
adsorption kinetics (Figure 4-S1). The concentration of nucleic acids at any position in the 
pore, C(r, z), was simulated at steady-state using the Transport of Diluted Species module of 
Comsol Multiphysics (version 4.4) with the parameters listed in Table 4-S1. To generate the 
data for Figure 4-1b-c, a parametric sweep was performed with various values of kon·γ, U, 
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Rp, and δm (Table 4-S2 and Table 4-S3). Then, the inlet flux (Jin = J|z = δm) and outlet flux 
(Jout = J|z = 0) were evaluated and used in Eq. S-1 to calculate capture efficiency. 
 𝐶𝐶𝑟𝑟𝐶𝐶𝑡𝑡𝐶𝐶𝑟𝑟𝑃𝑃 % = 1 − 𝐽𝐽𝑐𝑐𝑢𝑢𝑐𝑐
𝐽𝐽𝑐𝑐𝑐𝑐
 (S-3) 
 
Figure 4-S6. Schematic of flow-through simulation geometry.  Red represents the capture 
agent (γ) coated on the surface of the pore wall. 
 
Table 4-S1. Parameters used in the flow-through capture simulations. 
Parameter Description Value 
Rp Pore radius 0.56  – 17.78 μm 
δm Pore length (thickness of membrane) 0.316  – 3162 μm 
U Flow velocity 0.118 – 1000 mm/s 
D Diffusivity of nucleic acid molecule 10 μm2·s-1 
kon Nucleic acid binding rate constant 106 L·mol-1·s-1 
γ Surface concentration of capture agent 10-7 mol·m-2 
Cin Inlet concentration of nucleic acids 1 μM 
 
Table 4-S2. The product of kon·γ was varied to generate Capture % as a function of 
Damköhler number (Da) (Figure 4-1b).  Rp (1 μm), δm (100 μm),U (2 mm/s), D (10 μm2·s-1), 
and Cin (1 μM) were held constant. 
 
  
106 
kon·γ (m/s) kc (m/s) Da Jin (mol/s) Jout (mol/s) Capture % 
1.00E-07 1.62E-05 0.01 -3.92E-18 -3.88E-18 1.0 
2.15E-07 1.62E-05 0.01 -3.92E-18 -3.83E-18 2.1 
4.64E-07 1.62E-05 0.03 -3.92E-18 -3.74E-18 4.5 
1.00E-06 1.62E-05 0.06 -3.92E-18 -3.55E-18 9.3 
2.15E-06 1.62E-05 0.13 -3.92E-18 -3.19E-18 18.5 
4.64E-06 1.62E-05 0.29 -3.92E-18 -2.58E-18 34.2 
1.00E-05 1.62E-05 0.62 -3.92E-18 -1.75E-18 55.2 
2.15E-05 1.62E-05 1.33 -3.92E-18 -9.77E-19 75.0 
4.64E-05 1.62E-05 2.87 -3.92E-18 -5.03E-19 87.2 
1.00E-04 1.62E-05 6.17 -3.92E-18 -2.94E-19 92.5 
2.15E-04 1.62E-05 13.3 -3.92E-18 -2.11E-19 94.6 
4.64E-04 1.62E-05 28.7 -3.92E-18 -1.78E-19 95.5 
1.00E-03 1.62E-05 61.7 -3.92E-18 -1.63E-19 95.8 
2.15E-03 1.62E-05 133 -3.92E-18 -1.57E-19 96.0 
 
Table 4-S3. U, δm, or Rp was varied to generate Capture % as a function of Péclet number 
(Pe) (Figure 4-1c).  Cin (1 μM), kon·γ (10-4 m/s), and D (10 μm2·s-1) were held constant. 
 
U (m/s) δm (μm) Rp (μm) Pe Jin (mol/s) Jout (mol/s) Capture % 
1.18E-04 100 1 0.12 -2.46E-19 -2.32E-36 100.0 
2.68E-04 100 1 0.27 -5.32E-19 -1.00E-26 100.0 
6.11E-04 100 1 0.61 -1.20E-18 -4.11E-22 100.0 
1.39E-03 100 1 1.39 -2.72E-18 -7.21E-20 97.4 
3.16E-03 100 1 3.16 -6.19E-18 -1.11E-18 82.0 
7.20E-03 100 1 7.20 -1.41E-17 -5.92E-18 58.0 
1.64E-02 100 1 16.4 -3.21E-17 -2.02E-17 37.0 
3.73E-02 100 1 37.3 -7.30E-17 -5.70E-17 22.0 
8.48E-02 100 1 84.8 -1.66E-16 -1.46E-16 12.3 
1.93E-01 100 1 193 -3.78E-16 -3.54E-16 6.5 
4.39E-01 100 1 439 -8.60E-16 -8.32E-16 3.2 
1.00E+00 100 1 1000 -1.96E-15 -1.93E-15 1.6 
2.00E-03 3162 1 0.06 -3.90E-18 8.30E-39 100.0 
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2.00E-03 1000 1 0.20 -3.90E-18 -1.15E-28 100.0 
2.00E-03 316 1 0.63 -3.90E-18 -1.72E-21 100.0 
2.00E-03 100 1 2.00 -3.90E-18 -2.90E-19 92.6 
2.00E-03 31.6 1 6.32 -3.90E-18 -1.50E-18 61.5 
2.00E-03 10.0 1 20.0 -3.90E-18 -2.65E-18 32.1 
2.00E-03 3.16 1 63.2 -3.90E-18 -3.30E-18 15.4 
2.00E-03 1.00 1 200 -3.90E-18 -3.65E-18 6.4 
2.00E-03 0.316 1 632 -3.90E-18 -3.80E-18 2.6 
2.00E-03 100 0.56 0.63 -1.23E-18 -1.60E-21 99.9 
2.00E-03 100 1.00 2.00 -3.90E-18 -2.90E-19 92.6 
2.00E-03 100 1.78 6.32 -1.23E-17 -4.20E-18 65.9 
2.00E-03 100 3.16 20.0 -3.90E-17 -2.30E-17 41.0 
2.00E-03 100 5.62 63.2 -1.23E-16 -9.40E-17 23.6 
2.00E-03 100 10.00 200 -3.90E-16 -3.40E-16 12.8 
2.00E-03 100 17.78 632 -1.23E-15 -1.15E-15 6.5 
 
Geometry: The model was assembled using a cylindrical geometry drawn in 2D axially 
symmetric space, with r as the radial component and z the axial component (Figure 4-S1).  
The radius of the cylinder (Rp) varied from 0.56 μm to 17.78 μm; the length of the cylinder 
(δm) varied from 0.316 μm to 3162 μm (Table 4-S3). 
 
Transport: In a porous matrix, fluid flow can be approximated with a uniform velocity (U) 
independent of radius1.  The flow velocity varied from 1.18·10-4 m/s to 1 m/s (Table 4-S3).  
The top boundary of the cylinder (z = δm) was an inlet and the bottom boundary (z = 0) was 
an outlet.  The diffusion coefficient used was for DNA2, 10-11 m2/s. 
 
Kinetics:  The binding rate between nucleic acids and the capture agent was assumed to be 
second order with respect to nucleic acid concentration and capture agent surface 
concentration. We assumed the surface concentration of capture agent (γ) was in excess (and 
therefore unchanging during the course of the adsorption reaction) and estimated it to be 10-
7 mol/m2.  With a kinetic rate constant estimated from nucleic acid-cationic polymer 
kinetics3, the adsorption rate occurring at the pore wall is shown in Eq. S-2. 
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 𝑅𝑅𝑎𝑎𝑎𝑎𝑎𝑎 = 𝑘𝑘𝑐𝑐𝑐𝑐 ∙ 𝛾𝛾 ∙ 𝐶𝐶(𝑅𝑅𝑎𝑎, 𝑧𝑧) (S-4) 
Normally, adsorption kinetics include both an on and off rate.  However, in this situation, we 
excluded the off rate from analysis because it was insignificant compared to the on rate (kon 
~ 107 M-1s-1, koff ~ 10-3 s-1, reference 38 from the manuscript). 
 
Boundary conditions:  The inlet concentration of nucleic acid molecules (Cin = 10-6 mol/L) 
represents a normal nucleic acid concentration in human blood plasma4.  Axial symmetry 
was imposed at r = 0, and a flux boundary condition (Eq. S-3) was imposed at r = Rp to 
represent the adsorption of nucleic acid molecules to the surface of the pore wall. 
 𝑅𝑅𝑎𝑎𝑎𝑎𝑎𝑎  = 𝐷𝐷 𝜕𝜕𝐶𝐶(𝑟𝑟, 𝑧𝑧)𝜕𝜕𝑟𝑟 �𝑐𝑐=𝑅𝑅𝑝𝑝 (S-5) 
Mesh and solver settings: The geometry was meshed using a Free Triangular mesh with a 
maximum element size of 0.0525 𝜇𝜇m.  The Direct Stationary Solver (PARDISO) was used 
with a nested dissection multithreaded preordering algorithm and an auto scheduling method. 
 
Equation 3 and Figure 4-2b 
 
The number of pores in a membrane (np) can be calculated from the porosity (ϕ) as in Eq. S-
4. 
 𝜙𝜙 = 𝑛𝑛𝑎𝑎𝜋𝜋𝑅𝑅𝑎𝑎2
𝜋𝜋𝑅𝑅𝑚𝑚2
→ 𝑛𝑛𝑎𝑎 = 𝜙𝜙𝑅𝑅𝑚𝑚2𝑅𝑅𝑎𝑎2  (S-6) 
The flow rate through the entire membrane (Q) is the flow rate through each pore (Qp) 
multiplied by the number of pores (Q = npQp).  Using Eq. S-4 for np and solving for Qp gives 
the following: 
 𝑄𝑄𝑎𝑎 = 𝑄𝑄𝑅𝑅𝑎𝑎2𝜙𝜙𝑅𝑅𝑚𝑚2  (S-7) 
Eq. S-6 results from plugging Eqn S-5 into the relationship between pore flow rate and flow 
velocity (Qp = UπRp2).                        𝑈𝑈 = 𝑄𝑄𝑎𝑎
𝜋𝜋𝑅𝑅𝑎𝑎2
= 𝑄𝑄
𝜋𝜋𝜙𝜙𝑅𝑅𝑚𝑚2
 (S-8) 
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Then, using Eq. S-6 in Eq. 2 and setting the condition that Pe < 1 yields Eq. S-7.                              𝑃𝑃𝑃𝑃 = 𝑈𝑈𝑅𝑅𝑎𝑎2
𝐷𝐷𝛿𝛿𝑚𝑚
= 𝑄𝑄𝑅𝑅𝑎𝑎2
𝜋𝜋𝜙𝜙𝑅𝑅𝑚𝑚2 𝐷𝐷𝛿𝛿𝑚𝑚
< 1 (S-9) 
Solving Eq. S-7 for Q yields Eq. 3. ϕ = 0.6 and D = 10-11 m2/s were assumed for all 
calculations. 
 
To calculate the pressure drop as a function of pore radius (Rp) and membrane radius (Rm), 
Pouiselle flow was assumed (Eq. S-8).  Flow rate through the pore (Qp) was replaced with 
flow rate through the entire membrane (Q) using Eq. S-5.  Q (1 mL/min), μ (10-3 Pa·s), and 
ϕ (0.6) were held constant; Rp and Rm were varied from 1 to 3 μm and 1 to 3 mm, respectively. 
The results, along with regimes of Pe < 1 calculated from Eq. 2, are plotted in Figure 4-2b. 
 Δ𝑃𝑃 = 8𝜇𝜇𝑄𝑄𝑎𝑎𝛿𝛿𝑚𝑚
𝜋𝜋𝑅𝑅𝑎𝑎4
= 8𝜇𝜇𝑄𝑄𝛿𝛿𝑚𝑚
𝜋𝜋𝜙𝜙𝑅𝑅𝑎𝑎2𝑅𝑅𝑚𝑚2
 (S-10) 
 
DNA binding efficiency as a function of Pe 
 
100 ng of salmon sperm DNA (Invitrogen, CA) in 200 μL of 10 mM MES buffer (pH ~5) 
was flushed through a chitosan membrane with a radius of 2 mm at different flow rates via 
the syringe/luer lock system shown in Figure 4-S4. The inlet and eluate DNA concentration 
of each flush was measured with PicoGreen dye (Invitrogen, CA); converting to mass (mDNA), 
Eq. S-9 was then used to calculate the capture efficiency. 
𝐶𝐶𝑟𝑟𝐶𝐶𝑡𝑡𝐶𝐶𝑟𝑟𝑃𝑃 % = �1 −𝑚𝑚𝐷𝐷𝐷𝐷𝐴𝐴,𝑐𝑐𝑢𝑢𝑐𝑐
𝑚𝑚𝐷𝐷𝐷𝐷𝐴𝐴,𝑐𝑐𝑐𝑐 � · 100 (S-11) 
Pe was calculated via Eq. 2 and the results are plotted in Figure 4-S2.  This agrees with 
theoretical predictions that Pe > 1 results in reduced capture.  Also, layering the nylon 
membrane with chitosan does not significantly hinder flow rate or require untenable pressure 
drops to achieve flow rates of ~ 1 mL/min and efficient capture. 
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Figure 4-S7. Capture efficiency depends on flow rate. 
We clarify that capture efficiencies > 90% are only possible when the capture agent is in 
excess of the target DNA molecule and Pe < 1, which is the case for 100 ng of input DNA 
(Figure 4-S2). On the other hand, the purpose of the experiments in Figure 4-3 was to 
measure the total binding capacity of the chitosan membrane (i.e., occupy all the cationic 
binding sites). To accomplish this, larger quantities of DNA (1000 ng) were flowed through 
the membrane and the capture efficiency was not expected to be high; in fact, with each 
successive load, it should decrease to 0% until all binding sites are occupied. Indeed, we 
observed that the capture efficiency in Figure 4-3 varied from 60% in the first run to 20% in 
the fifth run—by the time the fifth load of 1000 ng DNA was flowed through the membrane, 
there were fewer binding sites available and thus the recovery was much lower than the first 
load when all binding sites were available. 
 
Compatibility of chitosan membrane with in situ amplification 
 
To test the compatibility of chitosan membranes with in situ PCR amplification, 1 μL of 
varying concentrations of λ DNA was wetted into chitosan membrane with a radius of 2 mm.  
The membrane was then placed in a well plate and 10 μL PCR mix was added to the well. 
Replicates containing 10 μL PCR mix with the same amount of λ DNA and no membrane 
present were also included.  The well plate was inserted into an Ilumina EcoTM real-time PCR 
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System (EC-101-1001) and thermal cycled; correct λ-phage DNA product was verified 
with melt curve analysis.  The PCR mix and thermal cycling conditions used were the same 
as described in the Experimental Section.  Figure 4-S3a shows that chitosan membranes are 
compatible with in situ PCR amplification down to ~2 copies/reaction. 
 
To test compatibility with in situ LAMP amplification, 20 copies of λ DNA were wetted into 
a chitosan membrane with a radius of 2 mm.  The membrane was then placed in a well plate 
and 10 μL LAMP mix was added to the well. Replicates containing 10 μL LAMP mix with 
20 copies of λ DNA and no membrane present were also included as solution controls.  The 
well plate was inserted into an Ilumina EcoTM real-time PCR System and incubated for 40 
min at 68 °C. Figure 4-S3b shows the real-time fluorescent traces representing DNA product. 
 
Figure 4-S8.  Compatibility of chitosan membranes with PCR and LAMP amplification. a) 
Dilutions of λ DNA were wetted onto chitosan membranes or placed into a well plate without 
a membrane; PCR mix was added and amplification was detected via melt curve analysis.  
Six replicates were run at each dilution; the percent of replicates positive for λ DNA product 
is shown (n = 6).  b) 20 copies of λ DNA were wetted onto chitosan membranes within a 
well plate, or placed into a well plate without a membrane; LAMP mix was added and 
amplification was detected via real-time fluorescence.  Three replicates were run for each 
sample; the fluorescent traces as a function of time are plotted. 
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LAMP reagents were purchased from Eiken Chemical (Tokyo, Japan), product code 
LMP207.  The LAMP mixture used for amplification of λ-phage DNA contained the 
following: 5 μL Reaction Mixture, 0.4 μL of Enyzme Mixture, 0.5 μL of 20X LAMP primer 
mixture (Table 4-S6), 0.25 μL of Calcein (Fd), and 3.85 μL of nuclease-free water. 
 
Details of capture and in situ amplification (Figure 4-5) 
 
Figure 4-S4 is a schematic of the syringe/luer lock system used to flow mL-scale volumes 
through chitosan membranes with a radius of 2 mm. Syringes were purchased from BD 
(Franklin Lakes, NJ) and luer locks (Catalog #LC78-J1A) were purchased from Nordson 
Medical (Westlake, Ohio). Table 4-S4 shows all the quantities of λ DNA, volumes of 10 mM 
MES buffer, and amounts of background DNA used to generate Figure 4-5. Salmon sperm 
DNA from Invitrogen (Carlsbad, CA) was used as “background DNA”. 
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Figure 4-S9.  Schematic of syringe/luer lock system used to flow mL-scale volumes 
through the chitosan membrane with a radius of 2 mm.  A chitosan membrane is placed in 
between two luer locks.  A syringe containing a nucleic acid sample is connected to the top 
luer lock and the plunger is compressed to flush the sample through the membrane.  Then, 
the luer locks are disconnected from the syringe, and taken apart, and the membrane 
containing captured nucleic acids is placed in a PCR tube along with amplification mix for 
thermal cycling. 
 
Table 4-S4. Volumes of 10 mM MES (2-(N-morpholino)ethanesulfonic acid) buffer and 
final concentrations of λ DNA used for Figure 4-5a.  The two fabrication methods are 
described in the Experimental Section. 
 
Copies of 
λ DNA 
Volume of 10 
mM MES 
buffer (mL) 
λ DNA 
Concentration 
(cop/mL) 
Background 
DNA added to 
MES buffer (ng) 
Positive 
membranes 
Total 
membranes 
tested 
Fabrication 
Method 
0 1 0 100 0 3 A 
0 3 0 100 0 3 B 
10 50 0.2 100 1 1 B 
10 50 0.2 100 1 4 A 
5 15 0.3 100 2 2 A 
10 30 0.3 100 1 2 A 
10 25 0.4 100 1 2 A 
5 10 0.5 100 2 2 A 
10 20 0.5 100 3 4 A 
25 50 0.5 100 1 1 B 
25 50 0.5 0 1 1 B 
9 10 0.9 10 6 6 B 
5 5 1.0 100 2 2 A 
10 10 1.0 100 1 2 A 
10 10 1.0 50 3 3 B 
9 5 1.8 0 6 6 B 
6 3 2.0 100 2 3 B 
10 5 2.0 50 2 3 B 
12 5 2.4 100 3 3 A 
10 4 2.5 100 2 2 A 
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5 1 5.0 100 5 5 A 
10 2 5.0 100 4 4 A 
6 1 6.0 100 3 3 B 
10 1 10.0 100 3 4 A 
20 2 10.0 100 2 2 A 
10 1 10.0 0 2 3 B 
20 1 20.0 100 5 5 A 
20 1 20.0 0 3 3 B 
 
To detect λ DNA product after in situ amplification, two methods were used.  i) After thermal 
cycling the membrane with PCR mix in a well plate, an appropriate amount of 6x gel loading 
dye and TE buffer was added to each well and pipette mixed.  Then, 5 μL of this solution 
was removed from the well, placed in a 1.2% agarose gel, and run for 50 min at 80V.  
Samples with DNA product at the same length as the λ PCR amplicon (322 base pairs) were 
considered positive.  An example of a gel image is shown in Figure 4-S5a. ii) After thermal 
cycling, the PCR reaction mixture was transferred to an empty well and an appropriate 
amount of 20X Evagreen dye (Biotium) and 10X TE buffer was added. A continuous melt 
curve was then obtained from 65–95 ˚C; samples with a peak around ~85 ˚C (the melting 
temperature of the λ PCR amplicon) were considered positive. (Figure 4-S5b). 
 
 
Figure 4-S10.  DNA detection after in situ amplification.  a) Varying concentrations of λ 
DNA in 10 mM MES buffer were flowed through chitosan membranes.  The membranes 
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were then placed in a well plate and thermal cycled.  After thermal cycling, each sample 
was run on a gel. Lanes 1–2: 5 copies/mL; Lanes 3–4: 2.5 copies/mL; Lane 5: positive control 
(10 copies of λ DNA in PCR mix, no membrane); Lane 6: negative control (0 copies of λ 
DNA in PCR mix, no membrane).  b) Dilutions of λ DNA were wetted onto chitosan 
membranes; PCR mix was added and melt curve fluorescent traces are plotted. Three 
replicates were run at each dilution. 
 
It is important to note that while Table 4-S4 includes experiments done on multiple batches 
of membranes over 8 months, it does not include all experiments that we performed with 
chitosan-coated nylon membranes. Using binding capacity measurements (described in 
Experimental Section) and DNA capture experiments (described in S-IV), we determined 
that there was batch-to-batch variation in the fabrication process.  Therefore, only those 
batches with consistent performance were analyzed and other batches that did not meet our 
standards were excluded from analysis. 
 
Table 4-S5 summarizes Table 4-S4 by binning the various experiments into concentration 
ranges and reporting a “% Positive membranes” along with the standard error. This data is 
then plotted in Figure 4-5a of the manuscript. 
 
Table 4-S5. Histogram of Table 4-S4 with concentration bins and standard error. 
Concentration 
(cop/mL) 
positive total positive/total SE 
0 0 6 0.00 0.00 
0.2 - 0.5 5 10 0.50 0.16 
0.5 - 0.9 6 7 0.86 0.13 
0.9 -  2.0 22 25 0.88 0.06 
2.0 - 10.0 24 26 0.92 0.05 
10.0 - 20.0 8 8 1.00 0.00 
 
To reliably detect ultra-low concentrations of nucleic acids from large volumes, we reduced 
the background DNA amount to 10 ng and relaxed the constraint imposed on the experiments 
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for Figure 4-5a that the solution be flowed through the membrane at 1 mL/min. We 
instead flowed through at ~0.3 mL/min and compared 50 mL solutions with 100 ng 
background DNA to 50 mL solutions with 10 ng background DNA. These experiments 
showed that 25 copies in 50 mL can be consistently detected when the flow rate and 
background DNA are reduced from the previous constraints of 1 mL/min and 100 ng. The 
data is shown in Table 4-S6 below and summarized in the manuscript with Figure 4-5b. 
 
Table 4-S6. Volumes of 10 mM MES (2-(N-morpholino)ethanesulfonic acid) buffer and 
final concentrations of λ DNA used for Figure 4-5b. The two fabrication methods are 
described in the Experimental Section. 
Copies 
of λ 
DNA 
Volume of 10 
mM MES 
buffer (mL) 
λ DNA 
Concentra-
tion (cop/mL) 
Background DNA 
added to MES 
buffer (ng) 
Positive 
membr-
anes 
Total 
membr-
anes tested 
Fabrication 
Method 
25 50 0.5 100 6 10 B 
25 50 0.5 10 9 9 B 
 
 
Primer sequences for 𝝀𝝀-phage DNA PCR amplification and 𝝀𝝀-phage DNA LAMP 
amplification 
 
A mixture of primers from Table 4-S7 was made at 5 μM each in nuclease-free water and 
used for the PCR amplification reactions described in this manuscript. 
 
Table 4-S7. Sequences for λ-phage DNA PCR primers. 
forward CGTTGCAGCAATATCTGGGC 
reverse TATTTTGCATCGAGCGCAGC 
 
A mixture of each primer from Table 4-S8 was made in nuclease-free water and used for the 
LAMP amplification reactions described in S-IV.  The concentration of each primer in the 
20X mixture is also listed. 
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Table 4-S8.  Sequences for λ-phage DNA LAMP primers5 and their concentration in the 
20X primer mix. 
Name Sequence Conc. 
FOP GGCTTGGCTCTGCTAACACGTT 4 μM 
BOP GGACGTTTGTAATGTCCGCTCC 4 μM 
FIP CAGCCAGCCGCAGCACGTTCGCTCATAGGAGATATGGTAGAGCCGC 32 μM 
BIP GAGAGAATTTGTACCACCTCCCACCGGGCACATAGCAGTCCTAGGGAC
AGT 
32 μM 
LOOPF CTGCATACGACGTGTCT 8 μM 
LOOPR ACCATCTATGACTGTACGCC 8 μM 
 
CDI functionalization of nylon membrane 
 
Before coating with chitosan, the LoProdyne membrane was functionalized with N,N 
carbonyldiimidazole (CDI) in methylene chloride according to the manufacturer’s protocol.  
The protocol is found at this website (http://www.pall.com/main/oem-materials-and-
devices/literature-library-details.page?id=4765) and is also copied below: 
 
LoProdyne LP membrane has hydroxyl surface chemistry. The membrane binds very little 
protein in standard binding tests using IgG or BSA. The membrane can be activated for 
covalent attachment using N, N® carbonyldiimidazole (CDI) in methylene chloride as 
follows: 
 
Dissolve 0.49 g CDI in 45 mL MeCl2.  
Add to a glass dish under a fume hood.  
Immerse sheet of LoProdyne LP membrane in this solution for 15 minutes, RT.  
Wash membrane 4X with 40 mL per wash MeCl2, 5 minutes per wash.  
Air dry at 60 °C for 3 minutes. 
Store in vacuum desiccator until use. 
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Complex solutions 
 
To test whether salts in solution could interfere with electrostatic binding and decrease the 
ability of chitosan membranes to capture and detect nucleic acids, we performed preliminary 
experiments in complex solutions. Ringer’s solution was used to mimic the salt concentration 
of plasma and was made according to the instructions at the following website: 
http://cshprotocols.cshlp.org/content/2008/1/pdb.rec11273.full?text_only=true. The 
information from the website is also pasted below: 
 
Ringer’s solution (pH 7.3-7.4) 
Reagent (amount to add): NaCl (7.2 gm), CaCl2 (0.17 gm), KCl (0.37 gm). 
Dissolve all reagents into reagent-grade H2O, and bring the final volume to 1 L. Adjust the 
pH to 7.3-7.4. Once thoroughly dissolved, filter through a 0.22-μm filter, aliquot into single-
use volumes (25-50 mL), and autoclave. 
 
The final salt concentration of the Ringer’s solution is ~125 mM.  5 mM EDTA was also 
tested because plasma is often processed and stored in an anticoagulant such as EDTA. 
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Chapter V 
 
Digital, ultra-sensitive, end-point protein measurements with large dynamic 
range via Brownian trapping with drift4 
 
Abstract 
 
This paper shows that the concept of Brownian trapping with drift can be applied to improve 
quantitative molecular measurements. It has the potential to combine the robustness of end-
point spatially-resolved readouts, the ultra-sensitivity of digital single-molecule 
measurements, and the large dynamic range of qPCR; furthermore, at low concentrations of 
analytes, it can provide a direct comparison of the signals arising from the analyte and from 
the background. It relies on the finding that molecules simultaneously diffusing, drifting (via 
slow flow) and binding to an array of non-saturable surface traps have an exponentially 
decreasing probability of escaping the traps over time, and therefore give rise to an 
exponentially decaying distribution of trapped molecules in space. This concept was tested 
with enzyme and protein measurements in a microfluidic device. 
 
Introduction 
 
Digital single-molecule measurements,1 such as digital PCR (dPCR)2 and digital 
immunoassays,3 compartmentalize molecules of the target analyte, and perform a detection 
reaction providing an “on” or “off” signal for each compartment (digital unit). Analyte 
concentration is then quantified by counting the signals and using a Poisson distribution. This 
methodology has been used in a wide range of applications to detect nucleic acids and 
proteins with ultra-sensitivity.4 
                                                 
4 This chapter was first published in Journal of the American Chemical Society with authorship belonging to 
Shencheng Ge, Weishan Liu, Travis Schlappi and Rustem Ismagilov. The original manuscript can be found 
at: http://dx.doi.org/10.1021/ja507849b. Specific contributions from each author are listed at the end of the 
chapter. 
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One limitation of digital measurements is that the dynamic range (i.e. the range between the 
lowest and highest concentrations in a sample that can be measured) is limited by the number 
of digital units in the assay. Quantitative real-time PCR (qPCR), has a much wider dynamic 
range because input concentration is calculated as an exponential function of the qPCR 
output, however this method is less convenient than an end-point measurement. Dynamic 
range in dPCR can be increased by introducing very large numbers of digital units 
(compartments),5 or using digital units of multiple sizes,6 which increases the dynamic range 
by more than ~ 100 fold. However, the multivolume strategy is not as effective for digital 
immunoassays that lack the exponential amplification of PCR. One strategy to improve 
dynamic range for digital immunoassays involves combining the digital readout with the 
analog readout, which has increased the dynamic range from 2.5 logs to 4.1 logs.7 Such 
improvement is desired, for example, in assays for the biomarker glial fibrillary acidic protein 
(GFAP) in traumatic brain injury.8 
 
Results and Discussion 
 
Our goal was to test whether it would be possible to combine into a single measurement (i) 
the high sensitivity of digital assays, in which individual molecules give rise to on/off signals 
(ii) the broad dynamic range (~ 108) characteristic of a technique like qPCR, in which large 
changes in the input concentration give rise to logarithmically smaller changes in the output 
(Cq); in other words, input concentration is calculated as an exponential function of the 
output; and (iii) a readout in which the input number of molecules is quantified by an end-
point spatial signal, which is more robust than the temporal signal from kinetic real time 
assays.9  
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Figure 5-1. A conceptual schematic of a digital measurement using Brownian trapping with 
drift. This concept aims to combine the ultra-sensitivity of digital detection (shown in blue) 
with the broad dynamic range inherent in real-time PCR assays, in which large changes in 
the input concentration give rise to logarithmically smaller changes in the output (shown in 
red). 
 
Here, we tested whether our goal could be reached by implementing the concept of Brownian 
trapping with drift10 in a microfluidic device (Fig. 5-1). In Brownian trapping, target objects 
move by diffusion and are captured by traps of radius 𝜌𝜌 and trap density 𝑣𝑣. When Brownian 
trapping is combined with directional drift 𝑈𝑈 of the target objects10, the probability of a target 
object eluding the traps, 𝑃𝑃(𝑡𝑡;𝑈𝑈, 𝑣𝑣, 𝜌𝜌), decays exponentially at long times with decay rate 
𝜆𝜆(𝑈𝑈, 𝑣𝑣,𝜌𝜌), a function of U, v, and 𝜌𝜌 (Eq. 1).10c 
 
Eq. 1                              𝑃𝑃(𝑡𝑡;𝑈𝑈, 𝑣𝑣,𝜌𝜌) ~ exp(−𝜆𝜆(𝑈𝑈, 𝑣𝑣,𝜌𝜌) ∙ 𝑡𝑡) 
 
This exponential decay only occurs when traps are not saturated by the targets during the 
experiment. This phenomenon has been analyzed mathematically in the context of charge 
carriers in semiconductors,10a diffusion-controlled reactions in the presence of a biasing 
field,10d and photoluminescence in the presence of electrical bias,10b but has not been applied 
to molecular analyses. 
 
To test Brownian trapping in a digital immunoassay (Fig. 5-1), we envisioned the target 
object was a protein analyte molecule, and the traps were areas containing a capture reagent, 
such as an antibody. Traps were distributed on the channel surface, configured to act as 
  
124 
digital units, and grouped into regions (Fig. 5-2). We envisioned introducing drift using 
a gentle advective flow of solution through the microfluidic channel. Under these conditions, 
each trap provides a digital on/off readout (Fig. 5-2). At low concentrations, we hypothesized 
that most analyte molecules would be trapped at the beginning of the channel and 
concentration could be estimated using the conventional Poisson statistics of digital 
immunoassays.3c However, at high concentrations, we hypothesized that analyte 
concentration could be estimated using a spatial analogue of Eq. 1 (see S1).  
 
 
Figure 5-2. An experimental design to test the concept of digital measurements based on 
Brownian trapping with advective drift. (A) Schematic of the design, which features a 
shallow channel (50 µm) on top of an array of microwells. A bead (orange) coated with a 
capture reagent (e.g. an antibody), is placed in each microwell. The channel guides the flow 
of the sample over the microwells, and target molecules (blue) are captured by the beads. 
After labeling, the microwells are compartmentalized by fluorocarbon for digital readout.  
(B) A photograph of an assembled device with 10 parallel arrays. (C) A fluorescent image 
of the digital readout. 
 
Our experimental design (Fig 5-2) satisfied four criteria arising from the concept of 
Brownian trapping with drift10 (we have not optimized experimental parameters, instead 
choosing one experimentally convenient combination; see SI). (i) Drift should dominate over 
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diffusion of the protein target (diffusion coefficient D ~ 10-11 m2/s) along the flow 
direction x (here, Péclet number Pex = UL/D ~ 103), with each region sufficiently long (L ~ 
10-3 m) and flow sufficiently high (U ~ 10-5 m/s). Under these conditions, the exponential 
decay over time (Eq. 1) would be manifested as an exponential decay over space (Fig. 5-1), 
effectively converting temporal distribution into spatial distribution. (ii) At the same time, 
flow should be slow enough that diffusion of the protein from the top to the bottom of the 
channel (H) is not slower than flow over one region (Pez = (U/L)/(D/H2) ~ 2.5); (iii) Each 
trap should have high binding capacity so it is not saturated by the targets during the 
experiment. Beads used for digital immunoassays3,4a,4c,4d satisfy this criterion. This criterion 
has not been met previously in innovative quantification approaches that flow a sample 
through a microfluidic channel to generate a density gradient on the channel surface.11 In 
such experiments, the protein signal decayed linearly over channel length instead of 
exponentially. (iv) The Damköhler number Da ~ kon[Ab]L/U, (estimated to be ~ 1, [Ab] is 
the concentration of the capture reagent) should be close to or greater than 1 to enable rapid 
capture of the target molecules once they diffuse to the traps. 
 
We tested this concept experimentally using a glass SlipChip device12 (Fig. 5-2B), which 
contained 10 parallel arrays created by dry-etching with C4F8, each containing 540,000 
microwells grouped into regions. Each well was loaded with a single bead coated with a 
capture antibody. We took advantage of the relative movement of the two plates of the 
SlipChip to achieve uniform and near-complete bead loading. As the sample passed over the 
wells, the protein targets were trapped on the beads, rapidly depleting the target analyte from 
the flowing solution.  
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Figure 5-3. Experimental evaluation of the digital protein measurement with Brownian 
trapping with drift.  A) Capture curves of biotinylated β-galactosidase with concentrations 
ranging from 10 aM to 0.3 nM. The red lines indicate data re-plotted in panels B, C, and D.  
B) A plot of the positive fraction of beads at the first region vs low analyte concentrations, 
from 9 aM to 20 fM. The dotted horizontal line represents the lower limit of quantification.  
C) A plot of Rq (region of quantification, threshold of 0.07 positive fraction) vs the logarithm 
of analyte concentration ranging from 1 fM to 1 pM.  D) A plot of Rq (threshold of 0.8 
positive fraction) vs the logarithm of analyte concentration ranging from 0.1 pM to 0.3 nM.  
E) A plot of the positive fraction of beads in the entire array in a standard digital protein 
assay at concentrations ranging from 0.1 fM to 10 nM. The dotted horizontal lines represent 
the upper and lower limits of quantification. 
 
We first used a simple model system with biotin-modified β-galactosidase as the target 
analyte (3 µL samples in a range of concentrations) and streptavidin-coated beads as the 
capture agents. First, the enzyme solution was flown over the beads through the channel at a 
  
127 
velocity of 17 µm/s for 1 h. Then a solution of fluorogenic substrate resorufin β-D-
galactopyranoside (RGP) was injected into the channel, immediately followed by a flow of 
FC40 to compartmentalize the beads in the microwells. Analyte concentration was estimated 
using the fraction of beads that captured at least one molecule (positive fraction of beads) 
3,4a,4c,4d  (Fig. 5-3A). Analyte molecules were preferentially captured in the upstream regions, 
so low analyte concentrations were quantified by the positive fraction of wells located in the 
first capture region (Fig. 5-3B). We calculated the limit of detection (LOD) from three times 
the standard deviation of the experimentally measured background signal to be 9 aM.  At 
higher concentrations, as is established,7 we used a fraction of 0.8 as the practical upper limit, 
corresponding to 20 fM (Fig. 5-3B). 
 
At high analyte concentrations, beads in the upstream regions contained many analyte 
molecules, precluding end-point digital quantification using those regions (we emphasize 
that beads, which could bind ~105 analyte molecules, were not expected to be fully saturated 
with analyte under those conditions). Analyte molecules were also captured in the 
downstream regions. As predicted, we observed that exponentially increasing analyte 
concentration gave rise to an approximately linear shift in the region where the capture curve 
crossed a threshold value of positive fraction (Figs. 5-3A, 5-3C, 5-3D). We refer to this 
region as Rq (region of quantification), analogous to Cq used in qPCR; its position depends 
on the value of the chosen threshold. Using a low threshold of 0.07 positive fraction (Fig. 5-
3C) provided a dynamic range that overlapped well with the digital calibration curve (Fig. 5-
3B) while extending it by ~ 102 (above 1 pM). Using a high threshold of 0.8 positive fraction 
(Fig. 5-3D) further extended the dynamic range above 0.3 nM. The combined dynamic range 
was ~ 4 x 107-fold, with a sensitivity of ~ 20 molecules in 3 µL. 
 
For comparison, in an identical SlipChip device we performed a standard digital protein 
assay in which the whole solution was injected into the device rapidly and kept stationary 
during a 1 h incubation, followed by detection as described above. The calculated dynamic 
range in this stationary assay ranged from 0.02 fM to 0.5 pM, demonstrating a range of ~ 
20,000-fold, and a sensitivity of ~ 30 molecules (Fig. 5-3E). Therefore, the digital 
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measurement based on Brownian trapping with drift showed similar sensitivity but a 
more than 1,000-fold improvement in dynamic range relative to the stationary digital assay 
in the same device. 
 
We then tested how this approach performs in a more complex, clinically relevant 
immunoassay for a human protein target, TNF-α in a 25% serum. To streamline the multi-
step ELISA protocol, we adopted a cartridge-with-spacers approach in which all reagents 
were loaded into a cartridge as plugs separated by FC40 fluorocarbon and air, then delivered 
into the channel13 (Fig. 5-S3). We performed calibrations with 8 μL samples containing 
known TNF-α concentrations in buffered 25% bovine serum. The captured TNF-α molecules 
were then incubated with 6.5 nM biotinylated detection antibody for 1 h, followed by a 0.5 
h incubation with 400 pM streptravidin-galactosidase conjugate and compartmentalization 
with fluorocarbon.  
 
 
Figure 5-4. A test of digital measurements based on Brownian trapping with advective drift 
using human TNF-α. (A) Capture curves obtained from 25% bovine serum samples spiked 
with increasing concentrations of recombinant TNF-α. From bottom to top, curves represent 
TNF-α concentrations of 0 pM, 0.01 pM, 0.02 pM, 0.1 pM, 1 pM, 10 pM, 100 pM, 1,000 
pM, and 2,000 pM. The blue line underlies the background signal level directly measured in 
the assays at low concentrations  (B) A plot of positive bead fraction at low concentration of 
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TNF-α corresponding to the vertical dotted red line in A. The dotted horizontal line 
represents the background signal + 3 S.D. The endogenous [TNF-α] in 25% pooled human 
serum is shown by the star symbol. C) A plot of Rq (region of quantification, threshold of 
0.11 positive fraction) vs the logarithm of TNF-α concentration ranging from 20 fM to 10 
pM.  D) A plot of Rq (threshold of 0.8 positive fraction) vs the logarithm of TNF-α 
concentration ranging from 1 pM to 2 nM.  
 
The measurement preserved ultra-sensitivity, with an LOD of 6 fM (Fig. 5-4B). We used this 
measurement to determine the endogenous concentration of TNF- in pooled human serum, 
which is below the detection limit of a conventional ELISA.14 The measured concentration 
was 0.031 ± 0.001 pM in 25% serum (Fig. 5-4B), which translates to 0.125 ± 0.004 pM in 
pure serum. This value is consistent with those determined previously using other single-
molecule approaches.4a,15 At higher concentrations, using a low threshold of 0.11 positive 
fraction (Fig. 5-4C) provided a dynamic range of ~103, and using a high threshold of 0.8 
positive fraction (Fig. 5-4D) extended it to 2 nM, for a total dynamic range of ~300,000 fold. 
While this is wider than the dynamic range achieved previously by digital readout alone (~ 
316-fold)3c or the digital and analog readouts combined (~ 13,000-fold),7 it is smaller than 
the dynamic range obtained under the more ideal conditions with enzymes (Fig. 5-3). 
 
Conclusion 
 
We conclude that the concept of Brownian trapping with drift can be used for digital 
measurements of proteins that combine high sensitivity of digital assays with large dynamic 
range of qPCR but with an end-point readout. This combination of features has not been 
demonstrated previously and may be advantageous even for nucleic acid quantification. 
These findings justify performing future work to understand how combinations of values 
(and their variability) of Pex, Pez, Da, capture efficiency, flow control, 16 device design and 
assay chemistry impact assay performance, and enable the design of optimal assays for a 
given analyte. For example, given the similarity to qPCR, we anticipate lower resolution at 
higher concentrations where errors in determining the Rq parameter would lead to 
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exponentially larger errors in quantification. It remains to be tested whether methods 
analogous to those used in qPCR (e.g. the use of spatial or color multiplexing to introduce 
quantification controls and/or introduce parallel assays targeting multiple epitopes of the 
same target) could be used with this approach. The low sample consumption and the use of 
smaller numbers of wells per measurement with a given dynamic range (see S8) would make 
this approach compatible with spatial multiplexing and single-cell analysis.17 Finally, we 
emphasize that at low concentrations of analyte the downstream regions provide a direct 
measurement of the background signal of the assay (Fig. 5-4A). This feature should be useful 
to improve assay fidelity. 
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Theoretical description and analysis 
Drift dominates the transport of analytes along a channel when the ratio of advection rate to 
diffusion rate is much greater than 1. The Péclet number characterizes this balance and is 
defined in the longitudinal direction as follows: 
 Eq. S1                   𝑃𝑃𝑃𝑃𝑥𝑥 = 𝑎𝑎𝑎𝑎𝑎𝑎𝑟𝑟𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 𝑐𝑐𝑎𝑎𝑐𝑐𝑟𝑟 𝑐𝑐𝑐𝑐 𝑥𝑥𝑎𝑎𝑐𝑐𝑑𝑑𝑑𝑑𝑢𝑢𝑎𝑎𝑐𝑐𝑐𝑐𝑐𝑐 𝑐𝑐𝑎𝑎𝑐𝑐𝑟𝑟 𝑐𝑐𝑐𝑐 𝑥𝑥 = 𝑈𝑈/𝐿𝐿𝐷𝐷/𝐿𝐿2 = 𝑈𝑈𝐿𝐿𝐷𝐷 . 
 
In our experiment, the target analyte (protein) had a diffusion coefficient D ~ 10-11 m2/s, drift 
velocity U ~ 10-5 m/s, and was flown past capture regions of length L ~ 10-3 m, resulting in 
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Pex ~ 103.  Thus, longitudinal transport of an analyte molecule and its distance traveled 
as a function of time, 𝑥𝑥(𝑡𝑡), can be formulated to ignore diffusion effects and depends only 
on drift velocity: 𝑥𝑥(𝑡𝑡) ≈ 𝑈𝑈𝑡𝑡. Replacing 𝑡𝑡 ≈ 𝑥𝑥/𝑈𝑈 in Eq 1 converts the exponential decay over 
time into an exponential decay over space. 
 
At the same time, flow should be slow enough that diffusion of the protein from the top to 
the bottom of the channel (H) is comparable relative to flow over one capture region.  This 
ensures that analyte molecules aren’t advected away before they have a chance to diffuse 
down to the capture beads. Again, the Péclet number formulates this comparison: 
 Eq. S2                   𝑃𝑃𝑃𝑃𝑧𝑧 = 𝑎𝑎𝑎𝑎𝑎𝑎𝑟𝑟𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 𝑐𝑐𝑎𝑎𝑐𝑐𝑟𝑟 𝑐𝑐𝑐𝑐 𝑥𝑥𝑎𝑎𝑐𝑐𝑑𝑑𝑑𝑑𝑢𝑢𝑎𝑎𝑐𝑐𝑐𝑐𝑐𝑐 𝑐𝑐𝑎𝑎𝑐𝑐𝑟𝑟 𝑐𝑐𝑐𝑐 𝑧𝑧 = 𝑈𝑈/𝐿𝐿𝐷𝐷/𝐻𝐻2. 
 
In our experimental setup, H = 50 µm, resulting in Pez ~ 2.5. 
 
Finally, for trapping to be effective and give rise to an exponential decay in space, the capture 
rate of analyte molecules onto the beads must be comparable to the transport rate away from 
the beads, as shown by the Damköhler number: 
 Eq. S3                   𝐷𝐷𝑟𝑟 = 𝑐𝑐𝑎𝑎𝑎𝑎𝑐𝑐𝑢𝑢𝑐𝑐𝑟𝑟 𝑐𝑐𝑎𝑎𝑐𝑐𝑟𝑟
𝑐𝑐𝑐𝑐𝑎𝑎𝑐𝑐𝑎𝑎𝑎𝑎𝑐𝑐𝑐𝑐𝑐𝑐 𝑐𝑐𝑎𝑎𝑐𝑐𝑟𝑟 𝑐𝑐𝑐𝑐 𝑥𝑥 = 𝑘𝑘𝑑𝑑𝑛𝑛[𝐴𝐴𝐴𝐴]𝑈𝑈/𝐿𝐿 . 
 
In our experimental setup, kon ~ 105 M-1 s-1, [Ab] ~ 10-7 M, resulting in 𝐷𝐷𝑟𝑟~1. 
 
Origin of the exponential decay in space 
 
Exponential decay in space is reasonable because if capture efficiency in each region is 
constant, then connecting the regions in series will result in an exponential relationship 
between analyte molecules captured and region number 
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Replacing 𝑡𝑡 = 𝑛𝑛 ∙ Δ𝑡𝑡 in Eq. 1, Eq. S4 represents the number of free analyte molecules in 
solution that survive up until the exit of region 𝑛𝑛 (𝑛𝑛 = 1,2,3 … ), where Δ𝑡𝑡 is the residence 
time over each region and 𝐶𝐶0 is the initial amount of analytes. 
 Eq. S4                   𝑁𝑁𝑑𝑑𝑐𝑐𝑟𝑟𝑟𝑟(𝑛𝑛) = 𝐶𝐶0𝑃𝑃−𝜆𝜆𝑐𝑐Δ𝑐𝑐 
 
Because the amount of captured molecules is simply the free molecules exiting the region 
subtracted from the free molecules entering the region, the capture efficiency can be 
calculated according to Eq. S5. Eq. S5                   𝛽𝛽 = captured molecules in region 𝑛𝑛surviving molecules entering region 𝑛𝑛= 𝐶𝐶0𝑃𝑃−𝜆𝜆(𝑐𝑐−1)𝛥𝛥𝑐𝑐 − 𝐶𝐶0𝑃𝑃−𝜆𝜆𝑐𝑐𝛥𝛥𝑐𝑐
𝐶𝐶0𝑃𝑃−𝜆𝜆(𝑐𝑐−1)𝛥𝛥𝑐𝑐 = 1 − 𝑃𝑃−𝜆𝜆𝛥𝛥𝑐𝑐 
Because 𝜆𝜆 and Δ𝑡𝑡 are both constant for this assay, the capture efficiency is constant in each 
region. 
 
If the capture efficiency is constant in each region and the regions are connected together in 
series, one would expect an exponential decay for the free analytes in solution because they 
are reduced by a factor of 𝛽𝛽 after each region. As long as there is an excess of capture 
antibodies, the capture process will only depend on the amount of free analytes in solution; 
thus, we also expect to see an exponential decay in captured analytes. In fact, solving Eq. S5 
for the amount of captured analyte molecules in region 𝑛𝑛 directly reveals this exponential 
relationship between captured analyte molecules (𝑁𝑁𝑐𝑐𝑎𝑎𝑎𝑎𝑐𝑐𝑢𝑢𝑐𝑐𝑟𝑟𝑎𝑎) and region number 𝑛𝑛. 
 Eq. S6                   𝑁𝑁𝑐𝑐𝑎𝑎𝑎𝑎𝑐𝑐𝑢𝑢𝑐𝑐𝑟𝑟𝑎𝑎(𝑛𝑛) = 𝛽𝛽𝐶𝐶0𝑃𝑃−𝜆𝜆(𝑐𝑐−1)Δ𝑐𝑐 
 
Materials 
 
The paramagnetic beads for enzyme were Agilent LodeStar 2.7 Streptavidin (Agilent 
Technologies, Santa Clara, CA). The magnetic beads for TNF-α assays were Agilent 
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LodeStar 2.7 Carboxyl (Agilent Technologies), covalently attached to the antibody by 
standard coupling chemistry. β-galactosidase from Escherichia coli (G3153, Sigma-Aldrich, 
St. Louis, MO) was biotinylated using the Chromalink biotinylation reagent and diluted in 
Starting Block T20 PBS (Thermo Scientific, Waltham, MA ). Monoclonal anti-TNF-α 
antibody, recombinant TNF-α calibrator, and detection anti-TNF-α antibody were purchased 
from R&D Systems (Minneapolis, MN). The Streptavidin-β-galactosidase (SβG) conjugate 
and the enzyme substrate RGP were purchased from Life Technologies (Grand Island, NY). 
Pooled human serum was purchased from ValleyBiomedical (Winchester, VA). Bovine 
serum was purchased from Thermo Scientific (Waltham, MA). Fluorocarbon oils FC40 and 
FC3283 were obtained from 3M (St. Paul, MN). RfOEG (triethyleneglycol mono[1H,1H-
perfluorooctyl]ether) was synthesized in the lab. 
  
Device fabrication 
 
Sodalime and borofloat glass plates coated with Cr and photoresist (Telic company, 
Valencia, CA) were used to fabricate the device. Standard photolithographic methods were 
used to transfer the designed pattern, including the microwells and channels, onto the glass 
plates. The photomask was designed using Autocad and then printed on a transparent film 
(CAD/Art Services, Bandon, OR) or a Cr mask (Photo sciences, Torrance, CA) (Figure 5-
S1). A PDMS/glass adapter was used to connect the tubing to the device. 
 
To fabricate the channels in the top plate of the device, we used a wet-etching method with 
hydrofluoric acid. Briefly, the back and side of the plate were taped to protect the bare glass 
from HF etching. Then the glass plates were immersed in HF etching solution at 40° C with 
continuous shaking. Photoresist/chrome served as the etching mask. All channels were 
etched to a depth of 50 µm. Typical etching rate under these conditions was 1.3 µm/min. 
After etching, plates were rinsed thoroughly with water to remove residual HF and blown 
dry with nitrogen. Remaining photoresist and the chromium layer were removed by acetone 
and chrome etchant. Through holes were drilled at both ends of the channels and then the 
plate was thoroughly cleaned with piranha solution. Finally, the plate was air plasma treated 
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for 100 s and subjected to gas-phase silanization using trichlorosilane (Tridecafluoro-
1,1,2,2 –tetrahydrooctyl; Gelest Inc., Morrisville, PA) . Briefly, the vacuum in a glass 
desiccator was pumped down to 0.4 Torr at room temperature to facilitate the vaporization 
of fluorosilane, and then the chamber was closed for 1 h. Next, the plate was baked at 95° C 
overnight and rinsed by FC3283 to remove unbound silane. The plate was further baked for 
at least 30 min to complete the fluorosilanization procedure. 
 
To fabricate microwells in the bottom half of the device for single-bead confinement, we 
used borofloat glass plates and a fluorine-based dry etching method with C4F8-based plasma. 
Briefly, the photoresist was removed from the glass plate following the photolithography 
step using acetone. The remaining Cr layer served as the dry-etching mask. The glass plate 
was mounted on a 6-in carrier wafer using thermogrease fomblin and subject to C4F8-based 
plasma etching (plasmalab 100, oxford instrument) under the following conditions: chamber 
pressure 10 mT, C4F8 flow rate 40 sccm, and ICP power 3000w. Typical etching rate under 
these conditions was 0.2–0.3 µm/min. Uniform single-bead loading per microwell is 
important for downstream digital readout and data interpretation using Poisson statistics. To 
improve etching uniformity across the plate, a two-step etching protocol was adopted. At the 
end of the first half of the etching step, the plate was removed from the chamber and 
subjected to a sonication-assisted wash to remove non-volatile residuals, such as sodium 
fluoride. Then the plate was rinsed by isopropanol and blown dry using nitrogen. The second 
half the etching step was performed with the plate rotated 180o to increase etching uniformity. 
 
A hydrophilic surface chemistry in the microwell is also important for successful bead 
loading, as hydrophobic wells fail to load beads. We chose to functionalize the microwell 
surface with PEG-silane both to render it hydrophilic and prevent non-specific protein 
adsorption. To fabricate PEGlated microwells on a hydrophobic surface, the dry-etched plate 
was first briefly etched with diluted HF in a sonication batch to regenerate the glass surface 
in the etched microwells. Then, the microwells were PEG-silanized. Briefly, 150 μL silane 
were dissolved in 100 mL toluene and then 80 μL HCl was added in a dropwise manner 
while the mixture was sonicated. The mixture was further sonicated for 10 min before use. 
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The plate was immersed in this mixture and subjected to brief sonication to ensure wetting 
of the microwells. The plate was incubated at room temperature on a shaker for 1 h and 
washed sequentially by toluene and ethanol. Next, the plate was baked at 150° C for 30 min 
to finish the PEG silanization procedure. To protect the PEG chemistry in the etched 
microwells from downstream fluorosilanization, sacrificial resist was used to preserve the 
surface chemistry. The plate was spin-coated with a negative photoresist NR9-3000PY 
(Futurrex, Franklin, NJ) and baked. Then the plate was flipped and exposed to UV light using 
the Cr as an embedded mask. The photoresist was developed according to manufacturer’s 
protocol. Next, the chrome layer was removed using chrome etchant. The plate was 
thoroughly rinsed by water and baked at 95° C for 30 min to dry. The plate was then air 
plasma treated and fluorosilanized using the protocol outlined above. Finally, the sacrificial 
photoresist was removed in hot DMSO (110° C, 10 min). The surface outside of the 
microwells functionalized with fluorinated silane is fluorophilic. This combination of 
hydrophilic and fluorophilic surface chemistry allows the microwells to be easily 
compartmentalized for downstream digital readout by simply flowing fluorocarbon oils over 
the microwells. 
 
To fabricate the PDMS/glass adapter, access holes were first drilled on a sodalime glass plate 
to match the inlet ports on the top half the device. A PDMS slab with matching access holes 
was then plasma-bonded to the glass plate. The complete adapter was plasma treated for 100 
sec and fluorosilanzed following the procedure outlined above. 
  
Device operation and bead loading 
 
The bottom half of the device was briefly sonicated in water to pre-wet the microwells. A 
wet cleanroom wipe was used to cover the regions of microwells. Then 100 µL of FC40 
containing 0.4 mg/ml fluoro-surfactant RfOEG was applied to the plate along the cloth edge 
and the top half of the device was assembled. The wipe was gently pulled out from the gap 
and the additional FC40 was injected into the channels using manual pipettes. At this stage, 
the device is ready for bead loading. 
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Capture reagent-coated magnetic beads were stored in starting block PBS solution at 4° C. 
Prior to use, the beads were concentrated to 75 mg/ml in the same buffer and then 2-3 µL of 
the bead slurry was injected to the channel. Next, the device was held on the edge of a magnet 
so that the channel axis aligned with the magnet edge and the beads in the channel were 
pulled uniformly toward the channel side. While held on the magnet, the top glass plate was 
gently slipped away from the magnet and the beads were physically scraped against the 
magnetic pulling force. As a result, the beads were actively pulled into the well while the 
unloaded beads were removed from the surface.  By using concentrated bead slurry and 
repeating the loading procedure, both high loading efficiency and uniformity in bead loading 
across the chip were obtained. Typical loading efficiency was >90%. The unloaded beads 
were collected, washed, and stored in TPBS for future use. Next, the device was manually 
aligned under a stereoscope so that the channels on the top plate aligned with the microwell 
features on the bottom. A PDMS/glass adapter was then used to connect Teflon tubing to the 
device inlets. The tubing contained the following solution sequence: FC40, 0.5 µL air, 2 µL 
FC40 and then 5 µL washing buffer (PBS with 0.05 % Tween-20). The solution sequence 
was pumped through the channel at a rate of 0.5ul/min to remove any loose beads. The 
microwells were finally resealed by FC40 and the device was stored on ice until use. 
 
Digital measurements of enzyme 
 
Test solutions of biotinylated β-galactosidase were prepared by diluting in TPBS with 1 mM 
MgCl2. The solutions of 3 µL are either (i) directly pipetted into the device and incubated for 
an hour; or (ii) gently aspirated into Teflon tubings and then delivered to the channels at 0.05 
µL/min for 1 h, controlled by a syringe pump equipped with a multi-syringe rack. The device 
is then washed with 30 µL PBS with 0.05 % Tween-20 per channel. The device then is loaded 
with 100 mM RGP in PBS with 0.05 % Tween-20 and 1 mM MgCl2, and digitized by flowing 
FC40 into the channels. The device was imaged after 15 minutes. 
 
Digital measurements of TNF-α 
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Standard ELISA procedure was followed to perform the on-chip digital immunoassay for 
TNF-α. Syringe pump and Teflon tubing preloaded with washing buffer and other reagent 
solution were used to deliver the solution to the device. In addition, the assay was performed 
on a magnet to minimize bead loss. 
 
Specifically, the calibrator sample were prepared in 25% bovine serum to 75% TPBS buffer. 
25% pooled human serum sample was similarly prepared to measure the endogenous 
concentration of TNF-α. The antibody and β-galactosidase -streptavidin conjugate was 
diluted in TPBS. The washing buffers were 1x and 5x PBS containing 0.1% Tween-20 (1x 
PBST and 5x PBST). The solutions was preloaded into Teflon tubing and delivered to the 10 
channels on the device simultaneously using a syringe pump equipped with a multi-syringe 
rack.  The flow rate was 2 µL/min except at 0.1 µL/min for the sample plug. Throughout the 
assay, as multiple air-aqueous, air-oil and aqueous-oil interfaces migrated through the bead-
loaded regions, the device was kept on a magnet to minimize bead loss. Solution sequence 
was stopped during incubation with detection antibody and enzyme conjugate and then 
resumed subsequently. The second (b) and third (c) solution sequences were pumped through 
the device from the opposite direction of the first solution sequence (a) to avoid potential 
cross-contamination of target analytes between regions. Details of the solution sequences 
were as follows (also see Fig. 5-S3): 
 
a. FC40, 0.5 µL air, 2 µL FC40, 2 µL 5x PBST, 0.5 µL air, 4 µL 5x PBST, 0.5 µL air, 2 µL 
1x PBST, 0.5 µL air, and 8 µL serum sample. 
b. FC40, 0.5 µL air, 2 µL FC40, 3 µL 5x PBST, 0.5 µL air, 3 µL 5x PBST, 0.5 µL air, 4 µL 
biotinylated detection antibody, 0.5 µL air, 4 µL 1x PBST. 
c. FC40, 0.5 µL air, 2 µL FC40, 2 µL enzyme substrate, 0.5 µL air, 3 µL 1x PBST, 0.5 µL 
air, 5 µL 5x PBST (total 5 repeats), 4 µL streptavidin-galactosidase conjugate, 0.5 µL 1x 
PBST. All aqueous solutions were supplemented with 1 mM MgCl2 to enhance the enzyme 
activity of β-galactosidase. 
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The total assay time takes ~ 6 h. Specifically, it takes ~0.5 h for bead loading, ~2 h for 
sample delivery for a volume of 8 µL, 1 h for incubation with a detection antibody, 0.5 h for 
incubation with streptavidin-galactosidase, ~0.5 h for washing, and ~1.5 h for incubation 
with substrate and subsequent imaging. 
 
Image acquisition and analysis 
 
Fluorescence images were acquired in TexasRed and GFP channels on an inverted 
microscope equipped with a 0.63x camera adapter and a digital CCD camera using the 
autofocus function to enhance quality. Positive bead count and total bead count were 
analyzed based on threshold fluorescence intensity and morphological criteria. The image 
acquisition, processing, and analysis were all performed using MetaMorph software 
(Molecular Devices, Sunnyvale, CA). 
 
Specifically, the acquired images were digitally processed and analyzed using the following 
sequence in Metamorph: (a) subtract the uniform background arising from the dark current 
of the camera; (b) flatten the field of view to remove the bias in fluorescent intensity resulting 
from non-uniform illumination; (c) apply “No Neighbors” function in Metamorph to reduce 
the haze effect and improve contrast.  
 
Next, the selection and quantification of positive beads were automatically performed using 
the Metamorph function of “threshold image” and “integrated morphometry analysis” based 
on the following criteria: (a) Fluorescence intensity > 500 (Figure 5-S5A); (b) “Area” range 
for inclusion: 2-50 pixels; (c) “Shape factor” range for inclusion: 0.9-1 inch. Finally, the 
correct selection of positive beads was confirmed visually. 
 
Achieving a given dynamic range with fewer wells in digital assay with drift relative to a 
standard digital assay 
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The Brownian trapping with drift format achieves a larger dynamic range with fewer 
wells than a standard digital format.  This can potentially be useful in single cell analysis, 
and in multiplexed assays, where one wants each cell to use as few wells as possible in order 
to fit them all onto a chip.  As an example, consider the theoretical calculation of dynamic 
ranges for a standard digital assay with 5000 wells compared to a digital assay with drift as 
described in this manuscript, but only containing 150 wells.  The volume of sample analyzed 
is 5 𝜇𝜇𝜇𝜇 and each well in both formats has a volume of 1 nL.  Labeling efficiencies and 
background effects are ignored as this is a simplified model intended to compare the dynamic 
ranges, not predict actual outcomes.   
  
Standard digital assay 
 
LDL is the lower detection limit and is defined as the concentration which would have a 95% 
chance of generating a least one positive well and equals the concentration calculated from 
three positive wells [1].  To calculate the concentration from three positive wells, one uses 
Eq. 2 from Reference [1], which is derived from the Poisson distribution. 
 
Eq. S7                   𝜇𝜇𝐷𝐷𝜇𝜇 = − ln �𝑤𝑤 − 3𝑤𝑤 �
𝑣𝑣
 
 
For 𝑤𝑤 = 5000 wells and a well volume 𝑣𝑣 = 1 nL, 𝜇𝜇𝐷𝐷𝜇𝜇 = 0.6 molecules/𝜇𝜇L. 
 
ULQ is the upper limit of quantification and is defined as the concentration which would 
have a 95% chance of generating at least one negative well and equals the concentration 
calculated on the basis of three negative wells [1]. 
 
Eq. S8                   𝑈𝑈𝜇𝜇𝑄𝑄 = − ln �3𝑤𝑤�
𝑣𝑣
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For 𝑤𝑤 = 5000 wells and a well volume 𝑣𝑣 = 1 nL, 𝑈𝑈𝑄𝑄𝜇𝜇 = 7.42 ∙ 103 molecules/𝜇𝜇L.  
Thus, the dynamic range, 𝑈𝑈𝜇𝜇𝑄𝑄/𝜇𝜇𝐷𝐷𝜇𝜇, is 104.09. 
 
Digital assay with drift 
 
The dynamic range of a digital assay with drift depends on how many regions there are, the 
capture efficiency of each region (𝛽𝛽), and the number of wells in each region.  Consider a 
microfluidic chip with 15 regions, 10 wells in each region, and a capture efficiency of 25%.  
The LDL for the drift assay can be calculated by asking what concentration one must start 
with in order to have three positive wells in the whole device.  At the completion of the assay, 
the total amount of captured analyte molecules is simply the analyte molecules escaping 
region 15 (calculated with Eq. S4) subtracted from the initial amount, 𝐶𝐶0. 
 Eq. S9                   𝑁𝑁𝑐𝑐𝑎𝑎𝑎𝑎𝑐𝑐𝑢𝑢𝑐𝑐𝑟𝑟𝑎𝑎 = 𝐶𝐶0 − 𝐶𝐶0𝑃𝑃−15𝜆𝜆Δ𝑐𝑐 
 
Setting Eq. S9 equal to Eq. S7 with 𝑤𝑤 = 150 and 𝑣𝑣 = 1 nL yields 𝐶𝐶0 = 𝜇𝜇𝐷𝐷𝜇𝜇 = 20.5 
molecules/𝜇𝜇L. 
 
The ULQ for the drift assay can be calculated by asking what concentration one must start 
with in order to have three negative wells in the final region (the preceding regions will all 
be saturated).  The amount of captured analyte molecules in the 15th region is found from Eq. 
S6.  
 Eq. S10                   𝑁𝑁𝑐𝑐𝑎𝑎𝑎𝑎𝑐𝑐𝑢𝑢𝑐𝑐𝑟𝑟𝑎𝑎(15) = 𝛽𝛽𝐶𝐶0𝑃𝑃−𝜆𝜆Δ𝑐𝑐(15−1) 
 
Setting Eq. S10 equal to Eq. S8 with 𝑤𝑤 = 10 and 𝑣𝑣 = 1 nL yields 𝐶𝐶0 = 𝑈𝑈𝑄𝑄𝜇𝜇 = 2.70 ∙ 105 
molecules/𝜇𝜇L.  Thus, the dynamic range is 104.12, which is comparable to the dynamic range 
of the standard digital assay, but with only 150 wells instead of 5000. 
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Figure 5-S1. Photomask design. (A) Each channel contains a total of 541,250 microwells 
(125 vertical x 4330 horizontal), arranged in a hexagonal pattern with a center-to-center 
spacing of 8 µm. Channels were divided into 22 regions, each of which consisted of 24,604 
microwells.  Horizontal stripes with a width of 100 µm were included to control the etching 
depth and uniformity across the chip. (B) Channels were arranged to precisely match the 
microwell features. An etching depth of 50 µm by isotropic HF etching yields an actual 
channel width of 1,000 µm.” 
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Figure 5-S2. Etching profile examined by SEM. Etching depth needs to be precisely 
controlled to confine single beads (A and B). The dimension for the etched microwells is 
approximately 3 µm in diameter and 3 µm in depth, just enough to accommodate a single 
2.7 µm bead. Over-etched microwells (C and D) can load more than one bead and thus were 
not used in the experiment.  
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Figure 5-S3. Solution sequences used for on-chip immunoassays. Solutions were loaded in 
Teflon tubing with air spacers and infused into channels using a syringe pump at a controlled 
flow rate. See experimental section for solution volumes. 
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Figure 5-S4. Device assembly and operation to perform the on-chip digital assay. (A) Two 
complementary microfluidic plates were assembled and aligned with the etched features 
facing each other. (B) The bead slurry was injected into the channels and then loaded into 
the microwells using a magnet and a slipping motion. Excess beads were removed and the 
plates were realigned.  
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Figure 5-S5.  Experimental results and analysis. (A) Histogram of average fluorescence 
intensity for negative and positive bead fractions. Fluorescence signals (“positive” beads) 
that arise from enzymatic activities are clearly differentiated from the background 
fluorescence signal (“negative” beads) and provides the justification of a fluorescence 
intensity threshold of 500 a.u. (red dashed line). (C-F) Characteristic readout images acquired 
at different positions (region numbers) along the channel for the 1.0 pM curve from Figure 
5-4. 
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Figure 5-S6. (A) Curves of best fit for Figure 5-3. The surface concentration of the captured 
enzyme molecules was simulated using COMSOL Multiphysics, based on a transport-and-
adsorption model. A 2D channel was built and meshed with a height of 50 μm and a length 
of 4 cm. The surface concentration of the capture agent was 1.4 x 10-9 mol/m2; the diffusion 
coefficient was 0.25 x 10-10 m2/s; the flow velocity was 17 μm/s; and the reaction time was 
3600 seconds. The kon for a mono-biotin-labeled enzyme and the streptavidin coated on beads 
was assumed to be 1.6 x 105 M-1 s-1; and it was assumed that the total kon is proportional to 
the number of biotin labeled to the enzyme, which follows a Poisson distribution with an 
average labeling ratio of 7.9. The koff was assumed to be 5 x 10-9 s-1. The surface concentration 
of the captured enzyme molecules was converted to positive fraction of beads assuming 
625,000 beads were loaded. (B) Curves of best fit for the data in Figure 5-4. Simulation for 
the concentration of the target molecules was performed similarly as above, with parameters 
as follows: channel height was 50 μm; channel length was 3 cm; surface concentration of 
capture antibody was 3.75 x 10-9 mol/m2; kon was 2 x 105 M-1 s-1; koff was 8 x 10-7 s-1; the 
diffusion coefficient was 0.9 x 10-10 m2/s; flow velocity was 33 μm/s; and reaction time was 
4800 seconds. The surface concentration of the captured target molecules was multiplied by 
a labeling efficiency of 4%, converted to a positive fraction of beads assuming 540,000 
beads, then added to the experimental measured background of 0.06 (positive fraction of 
beads). Given the complexity in the experiment including the matrix effect in the serum, 
heterogeneous activities of molecules, and non-specific binding, the theoretical fit to 
experimental data ranging from 0 pm to 1.0 pM was remarkable. The fits deviate from 
experimental data for the high concentration range (>1.0 pM, not shown) and the origin of 
the deviation will be a subject for future investigation. (C) Impact of drift velocity, and thus 
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capture efficiency, on assay performance. The concentration series from bottom to top is 
0 pM, 0.01 pM, 0.1 pM, 1 pM, 10 pM, 100 pM and 1000 pM. For each concentration 
condition, three drift velocities were simulated, represented by the blue (30 µm/s for 5400 s), 
red (as in B, 33 µm/s for 4800 s), and dashed lines (38 µm/s for 4200 s). The impact of the 
drift velocity on the position of the curves, thus the spatial distribution of the trapped analytes 
along the channel, is more substantial for the high concentration conditions. As a result, the 
drift velocity will have a more pronounced effect on the dynamic range of the assay than the 
sensitivity. 
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Chapter VI 
 
Localization of Short-Chain Polyphosphate Enhances its Ability to Clot 
Flowing Blood Plasma5 
 
Abstract 
 
Short-chain polyphosphate (polyP) is released from platelets upon platelet activation, but 
it is not clear if it contributes to thrombosis. PolyP has increased propensity to clot blood 
with increased polymer length and when localized onto particles, but it is unknown 
whether spatial localization of short-chain polyP can accelerate clotting of flowing blood. 
Here, numerical simulations predicted the effect of localization of polyP on clotting 
under flow, and this was tested in vitro using microfluidics. Synthetic polyP was more 
effective at triggering clotting of flowing blood plasma when localized on a surface than 
when solubilized in solution or when localized as nanoparticles, accelerating clotting at 
10–200 fold lower concentrations, particularly at low to sub-physiological shear rates 
typical of where thrombosis occurs in large veins or valves. Thus, sub-micromolar 
concentrations of short-chain polyP can accelerate clotting of flowing blood plasma 
under flow at low to sub-physiological shear rates. However, a physiological mechanism 
for the localization of polyP to platelet or vascular surfaces remains unknown. 
 
Introduction 
 
PolyP is an activator of blood coagulation through its ability to accelerate the activation of 
coagulation factors XII, XI, and V1,2, and by abrogating tissue factor pathway inhibitor 
                                                 
5 This chapter was first published in Scientific Reports with authorship belonging to Ju Hun Yeon, Nima 
Mazinani, Travis S. Schlappi, Karen Y. T. Chan, James R. Baylis, Stephanie A. Smith, Alexander J. 
Donovan, Damien Kudela, Galen D. Stucky, Ying Liu, James H. Morrissey, Christian J. Kastrup. The 
original manuscript can be found at: http://dx.doi.org/10.1038/srep42119. Specific contributions from each 
author are listed at the end of the chapter. 
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(TFPI) function3,4. Long-chain polyP (hundreds to thousands of residues long) appears 
to be a much more potent activator of clotting, via activation of factor XII and the contact 
pathway, than short-chain polyp5–7. Short-chain polyP (60–100 phosphate residues long) 
is found in dense granules of human platelets and granules of mast cells (acidocalcisomes) 
and released upon their activation, while long-chain polyP occurs in microbes and some 
mammalian cells, such as in prostate cancer7–10. A characteristic of long-chain polyP is 
its ability to aggregate into particles, and this spatial localization may possibly contribute 
to its propensity to accelerate clotting11. It is less clear if there is a pathophysiological role 
for polyP released from human cells in thrombosis3. Short-chain endogenous polyP 
facilitates activation of FXII in vitro, albeit at supraphysiological concentrations12. It can 
also contribute to clotting in vitro under flow when tissue factor (TF) is present13. It is 
well-known that the local concentration of activators can profoundly influence their ability 
to initiate the clotting of blood14. Localization of polyP onto particles also accelerates 
coagulation under stagnant conditions15. Thus, we hypothesized that short-chain polyP 
may be a more effective activator when spatially 
localized onto surfaces, capable of accelerating clotting of flowing blood in vitro without 
participation of TF. 
 
Initiation of blood coagulation is triggered when the local concentration of activators 
reaches a critical threshold, upon which the proteolytic cascade amplifies the local 
concentration of active enzymes to form a cross-linked fibrin mesh16,17. The spatial 
localization of activators to surfaces effectively increases their local concentration, 
allowing coagulation to be triggered with less total amount of activator18,19. Several 
activators have displayed this effect of spatial localization in microfluidic models of 
clotting, including TF, glass, and bacteria that activate prothrombin and factor X20. Flow 
influences coagulation in a variety of ways and enhances the effects of spatial 
localization21. Flow continuously strips clotting factors from catalytic surfaces, preventing 
activators from achieving a critical threshold and ultimately preventing clot initiation22,23. 
To accelerate clotting of flowing blood, greater amounts of activator need to be localized 
in order to achieve a higher local concentration24. In this study, we used numerical 
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simulations and a microfluidic model of thrombosis to investigate whether the ability 
of localization to enhance clotting extends to short-chain polyP in vitro under flow. The 
shear rates used in this study range from low to sub-physiological (i.e. pathological) shear. 
These low shear rates mimic those typical of where thrombosis 
occurs in large veins and valves, such as in deep vein thrombosis (DVT) or those associated 
with airplane economy class syndrome25–30. This microfluidic model of thrombosis 
enabled clotting of plasma, or lack thereof, to be monitored over many hours in the absence 
of TF. In contrast to coagulation that occurs from acute injury to vessels, such as from 
puncture that exposes large amounts of TF, thrombosis may initiate over longer periods of 
time and can be potentiated by factor XII2,31–35. Our experiments were designed to 
determine if localization of physiologically-relevant concentrations of platelet-length 
polyP could contribute to coagulation in vitro at low to sub-physiological shear, but they 
do not validate whether or not localization of platelet-length polyP contributes to 
thrombosis in vivo. 
 
Results 
 
Numerical simulations predict the localization of polyP will increase its coagulability 
at low shear rates. To initially examine how localizing polyP onto surfaces affects 
thrombin generation, we used a two-dimensional numerical simulation that considered 
diffusion, convection, and the rates of 41 reactions of the coagulation cascade 
(Supplementary Tables 6-S1–3). An established kinetic model for the coagulation cascade 
was used with the addition of polyP>1000 in three reactions that were previously 
characterized in kinetic assays1,4,5,7,20. PolyP was either spatially localized onto the 
surface of a cylindrical channel or dispersed throughout its volume. Shear rates were from 
1 s−1 to 120 s−1, a range that encompasses sub-physiological shear rates (< ~10 s−1) and 
shear rates in the inferior vena cava, venous valves, and large veins25–27,36. When polyP 
was localized onto the surface of the channel with a shear rate of 1 s−1, the local thrombin 
burst was 782-fold higher than when an equal amount of polyP was dispersed throughout 
the volume (1.83 × 10−8 M versus 2.34 × 10−11 M) (Fig. 6-1A). The amount of polyP in 
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the simulations was 7.54 × 10−9 mol, which equates to 30 μ M (with respect to 
phosphate monomer) when the total volume of the simulation was considered. The 
resulting thrombin burst was a consequence of the higher local concentration of polyP, 
which led to increased positive feedback from the coagulation cascade. Simulations 
showed that differences in thrombin generation persisted over various shear rates, up to 60 
s−1 (Fig. 6-1B). However, at a set distance, the difference decreased as shear rate increased, 
because thrombin was rapidly transported down-stream. 
 
 
Figure 6-1. Numerical simulations predict localization of polyP accelerates thrombin 
production at low shear rates. Two-dimensional numerical simulations of the human 
blood coagulation cascade, comparing the generation of thrombin by polyP dispersed 
throughout a cylindrical channel versus polyP immobilized on the channel surface. The 
channel was 20 mm long with a radius of 2 mm. The overall number of polyP molecules 
was the same in all simulations (7.54 × 10−9 moles). (A) Plots show [thrombin], which is 
the sum of concentrations of thrombin and meizothrombin, for a two-dimensional 
longitudinal cut of the cylinder at 500 s into the simulation. (B) The fold difference in the 
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maximum [thrombin] generated in the channel when polyP was surface-immobilized 
(SI-polyP) versus dispersed (D-polyP) at varying shear rates. 
 
Surface-immobilized polyP accelerates clotting of flowing blood plasma. To determine 
if SI-polyP was able to accelerate clotting of flowing blood plasma, synthetic polyP400 
was immobilized onto the walls of microfluidic channels (Fig. 6-2A). Half of each chamber 
was patterned with biotinylated lipids followed by an excess of streptavidin (Fig. 6-2B). 
Biotinylated-polyP400 was then flowed through the channel, becoming immobilized onto 
streptavidin. The surface concentration of SI-polyP400 was varied by diluting biotinylated-
polyP400 in a solution of biotin-PEG before coating the channel. The concentration of 
polyP was determined by DAPI staining. 
Fluorescence intensities from known concentrations of stained D-polyP, which was soluble 
and dispersed throughout the channel, were used to generate a standard curve and used to 
calculate the surface concentration of SI-polyP (Fig. 6-2C). The surface concentration of 
SI-polyP was 300 nmol/m2, and could be decreased to 60 nmol/m2 by diluting with biotin-
PEG. To test the ability of patterned polyP to induce clotting, platelet-poor human plasma 
was flowed through the chambers. Based on the simulation data, we tested the lowest shear 
(1 s−1) as it was predicted to have the largest effect on thrombin generation and therefor 
clotting. A range of shear rates are explored in later experiments. The plasma clotted 
selectively on areas with immobilized polyP400 (300 nmol/m2) in 50–70 min at a shear 
rate of 1 s−1. No clotting was observed over 5 hr in channels without polyP400 (Fig. 6-
2D). All polyP concentrations are reported in terms of phosphate monomer. 
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Figure 6-2. PolyP induces clotting of flowing blood plasma when localized on a surface 
at sub-physiological shear. (A) Schematic of biotinylated synthetic polyP (cyan) 
patterned onto the surface of half of a microfluidic channel, which induces production of 
thrombin and clotting (blue) of flowing blood plasma (grey). (B) Images of fluorescent-
labeled agents flowing and patterned along one side of a microfluidic channel. Biotinylated 
lipids (tagged red) self-assembled on the channel wall. Non-biotinylated lipids (not tagged 
in these images) were simultaneously flowed and patterned on the other side of the chamber 
using laminar flow patterning. Then, streptavidin (tagged green) was flowed through and 
bound to the biotinylated lipids, followed by flowing biotinylated polyP labeled with DAPI 
(cyan), which bound streptavidin. A substrate (blue) for thrombin was activated, indicating 
initiation of clotting, selectively on patterned polyP400 (300 nmol/m2). Scale bar is 250 
μm. (C) Quantifying of the amount of SI-polyP by measuring the fluorescence of DAPI 
bound to it. Channels with SI-polyP were compared to channels without polyP and to 
channels treated with polyP diluted with biotinylated PEG. Inset is a standard curve of 
known concentrations of solubilized D-polyP, which was used to calculate the surface 
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concentration of SI-polyP in coated channels. (D) The clotting times of normal human 
plasma flowing through channels coated with polyP400 at a shear rate of 1 s−1. *p = < 
0.01 compared to controls without polyP. Data indicate mean ± SEM, n = 3. 
 
Measuring clot times simultaneously at various shear rates. A microfluidic system 
containing six regions with varying shear rates was used to measure clot times of flowing 
blood plasma (Fig. 6-3A). The range of shear rates was 1–110 s−1, which encompasses 
physiological shear rates which occur in the inferior vena cava, venous valves, and large 
veins; as well as, sub-physiological shear rates (< ~10 s−1) that occur in pathological 
contexts25–28,36. These calculated shear rates were within 3–8% of the values obtained 
by measuring the flow velocity of micro particles by florescence microscopy. Clotting was 
monitored by visualizing the movement of fluorescent tracer beads specifically in the shear 
chambers, which became immobilized in clotted regions, and by a fluorogenic peptide 
substrate, which fluoresced when cleaved by thrombin during clotting (Fig. 6-3B). To 
characterize and determine the range of clot times of flowing blood plasma in the 
microfluidic system, coagulation factor VIIa (FVIIa) was used, and added to plasma at a 
range of concentrations (Fig. 6-3C). FVIIa does not circulate in plasma in appreciable 
amounts physiologically (~1% of total FVII circulates as FVIIa)37, but is administered 
during severe hemorrhage in some cases to aid in hemostasis at doses of 90 to 270 μ g/kg, 
which roughly corresponds to 1 to 4 μ g/mL in plasma38,39. In the device, plasma 
containing 16 μ g/mL of FVIIa clotted in approximately 20–40 min, plasma containing 4 
μ g/mL of FVIIa clotted in approximately 60 min, and plasma containing 4 ng/mL 
did not clot within 6 hr. Intermediate clotting times occurred with concentrations of 400 
ng/mL and 40 ng/mL and were dependent on shear rate. Clot formation always occurred 
from the channel wall, crudely mimicking how physiological thrombus formation occurs 
from the walls of blood vessels and is shear-dependent40. 
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Figure 6-3. The microfluidic system used to measure clotting over a range of shear 
rates. (A) Schematic of the microfluidic system. Box (dashed lines) indicates the region 
where shear rates were varied and clot times were measured. (B) Fluorescence images 
showing that clotting was detected by the cessation of flow of tracer beads (pink) and by 
the cleavage of a substrate for thrombin (blue). Scale bar is 250 μ m. (C) Assessing the 
range of clotting times in this flow system by adding various concentrations of FVIIa to 
the plasma. Data points indicate mean ± SEM, n = 3–4. Red circles indicate p = < 0.05 
between the data points, and blue circles indicate p = < 0.01 between the data points. 
 
Short-chain polyP accelerates clot formation faster when surface-localized than when 
dispersed in nanoparticles or in solution. PolyP160 was previously demonstrated to be 
a weak initiator of the contact pathway, but we examined the hypothesis that spatially 
localizing polyP160 onto a surface (SI-polyP160) would enhance its ability to contribute 
to clot formation compared to polyP160 dispersed as nanoparticles (NP-polyP160) or in 
solution (D-polyP160, Fig. 6-4A). With NP-polyP160 (1 μ M, 250 nm diameter, 
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Supplementary Fig. 6-S1), clotting occurred in approximately 170 min and 200 min at 
a shear rate of 1 s−1 and 22 s−1 respectively. When a similar amount of polyP160 was 
localized onto the channel surface, clotting occurred significantly faster than both NP-
polyP160 and D-polyP160. Clotting initiated from the parallel channel shear chamber 
walls, or in areas where the channel expanded from high to very low shear, and 
progressively grew outwards (Fig. 6-4B). Clotting with D-polyP160 (1 μ M) was 4- to 2.8-
fold slower than SI-polyP160 and 1.6- to 0-fold slower than NP-polyP160 at all shear rates. 
Overall, clotting occurred fastest with SI-polyP160 than dispersed polyP160 in either 
soluble or NP forms, even with 6–43 fold less SI-polyP160 in the channels. 
 
Platelet-length polyP can accelerate clotting when surface-localized. The concentration 
of polyP is approximately 1.1 mM in platelets, where it is stored in platelet dense granules, 
and can reach up to 2–7 μM in blood upon platelet activation41,42. To test whether 
synthetic polyP similar in length to those found in human platelets can clot flowing blood 
at physiological concentrations, polyP70 was tested (Fig. 6-4C). Soluble polyP70 (D-
polyP70) at 400 nM did not accelerate clotting of flowing blood plasma at the shear rates 
tested. In contrast, an equivalent amount of SI-polyP70 substantially accelerated clotting, 
to 70 min and 160 min at shear rates of 1 s−1 and 110 s−1 respectively. The amount of SI-
polyP70 used corresponded to a surface concentration of 24 nmol/m2 and a total 
concentration of around 400 nM in the volume of the channel. Initiation time of clotting by 
SI-polyP70 was dependent on FXII (Supplementary Fig. 6-S2). 
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Figure 6-4. PolyP accelerates clotting best when spatially localized onto surfaces, 
compared to soluble polyP and nanoparticles of polyP. (A) Clotting times of plasma by 
polyP160 at varying shear rates, comparing three states of polyP160: solubilized, self-
assembled nanoparticles, and surface-immobilized. (B) Time-lapse images showing SI-
polyP160 initiating clotting (detected by non-flowing beads) from the channel wall (dashed 
lines). Scale bar is 250 μ m. (C) Comparing three states of polyP70: solubilized, surface-
immobilized onto the microfluidic channels, and immobilized onto silica nanoparticles. 
Clotting tendencies of plasma containing silica nanoparticles coated with polyP70 (SNP-
polyP70) compared to soluble and surface-immobilized polyP70 under shear in the 
microfluidic device. (D) Comparing two states of long-chain polyP: surface immobilized 
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polyP400 and nanoparticles of self-assembled polyP>1000. (E) Schematic 
summarizing the relationship between spatial distribution of polyP and the acceleration of 
clotting in the above experiments. Data points indicate mean ± SEM, *p < 0.001, **p < 
0.0001, n = 3–4. Statistical analysis represents comparisons between whole curves. 
 
SI-polyP70 and D-polyP70 could not be directly compared to self-assembled nanoparticles 
of polyP70 (NP-polyP70), because the solubility of polyP70 is greater than longer chain 
polyP, and NP-polyP70 was not stable. Alternatively, we tested a second formulation of 
polyP nanoparticles, where polyP70 was coated on silica nanoparticles (SNP-polyP70)43. 
When SNP-polyP70 was added to plasma at varying shear, clotting occurred in 
approximately 70 min to 160 min at 200 μ g/mL and 80 min to > 360 min at 20 μ g/mL. 
These masses of SNP-polyP70 corresponded to concentrations of polyP70 of 6 μ M and 
0.6 μ M, respectively, but include both polyP70 and silica. Silica is also an activator of 
factor XII, so an equal comparison between SI-polyP70 and SNP-polyP70 cannot be made. 
Nevertheless, the clotting times of SI-polyP70 (400 nM) were significantly faster than 20 
μ g/mL of aSNP-polyP70, and were nearly identical to 200 μ g/mL of a SNP-polyP70 even 
though there was a 15-fold lower concentration of polyP70. 
 
Clotting by long-chain polyP is also enhanced by surface localization. To understand 
if the effect of surface localization extends to long-chain polyP, we tested a range of 
concentrations of long-chain polyP either surface localized (SI-polyP400) or dispersed as 
nanoparticles (NP-polyP>1000). PolyP>1000 naturally self-assembles, localizing into 
nanoparticles of 150 } 30 nm in diameter in solutions containing Ca2+ at low millimolar 
concentrations11. It is a known activator of clotting under static conditions when dispersed 
throughout plasma3. We compared NP-polyP>1000 to SI-polyP400, rather than SI-
polyP>1000, because surface patterning of polyP requires biotinylation of the polyP 
chains, and the biotinylation procedure caused degradation of long chain-lengths of polyP. 
When plasma was flowed over SI-polyP400, clotting occurred in approximately 60 min to 
100 min at 7 μM and 140 min to 170 min at 1 μ M at the shear rates examined (Fig. 6-4D). 
The clot times using NP-polyP>1000 demonstrated robust shear- and concentration-
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dependence at 2000, 200, 20, 7 and 1 μ M. NP-PolyP>1000 was most potent at 2000 μ 
M, initiating clotting at 60 min at 1 and 3 s−1, although requiring 285-fold more phosphate 
to match the propensity of SI-polyP400 to clot flowing plasma under the same conditions. 
 
Discussion 
 
Together, these data show that the spatial localization of synthetic polyP onto surfaces 
affects its ability to activate clotting under flow (Fig. 6-4E). Short-chain polyP polymers 
(polyP160 and polyP70) greatly accelerated clotting of flowing blood plasma at low to sub-
physiological shear when surface-localized onto the walls of microfluidic chambers 
compared to when they are dispersed (nanoparticle or soluble forms). Soluble short-chain 
polyP only clotted stagnant blood (near-zero flow) in our experiments, and clotting did not 
occur within a span of hours even at sub-physiological shear rates. Localization of polyP 
onto the surface of channels showed the greatest activity overall. The concentration at 
which SI-polyP70 accelerated clotting in vitro is well-within the range of amounts of polyP 
released into plasma following platelet activation. Although it is not known if polyP 
localizes to cell surfaces or thrombi, or to the extent polyP contributes to physiological or 
pathophysiological coagulation, it is important to identify scenarios in which polyP could 
potentially elicit a role. These results propose that if polyP can surface-localize it may 
contribute to clotting at sub-physiological shear following platelet activation, but further 
in vitro and in vivo experiments are necessary to verify that this is a potential mechanism. 
 
Remarkably, comparing SI-polyP70, SI-polyP160, and SI-polyP400, to each other shows 
that short-chain polyP could match the propensity of longer chain polyP to accelerate 
clotting under flow. SI-polyP70 accelerated clotting to a similar extent as SI-polyP160 and 
SI-polyP400 with a lower concentration of phosphate. Although clotting times were similar 
between them with respect to surface coverage of full-length polymers, this is likely 
because shorter chains have high surface coverage relative to the amount of monomer. 
Thus, clotting occurred faster with both increasing surface concentration of phosphate and 
increasing surface coverage. 
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The simulations predicted the trend observed in vitro. Localization creates high local 
concentrations of polyP, and in the numerical simulations this led to larger thrombin bursts 
due to increased positive feedback from the coagulation cascade. The simulations included 
polyP binding and inhibiting TFPI and accelerating activation of factors V and XI, which 
all occur in plasma. The mechanism is likely contact system mediated as under stagnant 
conditions FXII contributed to initiation of clotting by polyP, but we did not test this further 
in flow experiments. It was recently shown that short-chain polyP could complex with FXII 
in vitro to allostericly induce its activation at high polyP concentrations of 70–130 μ M12. 
This polyP-induced activation of FXII was enhanced in the presence of zinc ions, which is 
known to bind robustly to both FXII and PolyP3,12. Short-chain polyP can also contribute 
to clotting independently of FXII when TF is present13. The results here, without TF, 
indicate that localization can further increase the propensity of short-chain polyP to clot 
blood plasma. 
 
In these microfluidic experiments, shear rate and concentrations of either FVIIa or polyP 
influenced the clotting times over several hours. The shear rates mimicked the shear rates 
that are typical in large veins and valves; as well as, pathological shear which occurs it the 
context of thrombosis. The reported clotting times appear very long compared to clotting 
times in most in vitro, stagnant clotting assays, which occur in seconds to minutes. 
However, residence time of plasma in the microfluidic chambers was only ~10 sec, with 
plasma being continuously transported into and out of the chamber, and thus the rate of 
clotting cannot be directly compared to stagnant clotting assays. Long clot times were 
possible in this device, compared to most other flow systems, because platelet-poor plasma 
was recalcified on the device and because TF was not included44. The observed clotting 
times were much slower than what is typical in acute hemostasis and at high concentrations 
of TF, but they were within the time-frame that formation and growth of thrombi occurs 
inside veins and regions of low shear31–33. Thrombosis, in contrast to hemostasis, can 
involve progressive and gradual clot growth, where there is much less TF but increased 
contribution of factors XI and XII2,45. The clotting times measured in this microfluidic 
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system are more representative of clotting times that would occur during thrombosis 
inside intact veins, rather than punctured vessels or stagnant clotting assays. In addition, 
the shear rates used in our microfluidic model include the rates which occur in large veins. 
Though platelets appear to contribute more to arterial thrombi than venous 
thrombi, they also contribute to venous thrombosis46,47. For example, antiplatelet drugs 
have also been beneficial in treating venous thrombosis47–49. 
 
For several concentrations and chain-lengths of polyP, it was not possible to make 
equivalent comparisons between SI-polyP, NP-polyP, SNP-polyP, and D-polyP, because 
the chain-length and concentration are important determinants of whether polyP self-
assembles into particles or remains soluble. The solubility of short-chain polyP is greater 
than long-chain polyP, but solubility also depends on the concentration of polyP and Ca2+. 
For example, polyP160 can be formulated to be soluble or to form NP-polyP by varying 
the concentration of polyP and Ca2+ 11. We used concentrations of polyP160 well below 
its limit of solubility. PolyP160 was first dissolved into water and then diluted into plasma. 
When added to citrated plasma, soluble polyP likely remained dissolved, as 
plasma has insufficient free divalent cations to facilitate nanoparticle formation11. Once 
plasma is recalcified, polyP likely remains protein-bound even in the presence of low 
millimolar amounts of ionic calcium, at least for the 35 sec that it is present in the 
microfluidic devices (Supplementary Fig. 6-S3)11,50. In contrast, NP-polyP were formed 
by precipitating polyP160 in 5 mM Ca2+, generating nanoparticles that were stable for 
over 6 hr, as measured by dynamic light scattering. NP-polyP was diluted in the calcium-
saline solution that mixed with blood plasma inside the microfluidic devices to keep the 
nanoparticles intact. The stability of NP-polyP in plasma is unknown; however, NP-polyP 
was initially prepared under supersaturated conditions, and the solubility of NP-polyP 
displays hysteretic behavior11. Thus, a large portion of NP-polyP, once formed, likely 
remained as NPs in the microfluidic devices. Although synthetic polyP was used in these 
experiments, natural polyP is also typically bound to calcium51. 
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In summary, this work shows that spatial localization of synthetic polyP, including 
short-chain polyP, increases its propensity to accelerate clotting of blood plasma at low to 
sub-physiological shear. The observed clotting times were much slower than what is typical 
in hemostasis, but they were within the time-frame that thrombosis occurs inside veins, 
particularly post-operative deep vein thrombi, which form over a period of days32,33,52. 
The experiments were designed solely to test if surface-localization of short-chain polyP 
accelerates clot formation under flow, at venous and sub-physiological shear rates. An 
important observation from this was that when localized, short-chain polyP could match 
the ability of long-chain polyP to accelerate clotting. The concentration required to 
accelerate clotting is markedly reduced when polyP is spatially localized onto surfaces, and 
to a lesser extent, into particles, even under flow and without TF. These biophysical 
insights provide a potential biophysical mechanism by which platelet-length polyP could 
contribute to thrombosis in regions of low shear, but further work is required to validate if 
this mechanism could indeed extend to in vivo scenarios. This effect of localization may 
potentially contribute to clotting at higher shear when TF is present13. Although these in 
vitro results, in an artificial flow system, support the notion that platelet-derived polyP 
could contribute to coagulation in vivo, the flow system used here does not include many 
factors that normally regulate clotting, such as platelets, platelet-derived polyP, red blood 
cells, immune cells, endothelium and other soluble factors. For these reasons, appropriate 
in vivo models are necessary to verify whether platelet-derived polyP and its spatial 
localization contributes to clot formation and thrombosis. 
 
Materials and Methods 
 
Numerical Simulations. Thrombin generation was modeled with the Transport of Diluted 
Species module of Comsol Multiphysics 4.4 by adding diffusion and convection to a 
previously reported kinetic model20. Changes to the model included the addition of three 
rate equations to describe the activity of polyP: 1) the binding and inhibition of TFPI; TFPI 
+ polyP ↔ TFPI-polyP; kon = 4.0 × 105 M−1s−1, koff = 1.0 × 10−2s−1, 2) the activation of 
factor V; V + Xa + polyP → Va + Xa + polyP; k = 8.0 × 1012 M−2s−1, 3) the activation of 
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factor XI; XI + IIa + polyP → XIa + IIa + polyP; k = 8.8 × 109 M−2s−1 1,4,5,7,20. The 
diffusion coefficient for all soluble species was 5 × 10−11 m2/s and the velocity profile 
varied with the shear rate, 𝑣𝑣𝑧𝑧(𝑟𝑟) = 𝛾𝛾𝑤𝑤𝑅𝑅2 �1 − 𝑐𝑐𝑅𝑅�2, where vz is the velocity in the axial 
directionat each radial coordinate r, R is the cylinder radius, and γw is the shear rate at the 
cylinder wall. The chemical species were flowed into a cylindrical geometry of radius 2 
mm and length 20 mm. For each shear rate, [thrombin] was sampled after the incoming 
flow had displaced the channel volume 12.5 times. Both the experiments and simulations 
were performed in the same mass-transfer regime (Pe ≫ 1 and Gz > 3000). 
 
Preparing soluble polyP (D-polyP), self-assembled polyP nanoparticles (NP-polyP), 
polyP-coated silica nanoparticles (SNP-polyP), and surface-immobilized polyP (SI-
polyP). To make D-polyP, polyP was solubilized and diluted first in water and then added 
to citrated plasma (frozen citrated normal control plasma, Affinity Biologicals Inc.) prior 
to entering the microfluidic device. NP-polyP was generated as described previously11. 
Briefly, soluble polyP was added to a calcium solution (10 mM polyP, 5 mM CaCl2, 8 mM 
Tris, pH 6.0) followed by vortexing, during which polyP self-assembled into nanoparticles 
tightly bound to Ca2+ cations11. The formation and size of the nanoparticles were verified 
after adding them to this calcium solution by observing the scattering intensity and 
hydrodynamic diameter, as measured by dynamic light scattering (Zetasizer Nano ZSP, 
Malvern Instruments). NP-polyP formulations were added and diluted in calcium-saline 
solution, rather than the citrated-plasma, prior to entering the microfluidic device. The NP-
polyP were stable for over 6 hr in these solutions. SNP-polyP70 were made by covalently 
attaching polyP70 onto silica nanoparticles as previously described43. Synthetic PolyP was 
generated by solubilization from Maddrell salts and biotinylated as previously 
described7,50. Synthetic polyP has been previously characterized, including its chain 
length, counterions, and clotting activity7,11. Long-chain NP-polyP contained a 
heterogeneous preparation of very long, 
non-biotinylated polyP polymers ranging from around 200 mers to 1300 mers, referred to 
here as NP-PolyP>1000. Some experiments with SI-polyP employed heterogeneous long-
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chain biotinylated polyP consisting of chains 50 to 400 units in length, referred to here 
as biotin-polyP400. Some experiments employed fractionated material of narrower sizes 
(polyP70 and polyP160)7. All polyP concentrations are stated with respect to the 
concentration of phosphate monomer. 
 
Preparing microfluidic devices with SI-polyP. Microfluidic devices were prepared from 
polydimethylsiloxane (PDMS) as previously described53. Channel dimensions are listed 
as follows (length × width, 125 μm height for all channels): 1.67 mm × 1000 μm (1 s−1), 
3.33 mm × 500 μm (3 s−1), 5.83 mm × 286 μm (10 s−1), 8.33 mm × 200 μm (22 s−1), 12.50 
mm × 133 μm (55 s−1), 16.67 mm, 100 μm (110 s−1). The devices were incubated 
in saline and kept under vacuum overnight to hydrate and remove air from the channels. 
Devices remained soaked in saline throughout the experiment to aid in coating the surfaces 
with lipids, and to reduce convective flow during experiments in the absence of flow. The 
devices were coated with phosphatidylcholine (PC) vesicles to prevent activation of 
clotting on the PDMS surface. In devices that were not coated withSI-polyP, vesicles were 
prepared with egg PC (Avanti Polar Lipids, Alabaster, USA) and fluorescent Texas Red 
1,2-Dihexadecanoyl-sn-Glycero-3-Phosphoethanolamine (DHPE) (Invitrogen) in a 
99.5:0.5 molar ratio. Lipids were extruded through a 100 nm membrane using a Lipex 
Thermobarrel Extruder (Northern Lipids, Burnaby, Canada). The vesicle solution (10 
mg/mL in dH2O) were flowed through microfluidic channels at a rate of 1 μL/min for 15 
min and rinsed out with saline. The coating of PC on the channels was stable for at least 
10 hours (Supplementary Fig. 6-S4). For devices where polyP was surface-immobilized, 
the channel was first coated with biotinylated lipids (1 μL/min, 15 min) and rinsed out with 
saline. To prepare biotinylated vesicles, 1-oleoyl-2-[12[biotinyl(aminododecanoyl)]-sn-
glycero-3-phosphocholine (biotinylated-PC, Avanti Polar Lipids) was mixed with Egg PC 
and Texas Red DHPE in a molar ratio of 5.0:94.5:0.5 and extruded. Next, streptavidin (100 
μg/mL) conjugated to Alexa Fluor® 488 (Molecular Probes, Inc.) was flowed through the 
device (1 μL/min, 40 min) and then rinsed with saline to wash away the unbound, excess 
streptavidin. Finally, a solution of 
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biotin-polyP (50 μg/mL) and biotinylated-polyethylene glycol (biotin-PEG) (either 0 or 
99 molar equivalents to biotin-polyP) was flowed through the device (1 μL/min, 40 min), 
binding to the patterned streptavidin followed by a saline rinse, which resulted in SI-polyP 
being selectively patterned on the walls of the microfluidic device shear chambers. 
Liposomes and saline were flowed into the device through a combination of inlet and outlet 
channels to achieve laminar flow patterning, such that the parallel streams of fluids were 
at low Reynolds number (≪ 1) and maintained sharp boundaries and excluded the 
possibility of turbulent flow54,55. This patterning allowed specific channel walls of the 
device to be coated, either all channels in the device, the channels in the shear chambers, 
or one wall of the chambers. To measure the amount of polyP, it was stained by flowing 
DAPI (40 μg/mL in 15 mM Tris acetate, 300 mM NaCl, 30 mM EDTA, and 0.02% NaN3) 
into the device. Thrombin generation during clotting was detected by adding 125 μ g/mL 
of fluorescent peptide substrate for thrombin (Boc-Val-Pro-Arg-4-methylcoumaryl-7-
amide, Peptide Institute Inc.) into normal plasma. 
 
Flowing plasma and calcium into devices and measuring clotting. Flow rates were 
controlled using a syringe pump (Harvard Apparatus PHD 2000) by withdrawing solutions 
out of the outlets of the device at a rate of 1 μl/min. Shear rates in different channels were 
controlled by the width of each channel, while the residence time of plasma within the 
shear chambers were kept constant (~10 sec) by varying their respective lengths. Tubing 
connected to the outlets of the device were charged with 50 μ l of Egg PC vesicles to 
prevent clotting from initiating in the tubing or syringes. A solution of sodium citrate (10 
mM in dH2O) was initially pulled into both inlet channels to wash out the device and 
further charge the outlet tubing. Normal citrated human plasma (7 mM citrate) and 
calcium-saline solution (40 mM CaCl2 and 90 mM NaCl) were simultaneously pulled into 
the device and mixed at a ratio of 3:1 to recalcify the plasma, yielding a final free calcium 
concentration of 4–5 mM56. To measure clotting times, fluorescent beads (2.5 μ g/mL, 
Fluoresbrite Plain YG 1.0 Micron Microsphere, Polysciences Inc.), and in some 
experiments 125 μ g/mL fluorescent thrombin substrate, were mixed into the plasma and 
time-course imaging of each channel was performed using an epifluorescence microscope 
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(Leica DMI6000B). The fluorescent beads did not influence clotting times 
(Supplementary Fig. 6-S5). Clotting was determined by the immobilization of the 
fluorescent beads and in some experiments also by the generation of blue fluorescence 
upon cleavage of the thrombin substrate. In experiments where the effect of nanoparticle 
polyP (NP-polyP) on clotting was tested, the activators were mixed with the calcium 
solution prior to entering the device. For experiments with soluble polyP (D-polyP), polyP 
was added to the plasma instead to prevent nanoparticle formation. For experiments at zero 
shear, normal or congenital FXII-deficient plasma (Geroge King Bio-Medical, Inc.) and 
calcium were mixed together immediately before flowing them into the device and 
blocking all outlets to create stagnant plasma. 
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Supplementary Information 
Numerical Simulations 
Table 6-S1: Reactions and rate constants used in the simulations for Figure 6-1. 
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Rxn Model Expressions k1 k-1 kcat Refer
-
ences 
1 Xa + VII → Xa + VIIa 1.3·107 M-1s-1   (1) 
2 IIa + VII → IIa + VIIa 2.3·104 M-1s-1   (1) 
3 II + Xa → IIa + Xa 7.5·103 M-1s-1   (1) 
4 IIa + VIII → IIa + VIIIa 2.0·107 M-1s-1   (1) 
5 VIIIa + IXa ↔ IXaVIIa 1.0·107 M-1s-1 5.0·10-3 s-1  (1) 
6 IXaVIIa + X ↔ IXaVIIaX → IXaVIIa + 
Xa 
1.0·108 M-1s-1 1.0·10-3 s-1 8.2 s-1 (1) 
7 VIIIa ↔ VIIIa1L + VIIIa2 6.0·10-3 s-1 2.2·104 M-1s-
1 
 (1) 
8 IXaVIIIaX → VIIIa1L + VIIIa2 + X + 
IXa 
1.0·10-3 s-1   (1) 
9 IXaVIIIa → VIIIa1L + VIIIa2 + IXa 1.0·10-3 s-1   (1) 
10 IIa + V → IIa + Va 2.0·107 M-1s-1   (1) 
11 Xa+ Va ↔ XaVa 7.5·103 M-1s-1 0.2 s-1  (1) 
12 XaVa + II ↔ XaVaII → XaVa + mIIa 1.0·108 M-1s-1 103 s-1 63.5 s-1 (1) 
13 XaVa + mIIa → XaVa + IIa 1.5·107 M-1s-1   (1) 
14 Xa + TFPI ↔ XaTFPI 9.0·105 M-1s-1 3.6·10-4 s-1  (1) 
15 Xa + ATIII → XaATIII 1.5·10-3 M-1s-1   (1) 
16 mIIa + ATIII → mIIaATIII 7.1·103 M-1s-1   (1) 
17 IXa + ATIII → IXaATIII 4.9·102 M-1s-1   (1) 
18 IIa + ATIII → IIaATIII 7.1·103 M-1s-1   (1) 
19 XIIa + XII ↔ XIIaXII → XIIa + XIIa 1.0·108 M-1s-1 750 s-1 3.3·10-2 s-1 (1) 
20 XIIa + PK ↔ XIIaPK → XIIa + K 1.0·108 M-1s-1 3.6·103 s-1 40 s-1 (1) 
21 XII + K ↔ XIIK → XIIa + K 1.0·108 M-1s-1 45.3 s-1 5.7 s-1 (1) 
22 PK + K → K + K 2.7·104 M-1s-1   (1) 
23 K → KInhibited 1.1·10-2 s-1   (1) 
24 XIIa + C1inh → XIIaC1inh 3.6·103 M-1s-1   (1) 
25 XIIa + ATIII → XIIaATIII 21.6 M-1s-1   (1) 
26 XI + IIa ↔ XIIIa → XIa + IIa 1.0·108 M-1s-1 5.0 s-1 1.3·10-4 s-1 (1) 
27 XIIa + XI ↔ XIIaXI → XIIa + XIa 1.0·108 M-1s-1 200 s-1 5.7·10-4 s-1 (1) 
28 XIa + XI → XIa + XIa 3.19·106 M-1s-1   (1) 
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29 XIa + ATIII → XIaATIII 3.2·102 M-1s-1   (1) 
30 XIa + C1inh → XIaC1inh 1.8·103 M-1s-1   (1) 
31 XIa + a1AT → XIaa1AT 1.0·102 M-1s-1   (1) 
32 XIa + a2AP → XIaa2AP 4.3·103 M-1s-1   (1) 
33 XIa + IX ↔ XIaIX → XIa + IXa 1.0·108 M-1s-1 41 s-1 7.7 s-1 (1) 
34 IXa + X ↔ IXaX → IXa + Xa 1.0·108 M-1s-1 0.64 s-1 7.0·10-4 s-1 (1) 
35 Xa + VIII ↔ XaVIII → Xa + VIIIa 1.0·108 M-1s-1 2.1 s-1 0.023 s-1 (1) 
36 VIIa + IX ↔ VIIaIX → VIIa + IXa 1.0·108 M-1s-1 0.9 s-1 3.6·10-5 s-1 (1) 
37 VIIa + X ↔ VIIaX → VIIa + Xa 1.0·108 M-1s-1 210 s-1 1.6·10-6 s-1 (1) 
38* polyP + TFPI ↔ polyPTFPI 4.0·105 M-1s-1 1.0·10-2 s-1  (2),(3) 
39* V + Xa + polyP → Va + Xa + polyP 8.0·1012 M-2s-1   (1),(2) 
40* XI + IIa + polyP → XIa + IIa + polyP 8.8·109 M-2s-1   (3) 
*Reactions 38-40 are bulk reactions for dispered polyP simulations (D-polyP) and surface 
reactions for the surface-immobilized polyP simulations (SI-polyP). 
Reaction 38: polyP abrogates TFPI function (2). 
For polyP binding to TFPI, similar rate constants were used as when polyP binds and releases 
from other plasma proteins.  The association rate constant for the polyP reaction with  IIa, 
XI, and XIa ranges from 1.64·106 M-1s-1 to 5.12·106 M-1s-1 (3); thus, 1.0·106 M-1s-1 was 
chosen for 𝑘𝑘1,38.  The disassociation rate constant for the polyP reaction with  IIa, XI, and 
XIa ranges from 1.05·10-2 s-1 to 7.71·10-2 s-1 (3); thus, 1.0·10-2 s-1 was chosen for 𝑘𝑘−1,38. 
Reaction 39: polyP accelerates V activation by Xa (2). 
The activation of V to Va by IIa occurs with a rate constant (𝑘𝑘1,10) of 2.0·107 M-1s-1 (see 
Reaction 10 in Table 6-S1) (1).  The reaction is 𝑉𝑉 + 𝐼𝐼𝐼𝐼𝑟𝑟 → 𝑉𝑉𝑟𝑟 + 𝐼𝐼𝐼𝐼𝑟𝑟 and the rate law is: 
𝑑𝑑[𝑉𝑉𝑟𝑟]
𝑑𝑑𝑡𝑡
= 𝑘𝑘1,10[𝑉𝑉][𝐼𝐼𝐼𝐼𝑟𝑟] 
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PolyP accelerates the activation of V by Xa; we assume this occurs with a similar rate as 
that of V activation by IIa.  The reaction would be 𝑉𝑉 + 𝑋𝑋𝑟𝑟 + 𝐶𝐶𝑟𝑟𝑝𝑝𝑝𝑝𝑃𝑃 → 𝑉𝑉𝑟𝑟 + 𝑋𝑋𝑟𝑟 + 𝐶𝐶𝑟𝑟𝑝𝑝𝑝𝑝𝑃𝑃 
and the rate law would be:  
𝑑𝑑[𝑉𝑉𝑟𝑟]
𝑑𝑑𝑡𝑡
= 𝑘𝑘1,39[𝑉𝑉][𝑋𝑋𝑟𝑟][𝐶𝐶𝑟𝑟𝑝𝑝𝑝𝑝𝑃𝑃] 
To approximate the rate constant, we assume that 𝑘𝑘1,10 ~ 𝑘𝑘1,39[𝐶𝐶𝑟𝑟𝑝𝑝𝑝𝑝𝑃𝑃].  With a typical [𝐶𝐶𝑟𝑟𝑝𝑝𝑝𝑝𝑃𝑃]~1𝜇𝜇𝜇𝜇, this means that 𝑘𝑘1,39 ~ 2.0 ∙ 1013𝜇𝜇−2𝑠𝑠−1. 
Reaction 40: polyP enhances XI activation by thrombin (3). 
A simple reaction for polyP enhancing XI activation by thrombin would be 𝑋𝑋𝐼𝐼 + 𝐼𝐼𝐼𝐼𝑟𝑟 +
𝐶𝐶𝑟𝑟𝑝𝑝𝑝𝑝𝑃𝑃 → 𝑋𝑋𝐼𝐼𝑟𝑟 + 𝐼𝐼𝐼𝐼𝑟𝑟 + 𝐶𝐶𝑟𝑟𝑝𝑝𝑝𝑝𝑃𝑃.  The rate law would be: 
𝑑𝑑[𝑋𝑋𝐼𝐼𝑟𝑟]
𝑑𝑑𝑡𝑡
= 𝑘𝑘1,39[𝑋𝑋𝐼𝐼][𝐼𝐼𝐼𝐼𝑟𝑟][𝐶𝐶𝑟𝑟𝑝𝑝𝑝𝑝𝑃𝑃] 
For an estimate of the reaction rate constant for polyP enhancing XI activation, Figure 6-1A 
from Reference shows a XI activation rate of ~1 nM/min when ~5μM polyP is present.  The 
concentrations used in this figure were [𝑋𝑋𝐼𝐼] = 30 𝑛𝑛𝜇𝜇 and [𝐼𝐼𝐼𝐼𝑟𝑟] = 5 𝑛𝑛𝜇𝜇.  Therefore, 
𝑘𝑘1,40 ~ 1 𝑛𝑛𝜇𝜇𝑚𝑚𝑟𝑟𝑛𝑛(30 𝑛𝑛𝜇𝜇)(5 𝑛𝑛𝜇𝜇)(5 𝜇𝜇𝜇𝜇) ~2.2 · 1010 1𝜇𝜇2𝑠𝑠1 
For all polyP reactions, elementary mass action kinetics was assumed.  Also, the experiments 
that the rate constants were based on happened in test tubes, whereas the experiments 
performed for this paper happened in microfluidic devices.  To account for this, a factor 𝜂𝜂 
was multiplied to each polyP forward rate constant (𝑘𝑘1,38, 𝑘𝑘1,39, 𝑘𝑘1,40) and simulations were 
run to match the clotting time in the microfluidic device.  𝜂𝜂 was found to be ~0.4, so the final 
rate constants used are as appears in Table 6-S1 (𝑘𝑘1,38 = 4.0·105 M-1s-1, 𝑘𝑘1,39 = 8.0·1012 M-
2s-1, 𝑘𝑘1,40 = 8.8·109 M-2s-1). 
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Table 6-S2: Chemical species and their initial concentrations used in the simulations for 
Figure 6-1.  All initial concentrations were taken from Reference (1). 
Species Initial 
Concentration (M) 
VII 1·10-8 
VIIa 1·10-10 
Xa 0 
IIa 0 
X 1.6·10-7 
IX 9·10-8 
II 1.4·10-6 
VIII 7·10-10 
VIIIa 0 
IXaVIIIa 0 
IXaVIIIaX 0 
VIIIa1L 0 
VIIIa2 0 
V 2·10-8 
Va 0 
XaVa 0 
XaVaII 0 
mIIa 0 
TFPI 2.5·10-9 
XaTFPI 0 
ATIII 3.4·10-6 
XaATIII 0 
mIIaATIII 0 
IXaATIII 0 
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IIaATIII 0 
XII 3.4·10-7 
XIIa 0 
XIIaXII 0 
PK0 4.5·10-7 
XIIaPK 0 
XIIK 0 
K 0 
C1inh 2.5·10-6 
XIIaC1inh 0 
XIIaATIII 0 
XI 3.1·10-8 
XIIIa 0 
XIa 0 
XIIaXI 0 
XIaATIII 0 
XIaC1inh 0 
a1AT 4.5·10-5 
a2AP 1·10-6 
XIaa1AT 0 
XIaa2AP 0 
XIaIX 0 
IXaX 0 
XaVIII 0 
VIIaIX 0 
VIIaX 0 
KInhibited 0 
polyP  
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For the polyP concentration, the same number of polyP molecules (7.5·10-9 moles) was 
either i) localized to the surface of the cylinder, or ii) dispersed throughout the volume of the 
cylinder.  This corresponds to a surface polyP concentration of 3·10-5 mol/m2 in the SI-polyP 
simulations and a dispersed polyP concentration of 3·10-2 mol/m3 in the D-polyP simulations. 
Table 6-S3: Shear rates used in the simulations for Figure 6-1b and the resulting thrombin 
concentration for dispersed and localized polyP 
Shear 
rate 
[thrombin]SI-polyP 
(mol/m3) 
[thrombin]D-polyP 
(mol/m3) 
[thrombin]SI-polyP / 
[thrombin]D-polyP 
1 1.83·10-5 2.34·10-8 782.1 
4 1.72·10-9 1.65·10-11 104.2 
12 4.70·10-12 1.93·10-13 24.4 
24 8.40·10-14 2.98·10-14 2.8 
60 1.87·10-15 1.95·10-15 1.0 
120 2.40·10-16 2.36·10-16 1.0 
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Supplementary Figure 6-S1. Size distribution of NP-polyP160. Representative DLS data 
demonstrating NP-polyP160 consisting of particles with an average hydrodynamic diameter 
of 250 ± 65 nm. 
 
 
Supplementary Figure 6-S2. polyP facilitates clotting through activation of Factor XII. 
Clotting times of normal plasma and FXII-deficient plasma at zero-shear with SI-polyP70 or 
without (biotinylated-PC alone). Data indicate mean ± SEM, n=3. 
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Supplementary Figure 6-S3. DLS size distribution of soluble D-polyP160 and NP-
polyP160 in buffer and plasma. (A) Normal citrated plasma without polyP, which contains 
background intensity from components normally in plasma. (B-C) Aggregated and soluble 
polyP160 respectively in HEPES buffered saline. (D) Soluble polyP160 added to citrated 
plasma. (E) Preformed NP-polyP160 added to citrated plasma. (F) Soluble polyP160 was 
added to citrated plasma and recalcified; the graph of panel F resembles panel D (D-polyP) 
rather than panel E (NP-polyP). 
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Supplementary Figure S4. PC channel coverage and stability. (A) Representative time 
lapse images of a channel (white dashed lines) coated with PC/Texas Red DHPE (red) with 
citrated normal plasma flowing through it. (B) Fluorescence intensities in different regions 
of each shear chamber. Data indicate mean ± SEM. 
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